

ICD-9-CM	ICD-10-CM	Disorder, condition, or problem
292.89		Other (or unknown) substance intoxication
	F19.129	With mild use disorder
	F19.229	With moderate or severe use disorder
	F19.929	Without use disorder
292.81		Other (or unknown) substance intoxication delirium
	F19.121	With mild use disorder
	F19.221	With moderate or severe use disorder
	F19.921	Without use disorder
		Other (or unknown) substance use disorder
305.90	F19.10	Mild
304.90	F19.20	Moderate
304.90	F19.20	Severe
292.0	F19.239	Other (or unknown) substance withdrawal
292.0	F19.231	Other (or unknown) substance withdrawal delirium
		Other or unspecified stimulant use disorder
305.70	F15.10	Mild
304.40	F15.20	Moderate
304.40	F15.20	Severe
278.00	E66.9	Overweight or obesity
		Panic attack specifier
300.01	F41.0	Panic disorder
301.0	F60.0	Paranoid personality disorder
V61.20	Z62.820	Parent-child relational problem
302.2	F65.4	Pedophilic disorder
307.22	F95.1	Persistent (chronic) motor or vocal tic disorder
300.4	F34.1	Persistent depressive disorder (dysthymia)
V62.22	Z91.82	Personal history of military deployment
V15.59	Z91.5	Personal history of self-harm
310.1	F07.0	Personality change due to another medical condition
V62.89	Z60.0	Phase of life problem
292.89		Phencyclidine-induced anxiety disorder
	F16.180	With mild use disorder
	F16.280	With moderate or severe use disorder
	F16.980	Without use disorder
292.84		Phencyclidine-induced bipolar and related disorder
	F16.14	With mild use disorder
	F16.24	With moderate or severe use disorder
	F16.94	Without use disorder
292.84		Phencyclidine-induced depressive disorder
	F16.14	With mild use disorder
	F16.24	With moderate or severe use disorder
	F16.94	Without use disorder

ICD-9-CM	ICD-10-CM	Disorder, condition, or problem
292.9		Phencyclidine-induced psychotic disorder
	F16.159	With mild use disorder
	F16.259	With moderate or severe use disorder
	F16.959	Without use disorder
292.89		Phencyclidine intoxication
	F16.129	With mild use disorder
	F16.229	With moderate or severe use disorder
	F16.929	Without use disorder
292.81		Phencyclidine intoxication delirium
	F16.121	With mild use disorder
	F16.221	With moderate or severe use disorder
	F16.921	Without use disorder
		Phencyclidine use disorder
305.90	F16.10	Mild
304.60	F16.20	Moderate
304.60	F16.20	Severe
307.52		Pica
	F50.8	In adults
	F98.3	In children
309.81	F43.10	Posttraumatic stress disorder
302.75	F52.4	Premature (early) ejaculation
625.4	N94.3	Premenstrual dysphoric disorder
V62.21	Z56.82	Problem related to current military deployment status
V69.9	Z72.9	Problem related to lifestyle
V60.3	Z60.2	Problem related to living alone
V60.6	Z59.3	Problem related to living in a residential institution
V61.5	Z64.1	Problems related to multiparity
V62.5	Z65.3	Problems related to other legal circumstances
V62.5	Z65.2	Problems related to release from prison
V61.7	Z64.0	Problems related to unwanted pregnancy
307.21	F95.0	Provisional tic disorder
316	F54	Psychological factors affecting other medical conditions
		Psychotic disorder due to another medical condition
293.81	F06.2	With delusions
293.82	F06.0	With hallucinations
312.33	F63.1	Pyromania
327.42	G47.52	Rapid eye movement sleep behavior disorder
313.89	F94.1	Reactive attachment disorder
V61.10	Z63.0	Relationship distress with spouse or intimate partner
V62.89	Z65.8	Religious or spiritual problem
333.94	G25.81	Restless legs syndrome
307.53	F98.21	Rumination disorder

ICD-9-CM	ICD-10-CM	Disorder, condition, or problem
		Schizoaffective disorder
295.70	F25.0	Bipolar type
295.70	F25.1	Depressive type
301.20	F60.1	Schizoid personality disorder
295.90	F20.9	Schizophrenia
295.40	F20.81	Schizophreniform disorder
301.22	F21	Schizotypal personality disorder
292.89		Sedative-, hypnotic-, or anxiolytic-induced anxiety disorder
	F13.180	With mild use disorder
	F13.280	With moderate or severe use disorder
	F13.980	Without use disorder
292.84		Sedative-, hypnotic-, or anxiolytic-induced bipolar and related disorder
	F13.14	With mild use disorder
	F13.24	With moderate or severe use disorder
	F13.94	Without use disorder
	F13.921	Sedative-, hypnotic-, or anxiolytic-induced delirium
292.84		Sedative-, hypnotic-, or anxiolytic-induced depressive disorder
	F13.14	With mild use disorder
	F13.24	With moderate or severe use disorder
	F13.94	Without use disorder
292.82		Sedative-, hypnotic-, or anxiolytic-induced major neurocognitive disorder
	F13.27	With moderate or severe use disorder
	F13.97	Without use disorder
292.89		Sedative-, hypnotic-, or anxiolytic-induced mild neurocognitive disorder
	F13.288	With moderate or severe use disorder
	F13.988	Without use disorder
292.9		Sedative-, hypnotic-, or anxiolytic-induced psychotic disorder
	F13.159	With mild use disorder
	F13.259	With moderate or severe use disorder
	F13.959	Without use disorder
292.89		Sedative-, hypnotic-, or anxiolytic-induced sexual dysfunction
	F13.181	With mild use disorder
	F13.281	With moderate or severe use disorder
	F13.981	Without use disorder
292.85		Sedative-, hypnotic-, or anxiolytic-induced sleep disorder
	F13.182	With mild use disorder
	F13.282	With moderate or severe use disorder
	F13.982	Without use disorder
292.89		Sedative, hypnotic, or anxiolytic intoxication
	F13.129	With mild use disorder
	F13.229	With moderate or severe use disorder
	F13.929	Without use disorder

ICD-9-CM	ICD-10-CM	Disorder, condition, or problem
292.81		Sedative, hypnotic, or anxiolytic intoxication delirium
	F13.121	With mild use disorder
	F13.221	With moderate or severe use disorder
	F13.921	Without use disorder
		Sedative, hypnotic, or anxiolytic use disorder
305.40	F13.10	Mild
304.10	F13.20	Moderate
304.10	F13.20	Severe
292.0		Sedative, hypnotic, or anxiolytic withdrawal
	F13.232	With perceptual disturbances
	F13.239	Without perceptual disturbances
292.0	F13.231	Sedative, hypnotic, or anxiolytic withdrawal delirium
313.23	F94.0	Selective mutism
309.21	F93.0	Separation anxiety disorder
V65.49	Z70.9	Sex counseling
302.83	F65.51	Sexual masochism disorder
302.84	F65.52	Sexual sadism disorder
V61.8	Z62.891	Sibling relational problem
		Sleep-related hypoventilation
327.26	G47.36	Comorbid sleep-related hypoventilation
327.25	G47.35	Congenital central alveolar hypoventilation
327.24	G47.34	Idiopathic hypoventilation
300.23	F40.10	Social anxiety disorder (social phobia)
V62.4	Z60.4	Social exclusion or rejection
315.39	F80.89	Social (pragmatic) communication disorder
300.82	F45.1	Somatic symptom disorder
		Specific learning disorder
315.1	F81.2	With impairment in mathematics
315.00	F81.0	With impairment in reading
315.2	F81.81	With impairment in written expression
		Specific phobia
300.29	F40.218	Animal
300.29		Blood-injection-injury
	F40.230	Fear of blood
	F40.231	Fear of injections and transfusions
	F40.233	Fear of injury
	F40.232	Fear of other medical care
300.29	F40.228	Natural environment
300.29	F40.298	Other
300.29	F40.248	Situational
315.39	F80.0	Speech sound disorder
		Spouse or partner abuse, Psychological, Confirmed
995.82	T74.31XA	Initial encounter
995.82	T74.31XD	Subsequent encounter

ICD-9-CM	ICD-10-CM	Disorder, condition, or problem
		Spouse or partner abuse, Psychological, Suspected
995.82	T76.31XA	Initial encounter
995.82	T76.31XD	Subsequent encounter
		Spouse or partner neglect, Confirmed
995.85	T74.01XA	Initial encounter
995.85	T74.01XD	Subsequent encounter
		Spouse or partner neglect, Suspected
995.85	T76.01XA	Initial encounter
995.85	T76.01XD	Subsequent encounter
		Spouse or partner violence, Physical, Confirmed
995.81	T74.11XA	Initial encounter
995.81	T74.11XD	Subsequent encounter
		Spouse or partner violence, Physical, Suspected
995.81	T76.11XA	Initial encounter
995.81	T76.11XD	Subsequent encounter
		Spouse or partner violence, Sexual, Confirmed
995.83	T74.21XA	Initial encounter
995.83	T74.21XD	Subsequent encounter
		Spouse or partner violence, Sexual, Suspected
995.83	T76.21XA	Initial encounter
995.83	T76.21XD	Subsequent encounter
307.3	F98.4	Stereotypic movement disorder
		Stimulant intoxication (<i>see amphetamine or cocaine intoxication for specific codes</i>)
		Stimulant use disorder (<i>see amphetamine or cocaine use disorder for specific codes</i>)
		Stimulant withdrawal (<i>see amphetamine or cocaine withdrawal for specific codes</i>)
		Substance intoxication delirium (<i>see specific substances for codes</i>)
		Substance withdrawal delirium (<i>see specific substances for codes</i>)
		Substance/medication-induced anxiety disorder (<i>see specific substances for codes</i>)
		Substance/medication-induced bipolar and related disorder (<i>see specific substances for codes</i>)
		Substance/medication-induced depressive disorder (<i>see specific substances for codes</i>)
		Substance/medication-induced major or mild neurocognitive disorder (<i>see specific substances for codes</i>)
		Substance/medication-induced obsessive-compulsive and related disorder (<i>see specific substances for codes</i>)
		Substance/medication-induced psychotic disorder (<i>see specific substances for codes</i>)
		Substance/medication-induced sexual dysfunction (<i>see specific substances for codes</i>)
		Substance/medication-induced sleep disorder (<i>see specific substances for codes</i>)

ICD-9-CM	ICD-10-CM	Disorder, condition, or problem
333.99	G25.71	Tardive akathisia
333.85	G24.01	Tardive dyskinesia
333.72	G24.09	Tardive dystonia
V62.4	Z60.5	Target of (perceived) adverse discrimination or persecution
292.85		Tobacco-induced sleep disorder
	F17.208	With moderate or severe use disorder
		Tobacco use disorder
305.1	Z72.0	Mild
305.1	F17.200	Moderate
305.1	F17.200	Severe
292.0	F17.203	Tobacco withdrawal
307.23	F95.2	Tourette's disorder
302.3	F65.1	Transvestic disorder
312.39	F63.3	Trichotillomania (hair-pulling disorder)
V63.9	Z75.3	Unavailability or inaccessibility of health care facilities
V63.8	Z75.4	Unavailability or inaccessibility of other helping agencies
V62.82	Z63.4	Uncomplicated bereavement
291.9	F10.99	Unspecified alcohol-related disorder
300.00	F41.9	Unspecified anxiety disorder
314.01	F90.9	Unspecified attention-deficit/hyperactivity disorder
296.80	F31.9	Unspecified bipolar and related disorder
292.9	F15.99	Unspecified caffeine-related disorder
292.9	F12.99	Unspecified cannabis-related disorder
293.89	F06.1	Unspecified catatonia (<i>code first</i> 781.99 [R29.818] other symptoms involving nervous and musculoskeletal systems)
307.9	F80.9	Unspecified communication disorder
780.09	R41.0	Unspecified delirium
311	F32.9	Unspecified depressive disorder
312.9	F91.9	Unspecified disruptive, impulse-control, and conduct disorder
300.15	F44.9	Unspecified dissociative disorder
		Unspecified elimination disorder
787.60	R15.9	With fecal symptoms
788.30	R32	With urinary symptoms
307.50	F50.9	Unspecified feeding or eating disorder
302.6	F64.9	Unspecified gender dysphoria
292.9	F16.99	Unspecified hallucinogen-related disorder
V60.9	Z59.9	Unspecified housing or economic problem
780.54	G47.10	Unspecified hypersomnolence disorder
292.9	F18.99	Unspecified inhalant-related disorder
780.52	G47.00	Unspecified insomnia disorder
319	F79	Unspecified intellectual disability (intellectual developmental disorder)
300.9	F99	Unspecified mental disorder
294.9	F09	Unspecified mental disorder due to another medical condition
799.59	R41.9	Unspecified neurocognitive disorder

ICD-9-CM	ICD-10-CM	Disorder, condition, or problem
315.9	F89	Unspecified neurodevelopmental disorder
300.3	F42	Unspecified obsessive-compulsive and related disorder
292.9	F11.99	Unspecified opioid-related disorder
292.9	F19.99	Unspecified other (or unknown) substance-related disorder
302.9	F65.9	Unspecified paraphilic disorder
301.9	F60.9	Unspecified personality disorder
292.9	F16.99	Unspecified phencyclidine-related disorder
V62.9	Z60.9	Unspecified problem related to social environment
V62.9	Z65.9	Unspecified problem related to unspecified psychosocial circumstances
298.9	F29	Unspecified schizophrenia spectrum and other psychotic disorder
292.9	F13.99	Unspecified sedative-, hypnotic-, or anxiolytic-related disorder
302.70	F52.9	Unspecified sexual dysfunction
780.59	G47.9	Unspecified sleep-wake disorder
300.82	F45.9	Unspecified somatic symptom and related disorder
292.9		Unspecified stimulant-related disorder
	F15.99	Unspecified amphetamine or other stimulant-related disorder
	F14.99	Unspecified cocaine-related disorder
307.20	F95.9	Unspecified tic disorder
292.9	F17.209	Unspecified tobacco-related disorder
309.9	F43.9	Unspecified trauma- and stressor-related disorder
V61.8	Z62.29	Upbringing away from parents
V62.89	Z65.4	Victim of crime
V62.89	Z65.4	Victim of terrorism or torture
302.82	F65.3	Voyeuristic disorder
V40.31	Z91.83	Wandering associated with a mental disorder

Numerical Listing of DSM-5 Diagnoses and Codes (ICD-9-CM)

ICD-9-CM codes are to be used for coding purposes in the United States through
September 30, 2014.

ICD-9-CM	Disorder, condition, or problem
278.00	Overweight or obesity
290.40	Probable major vascular neurocognitive disorder, With behavioral disturbance
290.40	Probable major vascular neurocognitive disorder, Without behavioral disturbance
291.0	Alcohol intoxication delirium
291.0	Alcohol withdrawal delirium
291.1	Alcohol-induced major neurocognitive disorder, Amnestic confabulatory type
291.2	Alcohol-induced major neurocognitive disorder, Nonamnestic confabulatory type
291.81	Alcohol withdrawal
291.82	Alcohol-induced sleep disorder
291.89	Alcohol-induced anxiety disorder
291.89	Alcohol-induced bipolar and related disorder
291.89	Alcohol-induced depressive disorder
291.89	Alcohol-induced mild neurocognitive disorder
291.89	Alcohol-induced sexual dysfunction
291.9	Alcohol-induced psychotic disorder
291.9	Unspecified alcohol-related disorder
292.0	Amphetamine or other stimulant withdrawal
292.0	Caffeine withdrawal
292.0	Cannabis withdrawal
292.0	Cocaine withdrawal
292.0	Opioid withdrawal
292.0	Opioid withdrawal delirium
292.0	Other (or unknown) substance withdrawal
292.0	Other (or unknown) substance withdrawal delirium
292.0	Sedative, hypnotic, or anxiolytic withdrawal
292.0	Sedative, hypnotic, or anxiolytic withdrawal delirium
292.0	Tobacco withdrawal
292.81	Amphetamine (or other stimulant) intoxication delirium
292.81	Cannabis intoxication delirium
292.81	Cocaine intoxication delirium

ICD-9-CM	Disorder, condition, or problem
292.81	Inhalant intoxication delirium
292.81	Medication-induced delirium
292.81	Opioid intoxication delirium
292.81	Other hallucinogen intoxication delirium
292.81	Other (or unknown) substance intoxication delirium
292.81	Phencyclidine intoxication delirium
292.81	Sedative, hypnotic, or anxiolytic intoxication delirium
292.82	Inhalant-induced major neurocognitive disorder
292.82	Other (or unknown) substance-induced major neurocognitive disorder
292.82	Sedative-, hypnotic-, or anxiolytic-induced major neurocognitive disorder
292.84	Amphetamine (or other stimulant)-induced bipolar and related disorder
292.84	Amphetamine (or other stimulant)-induced depressive disorder
292.84	Cocaine-induced bipolar and related disorder
292.84	Cocaine-induced depressive disorder
292.84	Inhalant-induced depressive disorder
292.84	Opioid-induced depressive disorder
292.84	Other hallucinogen-induced bipolar and related disorder
292.84	Other hallucinogen-induced depressive disorder
292.84	Other (or unknown) substance-induced bipolar and related disorder
292.84	Other (or unknown) substance-induced depressive disorder
292.84	Phencyclidine-induced bipolar and related disorder
292.84	Phencyclidine-induced depressive disorder
292.84	Sedative-, hypnotic-, or anxiolytic-induced bipolar and related disorder
292.84	Sedative-, hypnotic-, or anxiolytic-induced depressive disorder
292.85	Amphetamine (or other stimulant)-induced sleep disorder
292.85	Caffeine-induced sleep disorder
292.85	Cannabis-induced sleep disorder
292.85	Cocaine-induced sleep disorder
292.85	Opioid-induced sleep disorder
292.85	Other (or unknown) substance-induced sleep disorder
292.85	Sedative-, hypnotic-, or anxiolytic-induced sleep disorder
292.85	Tobacco-induced sleep disorder
292.89	Amphetamine (or other stimulant)-induced anxiety disorder
292.89	Amphetamine (or other stimulant)-induced obsessive-compulsive and related disorder
292.89	Amphetamine (or other stimulant)-induced sexual dysfunction
292.89	Amphetamine or other stimulant intoxication
292.89	Caffeine-induced anxiety disorder
292.89	Cannabis-induced anxiety disorder
292.89	Cannabis intoxication
292.89	Cocaine-induced anxiety disorder
292.89	Cocaine-induced obsessive-compulsive and related disorder
292.89	Cocaine-induced sexual dysfunction
292.89	Cocaine intoxication
292.89	Hallucinogen persisting perception disorder

ICD-9-CM	Disorder, condition, or problem
292.89	Inhalant-induced anxiety disorder
292.89	Inhalant-induced mild neurocognitive disorder
292.89	Inhalant intoxication
292.89	Opioid-induced anxiety disorder
292.89	Opioid-induced sexual dysfunction
292.89	Opioid intoxication
292.89	Other hallucinogen-induced anxiety disorder
292.89	Other hallucinogen intoxication
292.89	Other (or unknown) substance-induced anxiety disorder
292.89	Other (or unknown) substance-induced mild neurocognitive disorder
292.89	Other (or unknown) substance-induced obsessive-compulsive and related disorder
292.89	Other (or unknown) substance-induced sexual dysfunction
292.89	Other (or unknown) substance intoxication
292.89	Phencyclidine-induced anxiety disorder
292.89	Phencyclidine intoxication
292.89	Sedative-, hypnotic-, or anxiolytic-induced anxiety disorder
292.89	Sedative-, hypnotic-, or anxiolytic-induced mild neurocognitive disorder
292.89	Sedative-, hypnotic-, or anxiolytic-induced sexual dysfunction
292.89	Sedative, hypnotic, or anxiolytic intoxication
292.9	Amphetamine (or other stimulant)-induced psychotic disorder
292.9	Cannabis-induced psychotic disorder
292.9	Cocaine-induced psychotic disorder
292.9	Inhalant-induced psychotic disorder
292.9	Other hallucinogen-induced psychotic disorder
292.9	Other (or unknown) substance-induced psychotic disorder
292.9	Phencyclidine-induced psychotic disorder
292.9	Sedative-, hypnotic-, or anxiolytic-induced psychotic disorder
292.9	Unspecified caffeine-related disorder
292.9	Unspecified cannabis-related disorder
292.9	Unspecified hallucinogen-related disorder
292.9	Unspecified inhalant-related disorder
292.9	Unspecified opioid-related disorder
292.9	Unspecified other (or unknown) substance-related disorder
292.9	Unspecified phencyclidine-related disorder
292.9	Unspecified sedative-, hypnotic-, or anxiolytic-related disorder
292.9	Unspecified stimulant-related disorder
292.9	Unspecified tobacco-related disorder
293.0	Delirium due to another medical condition
293.0	Delirium due to multiple etiologies
293.81	Psychotic disorder due to another medical condition, With delusions
293.82	Psychotic disorder due to another medical condition, With hallucinations
293.83	Bipolar and related disorder due to another medical condition
293.83	Depressive disorder due to another medical condition
293.84	Anxiety disorder due to another medical condition
293.89	Catatonia associated with another mental disorder (catatonia specifier)

ICD-9-CM	Disorder, condition, or problem
293.89	Catatonic disorder due to another medical condition
293.89	Unspecified catatonia (<i>code first</i> 781.99 other symptoms involving nervous and musculoskeletal systems)
294.10	Major neurocognitive disorder due to another medical condition, Without behavioral disturbance
294.10	Major neurocognitive disorder due to HIV infection, Without behavioral disturbance (<i>code first</i> 042 HIV infection)
294.10	Major neurocognitive disorder due to Huntington's disease, Without behavioral disturbance (<i>code first</i> 333.4 Huntington's disease)
294.10	Major neurocognitive disorder due to multiple etiologies, Without behavioral disturbance
294.10	Major neurocognitive disorder probably due to Parkinson's disease, Without behavioral disturbance (<i>code first</i> 332.0 Parkinson's disease)
294.10	Major neurocognitive disorder due to prion disease, Without behavioral disturbance (<i>code first</i> 046.79 prion disease)
294.10	Major neurocognitive disorder due to traumatic brain injury, Without behavioral disturbance (<i>code first</i> 907.0 late effect of intracranial injury without skull fracture)
294.10	Probable major frontotemporal neurocognitive disorder, Without behavioral disturbance (<i>code first</i> 331.19 frontotemporal disease)
294.10	Probable major neurocognitive disorder due to Alzheimer's disease, Without behavioral disturbance (<i>code first</i> 331.0 Alzheimer's disease)
294.10	Probable major neurocognitive disorder with Lewy bodies, Without behavioral disturbance (<i>code first</i> 331.82 Lewy body disease)
294.11	Major neurocognitive disorder due to another medical condition, With behavioral disturbance
294.11	Major neurocognitive disorder due to HIV infection, With behavioral disturbance (<i>code first</i> 042 HIV infection)
294.11	Major neurocognitive disorder due to Huntington's disease, With behavioral disturbance (<i>code first</i> 333.4 Huntington's disease)
294.11	Major neurocognitive disorder due to multiple etiologies, With behavioral disturbance
294.11	Major neurocognitive disorder probably due to Parkinson's disease, With behavioral disturbance (<i>code first</i> 332.0 Parkinson's disease)
294.11	Major neurocognitive disorder due to prion disease, With behavioral disturbance (<i>code first</i> 046.79 prion disease)
294.11	Major neurocognitive disorder due to traumatic brain injury, With behavioral disturbance (<i>code first</i> 907.0 late effect of intracranial injury without skull fracture)
294.11	Probable major frontotemporal neurocognitive disorder, With behavioral disturbance (<i>code first</i> 331.19 frontotemporal disease)
294.11	Probable major neurocognitive disorder due to Alzheimer's disease, With behavioral disturbance (<i>code first</i> 331.0 Alzheimer's disease)
294.11	Probable major neurocognitive disorder with Lewy bodies, With behavioral disturbance (<i>code first</i> 331.82 Lewy body disease)
294.8	Obsessive-compulsive and related disorder due to another medical condition
294.8	Other specified mental disorder due to another medical condition
294.9	Unspecified mental disorder due to another medical condition

ICD-9-CM	Disorder, condition, or problem
295.40	Schizophreniform disorder
295.70	Schizoaffective disorder, Bipolar type
295.70	Schizoaffective disorder, Depressive type
295.90	Schizophrenia
296.20	Major depressive disorder, Single episode, Unspecified
296.21	Major depressive disorder, Single episode, Mild
296.22	Major depressive disorder, Single episode, Moderate
296.23	Major depressive disorder, Single episode, Severe
296.24	Major depressive disorder, Single episode, With psychotic features
296.25	Major depressive disorder, Single episode, In partial remission
296.26	Major depressive disorder, Single episode, In full remission
296.30	Major depressive disorder, Recurrent episode, Unspecified
296.31	Major depressive disorder, Recurrent episode, Mild
296.32	Major depressive disorder, Recurrent episode, Moderate
296.33	Major depressive disorder, Recurrent episode, Severe
296.34	Major depressive disorder, Recurrent episode, With psychotic features
296.35	Major depressive disorder, Recurrent episode, In partial remission
296.36	Major depressive disorder, Recurrent episode, In full remission
296.40	Bipolar I disorder, Current or most recent episode hypomanic
296.40	Bipolar I disorder, Current or most recent episode hypomanic, Unspecified
296.40	Bipolar I disorder, Current or most recent episode manic, Unspecified
296.41	Bipolar I disorder, Current or most recent episode manic, Mild
296.42	Bipolar I disorder, Current or most recent episode manic, Moderate
296.43	Bipolar I disorder, Current or most recent episode manic, Severe
296.44	Bipolar I disorder, Current or most recent episode manic, With psychotic features
296.45	Bipolar I disorder, Current or most recent episode hypomanic, In partial remission
296.45	Bipolar I disorder, Current or most recent episode manic, In partial remission
296.46	Bipolar I disorder, Current or most recent episode hypomanic, In full remission
296.46	Bipolar I disorder, Current or most recent episode manic, In full remission
296.50	Bipolar I disorder, Current or most recent episode depressed, Unspecified
296.51	Bipolar I disorder, Current or most recent episode depressed, Mild
296.52	Bipolar I disorder, Current or most recent episode depressed, Moderate
296.53	Bipolar I disorder, Current or most recent episode depressed, Severe
296.54	Bipolar I disorder, Current or most recent episode depressed, With psychotic features
296.55	Bipolar I disorder, Current or most recent episode depressed, In partial remission
296.56	Bipolar I disorder, Current or most recent episode depressed, In full remission
296.7	Bipolar I disorder, Current or most recent episode unspecified
296.80	Unspecified bipolar and related disorder
296.89	Bipolar II disorder
296.89	Other specified bipolar and related disorder
296.99	Disruptive mood dysregulation disorder
297.1	Delusional disorder
298.8	Brief psychotic disorder
298.8	Other specified schizophrenia spectrum and other psychotic disorder

ICD-9-CM	Disorder, condition, or problem
298.9	Unspecified schizophrenia spectrum and other psychotic disorder
299.00	Autism spectrum disorder
300.00	Unspecified anxiety disorder
300.01	Panic disorder
300.02	Generalized anxiety disorder
300.09	Other specified anxiety disorder
300.11	Conversion disorder (functional neurological symptom disorder)
300.12	Dissociative amnesia
300.13	Dissociative amnesia, With dissociative fugue
300.14	Dissociative identity disorder
300.15	Other specified dissociative disorder
300.15	Unspecified dissociative disorder
300.19	Factitious disorder
300.22	Agoraphobia
300.23	Social anxiety disorder (social phobia)
300.29	Specific phobia, Animal
300.29	Specific phobia, Blood-injection-injury
300.29	Specific phobia, Natural environment
300.29	Specific phobia, Other
300.29	Specific phobia, Situational
300.3	Hoarding disorder
300.3	Obsessive-compulsive disorder
300.3	Other specified obsessive-compulsive and related disorder
300.3	Unspecified obsessive-compulsive and related disorder
300.4	Persistent depressive disorder (dysthymia)
300.6	Depersonalization/derealization disorder
300.7	Body dysmorphic disorder
300.7	Illness anxiety disorder
300.82	Somatic symptom disorder
300.82	Unspecified somatic symptom and related disorder
300.89	Other specified somatic symptom and related disorder
300.9	Other specified mental disorder
300.9	Unspecified mental disorder
301.0	Paranoid personality disorder
301.13	Cyclothymic disorder
301.20	Schizoid personality disorder
301.22	Schizotypal personality disorder
301.4	Obsessive-compulsive personality disorder
301.50	Histrionic personality disorder
301.6	Dependent personality disorder
301.7	Antisocial personality disorder
301.81	Narcissistic personality disorder
301.82	Avoidant personality disorder
301.83	Borderline personality disorder
301.89	Other specified personality disorder

ICD-9-CM	Disorder, condition, or problem
301.9	Unspecified personality disorder
302.2	Pedophilic disorder
302.3	Transvestic disorder
302.4	Exhibitionistic disorder
302.6	Gender dysphoria in children
302.6	Other specified gender dysphoria
302.6	Unspecified gender dysphoria
302.70	Unspecified sexual dysfunction
302.71	Male hypoactive sexual desire disorder
302.72	Erectile disorder
302.72	Female sexual interest/arousal disorder
302.73	Female orgasmic disorder
302.74	Delayed ejaculation
302.75	Premature (early) ejaculation
302.76	Genito-pelvic pain/penetration disorder
302.79	Other specified sexual dysfunction
302.81	Fetishistic disorder
302.82	Voyeuristic disorder
302.83	Sexual masochism disorder
302.84	Sexual sadism disorder
302.85	Gender dysphoria in adolescents and adults
302.89	Frotteuristic disorder
302.89	Other specified paraphilic disorder
302.9	Unspecified paraphilic disorder
303.00	Alcohol intoxication
303.90	Alcohol use disorder, Moderate
303.90	Alcohol use disorder, Severe
304.00	Opioid use disorder, Moderate
304.00	Opioid use disorder, Severe
304.10	Sedative, hypnotic, or anxiolytic use disorder, Moderate
304.10	Sedative, hypnotic, or anxiolytic use disorder, Severe
304.20	Cocaine use disorder, Moderate
304.20	Cocaine use disorder, Severe
304.30	Cannabis use disorder, Moderate
304.30	Cannabis use disorder, Severe
304.40	Amphetamine-type substance use disorder, Moderate
304.40	Amphetamine-type substance use disorder, Severe
304.40	Other or unspecified stimulant use disorder, Moderate
304.40	Other or unspecified stimulant use disorder, Severe
304.50	Other hallucinogen use disorder, Moderate
304.50	Other hallucinogen use disorder, Severe
304.60	Inhalant use disorder, Moderate
304.60	Inhalant use disorder, Severe
304.60	Phencyclidine use disorder, Moderate
304.60	Phencyclidine use disorder, Severe

ICD-9-CM	Disorder, condition, or problem
304.90	Other (or unknown) substance use disorder, Moderate
304.90	Other (or unknown) substance use disorder, Severe
305.00	Alcohol use disorder, Mild
305.1	Tobacco use disorder, Mild
305.1	Tobacco use disorder, Moderate
305.1	Tobacco use disorder, Severe
305.20	Cannabis use disorder, Mild
305.30	Other hallucinogen use disorder, Mild
305.40	Sedative, hypnotic, or anxiolytic use disorder, Mild
305.50	Opioid use disorder, Mild
305.60	Cocaine use disorder, Mild
305.70	Amphetamine-type substance use disorder, Mild
305.70	Other or unspecified stimulant use disorder, Mild
305.90	Caffeine intoxication
305.90	Inhalant use disorder, Mild
305.90	Other (or unknown) substance use disorder, Mild
305.90	Phencyclidine use disorder, Mild
307.0	Adult-onset fluency disorder
307.1	Anorexia nervosa
307.20	Other specified tic disorder
307.20	Unspecified tic disorder
307.21	Provisional tic disorder
307.22	Persistent (chronic) motor or vocal tic disorder
307.23	Tourette's disorder
307.3	Stereotypic movement disorder
307.42	Insomnia disorder
307.44	Hypersomnolence disorder
307.45	Circadian rhythm sleep-wake disorders, Advanced sleep phase type
307.45	Circadian rhythm sleep-wake disorders, Delayed sleep phase type
307.45	Circadian rhythm sleep-wake disorders, Irregular sleep-wake type
307.45	Circadian rhythm sleep-wake disorders, Non-24-hour sleep-wake type
307.45	Circadian rhythm sleep-wake disorders, Shift work type
307.45	Circadian rhythm sleep-wake disorders, Unspecified type
307.46	Non-rapid eye movement sleep arousal disorders, Sleep terror type
307.46	Non-rapid eye movement sleep arousal disorders, Sleepwalking type
307.47	Nightmare disorder
307.50	Unspecified feeding or eating disorder
307.51	Binge-eating disorder
307.51	Bulimia nervosa
307.52	Pica
307.53	Rumination disorder
307.59	Avoidant/restrictive food intake disorder
307.59	Other specified feeding or eating disorder
307.6	Enuresis
307.7	Encopresis
307.9	Unspecified communication disorder

ICD-9-CM	Disorder, condition, or problem
308.3	Acute stress disorder
309.0	Adjustment disorders, With depressed mood
309.21	Separation anxiety disorder
309.24	Adjustment disorders, With anxiety
309.28	Adjustment disorders, With mixed anxiety and depressed mood
309.3	Adjustment disorders, With disturbance of conduct
309.4	Adjustment disorders, With mixed disturbance of emotions and conduct
309.81	Posttraumatic stress disorder
309.89	Other specified trauma- and stressor-related disorder
309.9	Adjustment disorders, Unspecified
309.9	Unspecified trauma- and stressor-related disorder
310.1	Personality change due to another medical condition
311	Other specified depressive disorder
311	Unspecified depressive disorder
312.31	Gambling disorder
312.32	Kleptomania
312.33	Pyromania
312.34	Intermittent explosive disorder
312.39	Trichotillomania (hair-pulling disorder)
312.81	Conduct disorder, Childhood-onset type
312.82	Conduct disorder, Adolescent-onset type
312.89	Conduct disorder, Unspecified onset
312.89	Other specified disruptive, impulse-control, and conduct disorder
312.9	Unspecified disruptive, impulse-control, and conduct disorder
313.23	Selective mutism
313.81	Oppositional defiant disorder
313.89	Disinhibited social engagement disorder
313.89	Reactive attachment disorder
314.00	Attention-deficit/hyperactivity disorder, Predominantly inattentive presentation
314.01	Attention-deficit/hyperactivity disorder, Combined presentation
314.01	Attention-deficit/hyperactivity disorder, Predominantly hyperactive/impulsive presentation
314.01	Other specified attention-deficit/hyperactivity disorder
314.01	Unspecified attention-deficit/hyperactivity disorder
315.00	Specific learning disorder, With impairment in reading
315.1	Specific learning disorder, With impairment in mathematics
315.2	Specific learning disorder, With impairment in written expression
315.32	Language disorder
315.35	Childhood-onset fluency disorder (stuttering)
315.39	Social (pragmatic) communication disorder
315.39	Speech sound disorder
315.4	Developmental coordination disorder
315.8	Global developmental delay
315.8	Other specified neurodevelopmental disorder
315.9	Unspecified neurodevelopmental disorder
316	Psychological factors affecting other medical conditions

ICD-9-CM	Disorder, condition, or problem
317	Intellectual disability (intellectual developmental disorder), Mild
318.0	Intellectual disability (intellectual developmental disorder), Moderate
318.1	Intellectual disability (intellectual developmental disorder), Severe
318.2	Intellectual disability (intellectual developmental disorder), Profound
319	Unspecified intellectual disability (intellectual developmental disorder)
327.21	Central sleep apnea, Idiopathic central sleep apnea
327.23	Obstructive sleep apnea hypopnea
327.24	Sleep-related hypoventilation, Idiopathic hypoventilation
327.25	Sleep-related hypoventilation, Congenital central alveolar hypoventilation
327.26	Sleep-related hypoventilation, Comorbid sleep-related hypoventilation
327.42	Rapid eye movement sleep behavior disorder
331.83	Mild frontotemporal neurocognitive disorder
331.83	Mild neurocognitive disorder due to Alzheimer's disease
331.83	Mild neurocognitive disorder due to another medical condition
331.83	Mild neurocognitive disorder due to HIV infection
331.83	Mild neurocognitive disorder due to Huntington's disease
331.83	Mild neurocognitive disorder with Lewy bodies
331.83	Mild neurocognitive disorder due to multiple etiologies
331.83	Mild neurocognitive disorder due to Parkinson's disease
331.83	Mild neurocognitive disorder due to prion disease
331.83	Mild neurocognitive disorder due to traumatic brain injury
331.83	Mild vascular neurocognitive disorder
331.9	Major neurocognitive disorder possibly due to Parkinson's disease
331.9	Possible major frontotemporal neurocognitive disorder
331.9	Possible major neurocognitive disorder due to Alzheimer's disease
331.9	Possible major neurocognitive disorder with Lewy bodies
331.9	Possible major vascular neurocognitive disorder
333.1	Medication-induced postural tremor
332.1	Neuroleptic-induced parkinsonism
332.1	Other medication-induced parkinsonism
333.72	Medication-induced acute dystonia
333.72	Tardive dystonia
333.85	Tardive dyskinesia
333.92	Neuroleptic malignant syndrome
333.94	Restless legs syndrome
333.99	Medication-induced acute akathisia
333.99	Other medication-induced movement disorder
333.99	Tardive akathisia
347.00	Autosomal dominant cerebellar ataxia, deafness, and narcolepsy
347.00	Autosomal dominant narcolepsy, obesity, and type 2 diabetes
347.00	Narcolepsy without cataplexy but with hypocretin deficiency
347.01	Narcolepsy with cataplexy but without hypocretin deficiency
347.10	Narcolepsy secondary to another medical condition
625.4	Premenstrual dysphoric disorder
698.4	Excoriation (skin-picking) disorder

ICD-9-CM	Disorder, condition, or problem
780.09	Other specified delirium
780.09	Unspecified delirium
780.52	Other specified insomnia disorder
780.52	Unspecified insomnia disorder
780.54	Other specified hypersomnolence disorder
780.54	Unspecified hypersomnolence disorder
780.57	Central sleep apnea, Central sleep apnea comorbid with opioid use
780.59	Other specified sleep-wake disorder
780.59	Unspecified sleep-wake disorder
786.04	Central sleep apnea, Cheyne-Stokes breathing
787.60	Other specified elimination disorder, With fecal symptoms
787.60	Unspecified elimination disorder, With fecal symptoms
788.30	Unspecified elimination disorder, With urinary symptoms
788.39	Other specified elimination disorder, With urinary symptoms
799.59	Unspecified neurocognitive disorder
995.20	Other adverse effect of medication, Initial encounter
995.20	Other adverse effect of medication, Sequelae
995.20	Other adverse effect of medication, Subsequent encounter
995.29	Antidepressant discontinuation syndrome, Initial encounter
995.29	Antidepressant discontinuation syndrome, Sequelae
995.29	Antidepressant discontinuation syndrome, Subsequent encounter
995.51	Child psychological abuse, Confirmed, Initial encounter
995.51	Child psychological abuse, Confirmed, Subsequent encounter
995.51	Child psychological abuse, Suspected, Initial encounter
995.51	Child psychological abuse, Suspected, Subsequent encounter
995.52	Child neglect, Confirmed, Initial encounter
995.52	Child neglect, Confirmed, Subsequent encounter
995.52	Child neglect, Suspected, Initial encounter
995.52	Child neglect, Suspected, Subsequent encounter
995.53	Child sexual abuse, Confirmed, Initial encounter
995.53	Child sexual abuse, Confirmed, Subsequent encounter
995.53	Child sexual abuse, Suspected, Initial encounter
995.53	Child sexual abuse, Suspected, Subsequent encounter
995.54	Child physical abuse, Confirmed, Initial encounter
995.54	Child physical abuse, Confirmed, Subsequent encounter
995.54	Child physical abuse, Suspected, Initial encounter
995.54	Child physical abuse, Suspected, Subsequent encounter
995.81	Adult physical abuse by nonspouse or nonpartner, Confirmed, Initial encounter
995.81	Adult physical abuse by nonspouse or nonpartner, Confirmed, Subsequent encounter
995.81	Adult physical abuse by nonspouse or nonpartner, Suspected, Initial encounter
995.81	Adult physical abuse by nonspouse or nonpartner, Suspected, Subsequent encounter

ICD-9-CM	Disorder, condition, or problem
995.81	Spouse or partner violence, Physical, Confirmed, Initial encounter
995.81	Spouse or partner violence, Physical, Confirmed, Subsequent encounter
995.81	Spouse or partner violence, Physical, Suspected, Initial encounter
995.81	Spouse or partner violence, Physical, Suspected, Subsequent encounter
995.82	Adult psychological abuse by nonspouse or nonpartner, Confirmed, Initial encounter
995.82	Adult psychological abuse by nonspouse or nonpartner, Confirmed, Subsequent encounter
995.82	Adult psychological abuse by nonspouse or nonpartner, Suspected, Initial encounter
995.82	Adult psychological abuse by nonspouse or nonpartner, Suspected, Subsequent encounter
995.82	Spouse or partner abuse, Psychological, Confirmed, Initial encounter
995.82	Spouse or partner abuse, Psychological, Confirmed, Subsequent encounter
995.82	Spouse or partner abuse, Psychological, Suspected, Initial encounter
995.82	Spouse or partner abuse, Psychological, Suspected, Subsequent encounter
995.83	Adult sexual abuse by nonspouse or nonpartner, Confirmed, Initial encounter
995.83	Adult sexual abuse by nonspouse or nonpartner, Confirmed, Subsequent encounter
995.83	Adult sexual abuse by nonspouse or nonpartner, Suspected, Initial encounter
995.83	Adult sexual abuse by nonspouse or nonpartner, Suspected, Subsequent encounter
995.83	Spouse or partner violence, Sexual, Confirmed, Initial encounter
995.83	Spouse or partner violence, Sexual, Confirmed, Subsequent encounter
995.83	Spouse or partner violence, Sexual, Suspected, Initial encounter
995.83	Spouse or partner violence, Sexual, Suspected, Subsequent encounter
995.85	Spouse or partner neglect, Confirmed, Initial encounter
995.85	Spouse or partner neglect, Confirmed, Subsequent encounter
995.85	Spouse or partner neglect, Suspected, Initial encounter
995.85	Spouse or partner neglect, Suspected, Subsequent encounter
V15.41	Personal history (past history) of physical abuse in childhood
V15.41	Personal history (past history) of sexual abuse in childhood
V15.41	Personal history (past history) of spouse or partner violence, Physical
V15.41	Personal history (past history) of spouse or partner violence, Sexual
V15.42	Personal history (past history) of neglect in childhood
V15.42	Personal history (past history) of psychological abuse in childhood
V15.42	Personal history (past history) of spouse or partner neglect
V15.42	Personal history (past history) of spouse or partner psychological abuse
V15.49	Other personal history of psychological trauma
V15.59	Personal history of self-harm
V15.81	Nonadherence to medical treatment
V15.89	Other personal risk factors
V40.31	Wandering associated with a mental disorder
V60.0	Homelessness
V60.1	Inadequate housing
V60.2	Extreme poverty

ICD-9-CM	Disorder, condition, or problem
V60.2	Insufficient social insurance or welfare support
V60.2	Lack of adequate food or safe drinking water
V60.2	Low income
V60.3	Problem related to living alone
V60.6	Problem related to living in a residential institution
V60.89	Discord with neighbor, lodger, or landlord
V60.9	Unspecified housing or economic problem
V61.03	Disruption of family by separation or divorce
V61.10	Relationship distress with spouse or intimate partner
V61.11	Encounter for mental health services for victim of spouse or partner neglect
V61.11	Encounter for mental health services for victim of spouse or partner psychological abuse
V61.11	Encounter for mental health services for victim of spouse or partner violence, Physical
V61.11	Encounter for mental health services for victim of spouse or partner violence, Sexual
V61.12	Encounter for mental health services for perpetrator of spouse or partner neglect
V61.12	Encounter for mental health services for perpetrator of spouse or partner psychological abuse
V61.12	Encounter for mental health services for perpetrator of spouse or partner violence, Physical
V61.12	Encounter for mental health services for perpetrator of spouse or partner violence, Sexual
V61.20	Parent-child relational problem
V61.21	Encounter for mental health services for victim of child abuse by parent
V61.21	Encounter for mental health services for victim of child neglect by parent
V61.21	Encounter for mental health services for victim of child psychological abuse by parent
V61.21	Encounter for mental health services for victim of child sexual abuse by parent
V61.21	Encounter for mental health services for victim of nonparental child abuse
V61.21	Encounter for mental health services for victim of nonparental child neglect
V61.21	Encounter for mental health services for victim of nonparental child psychological abuse
V61.21	Encounter for mental health services for victim of nonparental child sexual abuse
V61.22	Encounter for mental health services for perpetrator of parental child abuse
V61.22	Encounter for mental health services for perpetrator of parental child neglect
V61.22	Encounter for mental health services for perpetrator of parental child psychological abuse
V61.22	Encounter for mental health services for perpetrator of parental child sexual abuse
V61.29	Child affected by parental relationship distress
V61.5	Problems related to multiparity
V61.7	Problems related to unwanted pregnancy
V61.8	High expressed emotion level within family
V61.8	Sibling relational problem

ICD-9-CM	Disorder, condition, or problem
V61.8	Upbringing away from parents
V62.21	Problem related to current military deployment status
V62.22	Exposure to disaster, war, or other hostilities
V62.22	Personal history of military deployment
V62.29	Other problem related to employment
V62.3	Academic or educational problem
V62.4	Acculturation difficulty
V62.4	Social exclusion or rejection
V62.4	Target of (perceived) adverse discrimination or persecution
V62.5	Conviction in civil or criminal proceedings without imprisonment
V62.5	Imprisonment or other incarceration
V62.5	Problems related to other legal circumstances
V62.5	Problems related to release from prison
V62.82	Uncomplicated bereavement
V62.83	Encounter for mental health services for perpetrator of nonparental child abuse
V62.83	Encounter for mental health services for perpetrator of nonparental child neglect
V62.83	Encounter for mental health services for perpetrator of nonparental child psychological abuse
V62.83	Encounter for mental health services for perpetrator of nonparental child sexual abuse
V62.83	Encounter for mental health services for perpetrator of nonspousal adult abuse
V62.89	Borderline intellectual functioning
V62.89	Discord with social service provider, including probation officer, case manager, or social services worker
V62.89	Other problem related to psychosocial circumstances
V62.89	Phase of life problem
V62.89	Religious or spiritual problem
V62.89	Victim of crime
V62.89	Victim of terrorism or torture
V62.9	Unspecified problem related to social environment
V62.9	Unspecified problem related to unspecified psychosocial circumstances
V63.8	Unavailability or inaccessibility of other helping agencies
V63.9	Unavailability or inaccessibility of health care facilities
V65.2	Malingering
V65.40	Other counseling or consultation
V65.49	Encounter for mental health services for victim of nonspousal adult abuse
V65.49	Sex counseling
V69.9	Problem related to lifestyle
V71.01	Adult antisocial behavior
V71.02	Child or adolescent antisocial behavior

Numerical Listing of DSM-5 Diagnoses and Codes (ICD-10-CM)

ICD-10-CM codes are to be used for coding purposes in the United States starting October 1, 2014.

ICD-10-CM	Disorder, condition, or problem
E66.9	Overweight or obesity
F01.50	Probable major vascular neurocognitive disorder, Without behavioral disturbance
F01.51	Probable major vascular neurocognitive disorder, With behavioral disturbance
F02.80	Major neurocognitive disorder due to another medical condition, Without behavioral disturbance
F02.80	Major neurocognitive disorder due to HIV infection, Without behavioral disturbance (<i>code first</i> B20 HIV infection)
F02.80	Major neurocognitive disorder due to Huntington's disease, Without behavioral disturbance (<i>code first</i> G10 Huntington's disease)
F02.80	Major neurocognitive disorder due to multiple etiologies, Without behavioral disturbance
F02.80	Major neurocognitive disorder probably due to Parkinson's disease, Without behavioral disturbance (<i>code first</i> G20 Parkinson's disease)
F02.80	Major neurocognitive disorder due to prion disease, Without behavioral disturbance (<i>code first</i> A81.9 prion disease)
F02.80	Major neurocognitive disorder due to traumatic brain injury, Without behavioral disturbance (<i>code first</i> S06.2X9S diffuse traumatic brain injury with loss of consciousness of unspecified duration, sequela)
F02.80	Probable major frontotemporal neurocognitive disorder, Without behavioral disturbance (<i>code first</i> G31.09 frontotemporal disease)
F02.80	Probable major neurocognitive disorder due to Alzheimer's disease, Without behavioral disturbance (<i>code first</i> G30.9 Alzheimer's disease)
F02.80	Probable major neurocognitive disorder with Lewy bodies, Without behavioral disturbance (<i>code first</i> G31.83 Lewy body disease)
F02.81	Major neurocognitive disorder due to another medical condition, With behavioral disturbance
F02.81	Major neurocognitive disorder due to HIV infection, With behavioral disturbance (<i>code first</i> B20 HIV infection)
F02.81	Major neurocognitive disorder due to Huntington's disease, With behavioral disturbance (<i>code first</i> G10 Huntington's disease)
F02.81	Major neurocognitive disorder due to multiple etiologies, With behavioral disturbance

ICD-10-CM	Disorder, condition, or problem
F02.81	Major neurocognitive disorder probably due to Parkinson's disease, With behavioral disturbance (<i>code first</i> G20 Parkinson's disease)
F02.81	Major neurocognitive disorder due to prion disease, With behavioral disturbance (<i>code first</i> A81.9 prion disease)
F02.81	Major neurocognitive disorder due to traumatic brain injury, With behavioral disturbance (<i>code first</i> S06.2X9S diffuse traumatic brain injury with loss of consciousness of unspecified duration, sequela)
F02.81	Probable major frontotemporal neurocognitive disorder, With behavioral disturbance (<i>code first</i> G31.09 frontotemporal disease)
F02.81	Probable major neurocognitive disorder due to Alzheimer's disease, With behavioral disturbance (<i>code first</i> G30.9 Alzheimer's disease)
F02.81	Probable major neurocognitive disorder with Lewy bodies, With behavioral disturbance (<i>code first</i> G31.83 Lewy body disease)
F05	Delirium due to another medical condition
F05	Delirium due to multiple etiologies
F06.0	Psychotic disorder due to another medical condition, With hallucinations
F06.1	Catatonia associated with another mental disorder (catatonia specifier)
F06.1	Catatonic disorder due to another medical condition
F06.1	Unspecified catatonia (<i>code first</i> R29.818 other symptoms involving nervous and musculoskeletal systems)
F06.2	Psychotic disorder due to another medical condition, With delusions
F06.31	Depressive disorder due to another medical condition, With depressive features
F06.32	Depressive disorder due to another medical condition, With major depressive-like episode
F06.33	Bipolar and related disorder due to another medical condition, With manic features
F06.33	Bipolar and related disorder due to another medical condition, With manic- or hypomanic-like episodes
F06.34	Bipolar and related disorder due to another medical condition, With mixed features
F06.34	Depressive disorder due to another medical condition, With mixed features
F06.4	Anxiety disorder due to another medical condition
F06.8	Obsessive-compulsive and related disorder due to another medical condition
F06.8	Other specified mental disorder due to another medical condition
F07.0	Personality change due to another medical condition
F09	Unspecified mental disorder due to another medical condition
F10.10	Alcohol use disorder, Mild
F10.121	Alcohol intoxication delirium, With mild use disorder
F10.129	Alcohol intoxication, With mild use disorder
F10.14	Alcohol-induced bipolar and related disorder, With mild use disorder
F10.14	Alcohol-induced depressive disorder, With mild use disorder
F10.159	Alcohol-induced psychotic disorder, With mild use disorder
F10.180	Alcohol-induced anxiety disorder, With mild use disorder
F10.181	Alcohol-induced sexual dysfunction, With mild use disorder
F10.182	Alcohol-induced sleep disorder, With mild use disorder
F10.20	Alcohol use disorder, Moderate
F10.20	Alcohol use disorder, Severe
F10.221	Alcohol intoxication delirium, With moderate or severe use disorder

ICD-10-CM	Disorder, condition, or problem
F10.229	Alcohol intoxication, With moderate or severe use disorder
F10.231	Alcohol withdrawal delirium
F10.232	Alcohol withdrawal, With perceptual disturbances
F10.239	Alcohol withdrawal, Without perceptual disturbances
F10.24	Alcohol-induced bipolar and related disorder, With moderate or severe use disorder
F10.24	Alcohol-induced depressive disorder, With moderate or severe use disorder
F10.259	Alcohol-induced psychotic disorder, With moderate or severe use disorder
F10.26	Alcohol-induced major neurocognitive disorder, Amnestic confabulatory type, With moderate or severe use disorder
F10.27	Alcohol-induced major neurocognitive disorder, Nonamnestic confabulatory type, With moderate or severe use disorder
F10.280	Alcohol-induced anxiety disorder, With moderate or severe use disorder
F10.281	Alcohol-induced sexual dysfunction, With moderate or severe use disorder
F10.282	Alcohol-induced sleep disorder, With moderate or severe use disorder
F10.288	Alcohol-induced mild neurocognitive disorder, With moderate or severe use disorder
F10.921	Alcohol intoxication delirium, Without use disorder
F10.929	Alcohol intoxication, Without use disorder
F10.94	Alcohol-induced bipolar and related disorder, Without use disorder
F10.94	Alcohol-induced depressive disorder, Without use disorder
F10.959	Alcohol-induced psychotic disorder, Without use disorder
F10.96	Alcohol-induced major neurocognitive disorder, Amnestic confabulatory type, Without use disorder
F10.97	Alcohol-induced major neurocognitive disorder, Nonamnestic confabulatory type, Without use disorder
F10.980	Alcohol-induced anxiety disorder, Without use disorder
F10.981	Alcohol-induced sexual dysfunction, Without use disorder
F10.982	Alcohol-induced sleep disorder, Without use disorder
F10.988	Alcohol-induced mild neurocognitive disorder, Without use disorder
F10.99	Unspecified alcohol-related disorder
F11.10	Opioid use disorder, Mild
F11.121	Opioid intoxication delirium, With mild use disorder
F11.122	Opioid intoxication, With perceptual disturbances, With mild use disorder
F11.129	Opioid intoxication, Without perceptual disturbances, With mild use disorder
F11.14	Opioid-induced depressive disorder, With mild use disorder
F11.181	Opioid-induced sexual dysfunction, With mild use disorder
F11.182	Opioid-induced sleep disorder, With mild use disorder
F11.188	Opioid-induced anxiety disorder, With mild use disorder
F11.20	Opioid use disorder, Moderate
F11.20	Opioid use disorder, Severe
F11.221	Opioid intoxication delirium, With moderate or severe use disorder
F11.222	Opioid intoxication, With perceptual disturbances, With moderate or severe use disorder
F11.229	Opioid intoxication, Without perceptual disturbances, With moderate or severe use disorder
F11.23	Opioid withdrawal

ICD-10-CM	Disorder, condition, or problem
F11.23	Opioid withdrawal delirium
F11.24	Opioid-induced depressive disorder, With moderate or severe use disorder
F11.281	Opioid-induced sexual dysfunction, With moderate or severe use disorder
F11.282	Opioid-induced sleep disorder, With moderate or severe use disorder
F11.288	Opioid-induced anxiety disorder, With moderate or severe use disorder
F11.921	Opioid-induced delirium
F11.921	Opioid intoxication delirium, Without use disorder
F11.922	Opioid intoxication, With perceptual disturbances, Without use disorder
F11.929	Opioid intoxication, Without perceptual disturbances, Without use disorder
F11.94	Opioid-induced depressive disorder, Without use disorder
F11.981	Opioid-induced sexual dysfunction, Without use disorder
F11.982	Opioid-induced sleep disorder, Without use disorder
F11.988	Opioid-induced anxiety disorder, Without use disorder
F11.99	Unspecified opioid-related disorder
F12.10	Cannabis use disorder, Mild
F12.121	Cannabis intoxication delirium, With mild use disorder
F12.122	Cannabis intoxication, With perceptual disturbances, With mild use disorder
F12.129	Cannabis intoxication, Without perceptual disturbances, With mild use disorder
F12.159	Cannabis-induced psychotic disorder, With mild use disorder
F12.180	Cannabis-induced anxiety disorder, With mild use disorder
F12.188	Cannabis-induced sleep disorder, With mild use disorder
F12.20	Cannabis use disorder, Moderate
F12.20	Cannabis use disorder, Severe
F12.221	Cannabis intoxication delirium, With moderate or severe use disorder
F12.222	Cannabis intoxication, With perceptual disturbances, With moderate or severe use disorder
F12.229	Cannabis intoxication, Without perceptual disturbances, With moderate or severe use disorder
F12.259	Cannabis-induced psychotic disorder, With moderate or severe use disorder
F12.280	Cannabis-induced anxiety disorder, With moderate or severe use disorder
F12.288	Cannabis-induced sleep disorder, With moderate or severe use disorder
F12.288	Cannabis withdrawal
F12.921	Cannabis intoxication delirium, Without use disorder
F12.922	Cannabis intoxication, With perceptual disturbances, Without use disorder
F12.929	Cannabis intoxication, Without perceptual disturbances, Without use disorder
F12.959	Cannabis-induced psychotic disorder, Without use disorder
F12.980	Cannabis-induced anxiety disorder, Without use disorder
F12.988	Cannabis-induced sleep disorder, Without use disorder
F12.99	Unspecified cannabis-related disorder
F13.10	Sedative, hypnotic, or anxiolytic use disorder, Mild
F13.121	Sedative, hypnotic, or anxiolytic intoxication delirium, With mild use disorder
F13.129	Sedative, hypnotic, or anxiolytic intoxication, With mild use disorder
F13.14	Sedative-, hypnotic-, or anxiolytic-induced bipolar and related disorder, With mild use disorder
F13.14	Sedative-, hypnotic-, or anxiolytic-induced depressive disorder, With mild use disorder

ICD-10-CM	Disorder, condition, or problem
F13.159	Sedative-, hypnotic-, or anxiolytic-induced psychotic disorder, With mild use disorder
F13.180	Sedative-, hypnotic-, or anxiolytic-induced anxiety disorder, With mild use disorder
F13.181	Sedative-, hypnotic-, or anxiolytic-induced sexual dysfunction, With mild use disorder
F13.182	Sedative-, hypnotic-, or anxiolytic-induced sleep disorder, With mild use disorder
F13.20	Sedative, hypnotic, or anxiolytic use disorder, Moderate
F13.20	Sedative, hypnotic, or anxiolytic use disorder, Severe
F13.221	Sedative, hypnotic, or anxiolytic intoxication delirium, With moderate or severe use disorder
F13.229	Sedative, hypnotic, or anxiolytic intoxication, With moderate or severe use disorder
F13.231	Sedative, hypnotic, or anxiolytic withdrawal delirium
F13.232	Sedative, hypnotic, or anxiolytic withdrawal, With perceptual disturbances
F13.239	Sedative, hypnotic, or anxiolytic withdrawal, Without perceptual disturbances
F13.24	Sedative-, hypnotic-, or anxiolytic-induced bipolar and related disorder, With moderate or severe use disorder
F13.24	Sedative-, hypnotic-, or anxiolytic-induced depressive disorder, With moderate or severe use disorder
F13.259	Sedative-, hypnotic-, or anxiolytic-induced psychotic disorder, With moderate or severe use disorder
F13.27	Sedative-, hypnotic-, or anxiolytic-induced major neurocognitive disorder, With moderate or severe use disorder
F13.280	Sedative-, hypnotic-, or anxiolytic-induced anxiety disorder, With moderate or severe use disorder
F13.281	Sedative-, hypnotic-, or anxiolytic-induced sexual dysfunction, With moderate or severe use disorder
F13.282	Sedative-, hypnotic-, or anxiolytic-induced sleep disorder, With moderate or severe use disorder
F13.288	Sedative-, hypnotic-, or anxiolytic-induced mild neurocognitive disorder, With moderate or severe use disorder
F13.921	Sedative-, hypnotic-, or anxiolytic-induced delirium
F13.921	Sedative, hypnotic, or anxiolytic intoxication delirium, Without use disorder
F13.929	Sedative, hypnotic, or anxiolytic intoxication, Without use disorder
F13.94	Sedative-, hypnotic-, or anxiolytic-induced bipolar and related disorder, Without use disorder
F13.94	Sedative-, hypnotic-, or anxiolytic-induced depressive disorder, Without use disorder
F13.959	Sedative-, hypnotic-, or anxiolytic-induced psychotic disorder, Without use disorder
F13.97	Sedative-, hypnotic-, or anxiolytic-induced major neurocognitive disorder, Without use disorder
F13.980	Sedative-, hypnotic-, or anxiolytic-induced anxiety disorder, Without use disorder
F13.981	Sedative-, hypnotic-, or anxiolytic-induced sexual dysfunction, Without use disorder
F13.982	Sedative-, hypnotic-, or anxiolytic-induced sleep disorder, Without use disorder
F13.988	Sedative-, hypnotic-, or anxiolytic-induced mild neurocognitive disorder, Without use disorder

ICD-10-CM	Disorder, condition, or problem
F13.99	Unspecified sedative-, hypnotic-, or anxiolytic-related disorder
F14.10	Cocaine use disorder, Mild
F14.121	Cocaine intoxication delirium, With mild use disorder
F14.122	Cocaine intoxication, With perceptual disturbances, With mild use disorder
F14.129	Cocaine intoxication, Without perceptual disturbances, With mild use disorder
F14.14	Cocaine-induced bipolar and related disorder, With mild use disorder
F14.14	Cocaine-induced depressive disorder, With mild use disorder
F14.159	Cocaine-induced psychotic disorder, With mild use disorder
F14.180	Cocaine-induced anxiety disorder, With mild use disorder
F14.181	Cocaine-induced sexual dysfunction, With mild use disorder
F14.182	Cocaine-induced sleep disorder, With mild use disorder
F14.188	Cocaine-induced obsessive-compulsive and related disorder, With mild use disorder
F14.20	Cocaine use disorder, Moderate
F14.20	Cocaine use disorder, Severe
F14.221	Cocaine intoxication delirium, With moderate or severe use disorder
F14.222	Cocaine intoxication, With perceptual disturbances, With moderate or severe use disorder
F14.229	Cocaine intoxication, Without perceptual disturbances, With moderate or severe use disorder
F14.23	Cocaine withdrawal
F14.24	Cocaine-induced bipolar and related disorder, With moderate or severe use disorder
F14.24	Cocaine-induced depressive disorder, With moderate or severe use disorder
F14.259	Cocaine-induced psychotic disorder, With moderate or severe use disorder
F14.280	Cocaine-induced anxiety disorder, With moderate or severe use disorder
F14.281	Cocaine-induced sexual dysfunction, With moderate or severe use disorder
F14.282	Cocaine-induced sleep disorder, With moderate or severe use disorder
F14.288	Cocaine-induced obsessive-compulsive and related disorder, With moderate or severe use disorder
F14.921	Cocaine intoxication delirium, Without use disorder
F14.922	Cocaine intoxication, With perceptual disturbances, Without use disorder
F14.929	Cocaine intoxication, Without perceptual disturbances, Without use disorder
F14.94	Cocaine-induced bipolar and related disorder, Without use disorder
F14.94	Cocaine-induced depressive disorder, Without use disorder
F14.959	Cocaine-induced psychotic disorder, Without use disorder
F14.980	Cocaine-induced anxiety disorder, Without use disorder
F14.981	Cocaine-induced sexual dysfunction, Without use disorder
F14.982	Cocaine-induced sleep disorder, Without use disorder
F14.988	Cocaine-induced obsessive-compulsive and related disorder, Without use disorder
F14.99	Unspecified stimulant-related disorder, Unspecified Cocaine-related disorder
F15.10	Amphetamine-type substance use disorder, Mild
F15.10	Other or unspecified stimulant use disorder, Mild
F15.121	Amphetamine (or other stimulant) intoxication delirium, With mild use disorder
F15.122	Amphetamine or other stimulant intoxication, With perceptual disturbances, With mild use disorder

ICD-10-CM	Disorder, condition, or problem
F15.129	Amphetamine or other stimulant intoxication, Without perceptual disturbances, With mild use disorder
F15.14	Amphetamine (or other stimulant)–induced bipolar and related disorder, With mild use disorder
F15.14	Amphetamine (or other stimulant)–induced depressive disorder, With mild use disorder
F15.159	Amphetamine (or other stimulant)–induced psychotic disorder, With mild use disorder
F15.180	Amphetamine (or other stimulant)–induced anxiety disorder, With mild use disorder
F15.180	Caffeine-induced anxiety disorder, With mild use disorder
F15.181	Amphetamine (or other stimulant)–induced sexual dysfunction, With mild use disorder
F15.182	Amphetamine (or other stimulant)–induced sleep disorder, With mild use disorder
F15.182	Caffeine-induced sleep disorder, With mild use disorder
F15.188	Amphetamine (or other stimulant)–induced obsessive-compulsive and related disorder, With mild use disorder
F15.20	Amphetamine-type substance use disorder, Moderate
F15.20	Amphetamine-type substance use disorder, Severe
F15.20	Other or unspecified stimulant use disorder, Moderate
F15.20	Other or unspecified stimulant use disorder, Severe
F15.221	Amphetamine (or other stimulant) intoxication delirium, With moderate or severe use disorder
F15.222	Amphetamine or other stimulant intoxication, With perceptual disturbances, With moderate or severe use disorder
F15.229	Amphetamine or other stimulant intoxication, Without perceptual disturbances, With moderate or severe use disorder
F15.23	Amphetamine or other stimulant withdrawal
F15.24	Amphetamine (or other stimulant)–induced bipolar and related disorder, With moderate or severe use disorder
F15.24	Amphetamine (or other stimulant)–induced depressive disorder, With moderate or severe use disorder
F15.259	Amphetamine (or other stimulant)–induced psychotic disorder, With moderate or severe use disorder
F15.280	Amphetamine (or other stimulant)–induced anxiety disorder, With moderate or severe use disorder
F15.280	Caffeine-induced anxiety disorder, With moderate or severe use disorder
F15.281	Amphetamine (or other stimulant)–induced sexual dysfunction, With moderate or severe use disorder
F15.282	Amphetamine (or other stimulant)–induced sleep disorder, With moderate or severe use disorder
F15.282	Caffeine-induced sleep disorder, With moderate or severe use disorder
F15.288	Amphetamine (or other stimulant)–induced obsessive-compulsive and related disorder, With moderate or severe use disorder
F15.921	Amphetamine (or other stimulant)–induced delirium
F15.921	Amphetamine (or other stimulant) intoxication delirium, Without use disorder
F15.922	Amphetamine or other stimulant intoxication, With perceptual disturbances, Without use disorder

ICD-10-CM	Disorder, condition, or problem
F15.929	Amphetamine or other stimulant intoxication, Without perceptual disturbances, Without use disorder
F15.929	Caffeine intoxication
F15.93	Caffeine withdrawal
F15.94	Amphetamine (or other stimulant)–induced bipolar and related disorder, Without use disorder
F15.94	Amphetamine (or other stimulant)–induced depressive disorder, Without use disorder
F15.959	Amphetamine (or other stimulant)–induced psychotic disorder, Without use disorder
F15.980	Amphetamine (or other stimulant)–induced anxiety disorder, Without use disorder
F15.980	Caffeine-induced anxiety disorder, Without use disorder
F15.981	Amphetamine (or other stimulant)–induced sexual dysfunction, Without use disorder
F15.982	Amphetamine (or other stimulant)–induced sleep disorder, Without use disorder
F15.982	Caffeine-induced sleep disorder, Without use disorder
F15.988	Amphetamine (or other stimulant)–induced obsessive-compulsive and related disorder, Without use disorder
F15.99	Unspecified amphetamine or other stimulant-related disorder
F15.99	Unspecified caffeine-related disorder
F16.10	Other hallucinogen use disorder, Mild
F16.10	Phencyclidine use disorder, Mild
F16.121	Other hallucinogen intoxication delirium, With mild use disorder
F16.121	Phencyclidine intoxication delirium, With mild use disorder
F16.129	Other hallucinogen intoxication, With mild use disorder
F16.129	Phencyclidine intoxication, With mild use disorder
F16.14	Other hallucinogen–induced bipolar and related disorder, With mild use disorder
F16.14	Other hallucinogen–induced depressive disorder, With mild use disorder
F16.14	Phencyclidine-induced bipolar and related disorder, With mild use disorder
F16.14	Phencyclidine-induced depressive disorder, With mild use disorder
F16.159	Other hallucinogen–induced psychotic disorder, With mild use disorder
F16.159	Phencyclidine-induced psychotic disorder, With mild use disorder
F16.180	Other hallucinogen–induced anxiety disorder, With mild use disorder
F16.180	Phencyclidine-induced anxiety disorder, With mild use disorder
F16.20	Other hallucinogen use disorder, Moderate
F16.20	Other hallucinogen use disorder, Severe
F16.20	Phencyclidine use disorder, Moderate
F16.20	Phencyclidine use disorder, Severe
F16.221	Other hallucinogen intoxication delirium, With moderate or severe use disorder
F16.221	Phencyclidine intoxication delirium, With moderate or severe use disorder
F16.229	Other hallucinogen intoxication, With moderate or severe use disorder
F16.229	Phencyclidine intoxication, With moderate or severe use disorder
F16.24	Other hallucinogen–induced bipolar and related disorder, With moderate or severe use disorder

ICD-10-CM	Disorder, condition, or problem
F16.24	Other hallucinogen-induced depressive disorder, With moderate or severe use disorder
F16.24	Phencyclidine-induced bipolar and related disorder, With moderate or severe use disorder
F16.24	Phencyclidine-induced depressive disorder, With moderate or severe use disorder
F16.259	Other hallucinogen-induced psychotic disorder, With moderate or severe use disorder
F16.259	Phencyclidine-induced psychotic disorder, With moderate or severe use disorder
F16.280	Other hallucinogen-induced anxiety disorder, With moderate or severe use disorder
F16.280	Phencyclidine-induced anxiety disorder, With moderate or severe use disorder
F16.921	Other hallucinogen intoxication delirium, Without use disorder
F16.921	Phencyclidine intoxication delirium, Without use disorder
F16.929	Other hallucinogen intoxication, Without use disorder
F16.929	Phencyclidine intoxication, Without use disorder
F16.94	Other hallucinogen-induced bipolar and related disorder, Without use disorder
F16.94	Other hallucinogen-induced depressive disorder, Without use disorder
F16.94	Phencyclidine-induced bipolar and related disorder, Without use disorder
F16.94	Phencyclidine-induced depressive disorder, Without use disorder
F16.959	Other hallucinogen-induced psychotic disorder, Without use disorder
F16.959	Phencyclidine-induced psychotic disorder, Without use disorder
F16.980	Other hallucinogen-induced anxiety disorder, Without use disorder
F16.980	Phencyclidine-induced anxiety disorder, Without use disorder
F16.983	Hallucinogen persisting perception disorder
F16.99	Unspecified hallucinogen-related disorder
F16.99	Unspecified phencyclidine-related disorder
F17.200	Tobacco use disorder, Moderate
F17.200	Tobacco use disorder, Severe
F17.203	Tobacco withdrawal
F17.208	Tobacco-induced sleep disorder, With moderate or severe use disorder
F17.209	Unspecified tobacco-related disorder
F18.10	Inhalant use disorder, Mild
F18.121	Inhalant intoxication delirium, With mild use disorder
F18.129	Inhalant intoxication, With mild use disorder
F18.14	Inhalant-induced depressive disorder, With mild use disorder
F18.159	Inhalant-induced psychotic disorder, With mild use disorder
F18.17	Inhalant-induced major neurocognitive disorder, With mild use disorder
F18.180	Inhalant-induced anxiety disorder, With mild use disorder
F18.188	Inhalant-induced mild neurocognitive disorder, With mild use disorder
F18.20	Inhalant use disorder, Moderate
F18.20	Inhalant use disorder, Severe
F18.221	Inhalant intoxication delirium, With moderate or severe use disorder
F18.229	Inhalant intoxication, With moderate or severe use disorder
F18.24	Inhalant-induced depressive disorder, With moderate or severe use disorder
F18.259	Inhalant-induced psychotic disorder, With moderate or severe use disorder

ICD-10-CM	Disorder, condition, or problem
F18.27	Inhalant-induced major neurocognitive disorder, With moderate or severe use disorder
F18.280	Inhalant-induced anxiety disorder, With moderate or severe use disorder
F18.288	Inhalant-induced mild neurocognitive disorder, With moderate or severe use disorder
F18.921	Inhalant intoxication delirium, Without use disorder
F18.929	Inhalant intoxication, Without use disorder
F18.94	Inhalant-induced depressive disorder, Without use disorder
F18.959	Inhalant-induced psychotic disorder, Without use disorder
F18.97	Inhalant-induced major neurocognitive disorder, Without use disorder
F18.980	Inhalant-induced anxiety disorder, Without use disorder
F18.988	Inhalant-induced mild neurocognitive disorder, Without use disorder
F18.99	Unspecified inhalant-related disorder
F19.10	Other (or unknown) substance use disorder, Mild
F19.121	Other (or unknown) substance intoxication delirium, With mild use disorder
F19.129	Other (or unknown) substance intoxication, With mild use disorder
F19.14	Other (or unknown) substance-induced bipolar and related disorder, With mild use disorder
F19.14	Other (or unknown) substance-induced depressive disorder, With mild use disorder
F19.159	Other (or unknown) substance-induced psychotic disorder, With mild use disorder
F19.17	Other (or unknown) substance-induced major neurocognitive disorder, With mild use disorder
F19.180	Other (or unknown) substance-induced anxiety disorder, With mild use disorder
F19.181	Other (or unknown) substance-induced sexual dysfunction, With mild use disorder
F19.182	Other (or unknown) substance-induced sleep disorder, With mild use disorder
F19.188	Other (or unknown) substance-induced mild neurocognitive disorder, With mild use disorder
F19.188	Other (or unknown) substance-induced obsessive-compulsive and related disorder, With mild use disorder
F19.20	Other (or unknown) substance use disorder, Moderate
F19.20	Other (or unknown) substance use disorder, Severe
F19.221	Other (or unknown) substance intoxication delirium, With moderate or severe use disorder
F19.229	Other (or unknown) substance intoxication, With moderate or severe use disorder
F19.231	Other (or unknown) substance withdrawal delirium
F19.239	Other (or unknown) substance withdrawal
F19.24	Other (or unknown) substance-induced bipolar and related disorder, With moderate or severe use disorder
F19.24	Other (or unknown) substance-induced depressive disorder, With moderate or severe use disorder
F19.259	Other (or unknown) substance-induced psychotic disorder, With moderate or severe use disorder
F19.27	Other (or unknown) substance-induced major neurocognitive disorder, With moderate or severe use disorder

ICD-10-CM	Disorder, condition, or problem
F19.280	Other (or unknown) substance-induced anxiety disorder, With moderate or severe use disorder
F19.281	Other (or unknown) substance-induced sexual dysfunction, With moderate or severe use disorder
F19.282	Other (or unknown) substance-induced sleep disorder, With moderate or severe use disorder
F19.288	Other (or unknown) substance-induced mild neurocognitive disorder, With moderate or severe use disorder
F19.288	Other (or unknown) substance-induced obsessive-compulsive and related disorder, With moderate or severe use disorder
F19.921	Other (or unknown) substance-induced delirium
F19.921	Other (or unknown) substance intoxication delirium, Without use disorder
F19.929	Other (or unknown) substance intoxication, Without use disorder
F19.94	Other (or unknown) substance-induced bipolar and related disorder, Without use disorder
F19.94	Other (or unknown) substance-induced depressive disorder, Without use disorder
F19.959	Other (or unknown) substance-induced psychotic disorder, Without use disorder
F19.97	Other (or unknown) substance-induced major neurocognitive disorder, Without use disorder
F19.980	Other (or unknown) substance-induced anxiety disorder, Without use disorder
F19.981	Other (or unknown) substance-induced sexual dysfunction, Without use disorder
F19.982	Other (or unknown) substance-induced sleep disorder, Without use disorder
F19.988	Other (or unknown) substance-induced mild neurocognitive disorder, Without use disorder
F19.988	Other (or unknown) substance-induced obsessive-compulsive and related disorder, Without use disorder
F19.99	Unspecified other (or unknown) substance-related disorder
F20.81	Schizophreniform disorder
F20.9	Schizophrenia
F21	Schizotypal personality disorder
F22	Delusional disorder
F23	Brief psychotic disorder
F25.0	Schizoaffective disorder, Bipolar type
F25.1	Schizoaffective disorder, Depressive type
F28	Other specified schizophrenia spectrum and other psychotic disorder
F29	Unspecified schizophrenia spectrum and other psychotic disorder
F31.0	Bipolar I disorder, Current or most recent episode hypomanic
F31.11	Bipolar I disorder, Current or most recent episode manic, Mild
F31.12	Bipolar I disorder, Current or most recent episode manic, Moderate
F31.13	Bipolar I disorder, Current or most recent episode manic, Severe
F31.2	Bipolar I disorder, Current or most recent episode manic, With psychotic features
F31.31	Bipolar I disorder, Current or most recent episode depressed, Mild
F31.32	Bipolar I disorder, Current or most recent episode depressed, Moderate
F31.4	Bipolar I disorder, Current or most recent episode depressed, Severe
F31.5	Bipolar I disorder, Current or most recent episode depressed, With psychotic features

ICD-10-CM	Disorder, condition, or problem
F31.71	Bipolar I disorder, Current or most recent episode hypomanic, In partial remission
F31.72	Bipolar I disorder, Current or most recent episode hypomanic, In full remission
F31.73	Bipolar I disorder, Current or most recent episode manic, In partial remission
F31.74	Bipolar I disorder, Current or most recent episode manic, In full remission
F31.75	Bipolar I disorder, Current or most recent episode depressed, In partial remission
F31.76	Bipolar I disorder, Current or most recent episode depressed, In full remission
F31.81	Bipolar II disorder
F31.89	Other specified bipolar and related disorder
F31.9	Bipolar I disorder, Current or most recent episode depressed, Unspecified
F31.9	Bipolar I disorder, Current or most recent episode hypomanic, Unspecified
F31.9	Bipolar I disorder, Current or most recent episode manic, Unspecified
F31.9	Bipolar I disorder, Current or most recent episode unspecified
F31.9	Unspecified bipolar and related disorder
F32.0	Major depressive disorder, Single episode, Mild
F32.1	Major depressive disorder, Single episode, Moderate
F32.2	Major depressive disorder, Single episode, Severe
F32.3	Major depressive disorder, Single episode, With psychotic features
F32.4	Major depressive disorder, Single episode, In partial remission
F32.5	Major depressive disorder, Single episode, In full remission
F32.8	Other specified depressive disorder
F32.9	Major depressive disorder, Single episode, Unspecified
F32.9	Unspecified depressive disorder
F33.0	Major depressive disorder, Recurrent episode, Mild
F33.1	Major depressive disorder, Recurrent episode, Moderate
F33.2	Major depressive disorder, Recurrent episode, Severe
F33.3	Major depressive disorder, Recurrent episode, With psychotic features
F33.41	Major depressive disorder, Recurrent episode, In partial remission
F33.42	Major depressive disorder, Recurrent episode, In full remission
F33.9	Major depressive disorder, Recurrent episode, Unspecified
F34.0	Cyclothymic disorder
F34.1	Persistent depressive disorder (dysthymia)
F34.8	Disruptive mood dysregulation disorder
F40.00	Agoraphobia
F40.10	Social anxiety disorder (social phobia)
F40.218	Specific phobia, Animal
F40.228	Specific phobia, Natural environment
F40.230	Specific phobia, Fear of blood
F40.231	Specific phobia, Fear of injections and transfusions
F40.232	Specific phobia, Fear of other medical care
F40.233	Specific phobia, Fear of injury
F40.248	Specific phobia, Situational
F40.298	Specific phobia, Other
F41.0	Panic disorder
F41.1	Generalized anxiety disorder
F41.8	Other specified anxiety disorder

ICD-10-CM	Disorder, condition, or problem
F41.9	Unspecified anxiety disorder
F42	Hoarding disorder
F42	Obsessive-compulsive disorder
F42	Other specified obsessive-compulsive and related disorder
F42	Unspecified obsessive-compulsive and related disorder
F43.0	Acute stress disorder
F43.10	Posttraumatic stress disorder
F43.20	Adjustment disorders, Unspecified
F43.21	Adjustment disorders, With depressed mood
F43.22	Adjustment disorders, With anxiety
F43.23	Adjustment disorders, With mixed anxiety and depressed mood
F43.24	Adjustment disorders, With disturbance of conduct
F43.25	Adjustment disorders, With mixed disturbance of emotions and conduct
F43.8	Other specified trauma- and stressor-related disorder
F43.9	Unspecified trauma- and stressor-related disorder
F44.0	Dissociative amnesia
F44.1	Dissociative amnesia, With dissociative fugue
F44.4	Conversion disorder (functional neurological symptom disorder), With abnormal movement
F44.4	Conversion disorder (functional neurological symptom disorder), With speech symptoms
F44.4	Conversion disorder (functional neurological symptom disorder), With swallowing symptoms
F44.4	Conversion disorder (functional neurological symptom disorder), With weakness/paralysis
F44.5	Conversion disorder (functional neurological symptom disorder), With attacks or seizures
F44.6	Conversion disorder (functional neurological symptom disorder), With anesthesia or sensory loss
F44.6	Conversion disorder (functional neurological symptom disorder), With special sensory symptoms
F44.7	Conversion disorder (functional neurological symptom disorder), With mixed symptoms
F44.81	Dissociative identity disorder
F44.89	Other specified dissociative disorder
F44.9	Unspecified dissociative disorder
F45.1	Somatic symptom disorder
F45.21	Illness anxiety disorder
F45.22	Body dysmorphic disorder
F45.8	Other specified somatic symptom and related disorder
F45.9	Unspecified somatic symptom and related disorder
F48.1	Depersonalization/derealization disorder
F50.01	Anorexia nervosa, Restricting type
F50.02	Anorexia nervosa, Binge-eating/purging type
F50.2	Bulimia nervosa
F50.8	Avoidant/restrictive food intake disorder

ICD-10-CM	Disorder, condition, or problem
F50.8	Binge-eating disorder
F50.8	Other specified feeding or eating disorder
F50.8	Pica, in adults
F50.9	Unspecified feeding or eating disorder
F51.01	Insomnia disorder
F51.11	Hypersomnolence disorder
F51.3	Non-rapid eye movement sleep arousal disorders, Sleepwalking type
F51.4	Non-rapid eye movement sleep arousal disorders, Sleep terror type
F51.5	Nightmare disorder
F52.0	Male hypoactive sexual desire disorder
F52.21	Erectile disorder
F52.22	Female sexual interest/arousal disorder
F52.31	Female orgasmic disorder
F52.32	Delayed ejaculation
F52.4	Premature (early) ejaculation
F52.6	Genito-pelvic pain/penetration disorder
F52.8	Other specified sexual dysfunction
F52.9	Unspecified sexual dysfunction
F54	Psychological factors affecting other medical conditions
F60.0	Paranoid personality disorder
F60.1	Schizoid personality disorder
F60.2	Antisocial personality disorder
F60.3	Borderline personality disorder
F60.4	Histrionic personality disorder
F60.5	Obsessive-compulsive personality disorder
F60.6	Avoidant personality disorder
F60.7	Dependent personality disorder
F60.81	Narcissistic personality disorder
F60.89	Other specified personality disorder
F60.9	Unspecified personality disorder
F63.0	Gambling disorder
F63.1	Pyromania
F63.2	Kleptomania
F63.3	Trichotillomania (hair-pulling disorder)
F63.81	Intermittent explosive disorder
F64.1	Gender dysphoria in adolescents and adults
F64.2	Gender dysphoria in children
F64.8	Other specified gender dysphoria
F64.9	Unspecified gender dysphoria
F65.0	Fetishistic disorder
F65.1	Transvestic disorder
F65.2	Exhibitionistic disorder
F65.3	Voyeuristic disorder
F65.4	Pedophilic disorder
F65.51	Sexual masochism disorder
F65.52	Sexual sadism disorder

ICD-10-CM	Disorder, condition, or problem
F65.81	Frotteuristic disorder
F65.89	Other specified paraphilic disorder
F65.9	Unspecified paraphilic disorder
F68.10	Factitious disorder
F70	Intellectual disability (intellectual developmental disorder), Mild
F71	Intellectual disability (intellectual developmental disorder), Moderate
F72	Intellectual disability (intellectual developmental disorder), Severe
F73	Intellectual disability (intellectual developmental disorder), Profound
F79	Unspecified intellectual disability (intellectual developmental disorder)
F80.0	Speech sound disorder
F80.2	Language disorder
F80.81	Childhood-onset fluency disorder (stuttering)
F80.89	Social (pragmatic) communication disorder
F80.9	Unspecified communication disorder
F81.0	Specific learning disorder, With impairment in reading
F81.2	Specific learning disorder, With impairment in mathematics
F81.81	Specific learning disorder, With impairment in written expression
F82	Developmental coordination disorder
F84.0	Autism spectrum disorder
F88	Global developmental delay
F88	Other specified neurodevelopmental disorder
F89	Unspecified neurodevelopmental disorder
F90.0	Attention-deficit/hyperactivity disorder, Predominantly inattentive presentation
F90.1	Attention-deficit/hyperactivity disorder, Predominantly hyperactive/impulsive presentation
F90.2	Attention-deficit/hyperactivity disorder, Combined presentation
F90.8	Other specified attention-deficit/hyperactivity disorder
F90.9	Unspecified attention-deficit/hyperactivity disorder
F91.1	Conduct disorder, Childhood-onset type
F91.2	Conduct disorder, Adolescent-onset type
F91.3	Oppositional defiant disorder
F91.8	Other specified disruptive, impulse-control, and conduct disorder
F91.9	Conduct disorder, Unspecified onset
F91.9	Unspecified disruptive, impulse-control, and conduct disorder
F93.0	Separation anxiety disorder
F94.0	Selective mutism
F94.1	Reactive attachment disorder
F94.2	Disinhibited social engagement disorder
F95.0	Provisional tic disorder
F95.1	Persistent (chronic) motor or vocal tic disorder
F95.2	Tourette's disorder
F95.8	Other specified tic disorder
F95.9	Unspecified tic disorder
F98.0	Enuresis
F98.1	Encopresis
F98.21	Rumination disorder

ICD-10-CM	Disorder, condition, or problem
F98.3	Pica, in children
F98.4	Stereotypic movement disorder
F98.5	Adult-onset fluency disorder
F99	Other specified mental disorder
F99	Unspecified mental disorder
G21.0	Neuroleptic malignant syndrome
G21.11	Neuroleptic-induced parkinsonism
G21.19	Other medication-induced parkinsonism
G24.01	Tardive dyskinesia
G24.02	Medication-induced acute dystonia
G24.09	Tardive dystonia
G25.1	Medication-induced postural tremor
G25.71	Medication-induced acute akathisia
G25.71	Tardive akathisia
G25.79	Other medication-induced movement disorder
G25.81	Restless legs syndrome
G31.84	Mild frontotemporal neurocognitive disorder
G31.84	Mild neurocognitive disorder due to Alzheimer's disease
G31.84	Mild neurocognitive disorder due to another medical condition
G31.84	Mild neurocognitive disorder due to HIV infection
G31.84	Mild neurocognitive disorder due to Huntington's disease
G31.84	Mild neurocognitive disorder with Lewy bodies
G31.84	Mild neurocognitive disorder due to multiple etiologies
G31.84	Mild neurocognitive disorder due to Parkinson's disease
G31.84	Mild neurocognitive disorder due to prion disease
G31.84	Mild neurocognitive disorder due to traumatic brain injury
G31.84	Mild vascular neurocognitive disorder
G31.9	Major neurocognitive disorder possibly due to Parkinson's disease
G31.9	Possible major frontotemporal neurocognitive disorder
G31.9	Possible major neurocognitive disorder due to Alzheimer's disease
G31.9	Possible major neurocognitive disorder with Lewy bodies
G31.9	Possible major vascular neurocognitive disorder
G47.00	Unspecified insomnia disorder
G47.09	Other specified insomnia disorder
G47.10	Unspecified hypersomnolence disorder
G47.19	Other specified hypersomnolence disorder
G47.20	Circadian rhythm sleep-wake disorders, Unspecified type
G47.21	Circadian rhythm sleep-wake disorders, Delayed sleep phase type
G47.22	Circadian rhythm sleep-wake disorders, Advanced sleep phase type
G47.23	Circadian rhythm sleep-wake disorders, Irregular sleep-wake type
G47.24	Circadian rhythm sleep-wake disorders, Non-24-hour sleep-wake type
G47.26	Circadian rhythm sleep-wake disorders, Shift work type
G47.31	Central sleep apnea, Idiopathic central sleep apnea

ICD-10-CM	Disorder, condition, or problem
G47.33	Obstructive sleep apnea hypopnea
G47.34	Sleep-related hypoventilation, Idiopathic hypoventilation
G47.35	Sleep-related hypoventilation, Congenital central alveolar hypoventilation
G47.36	Sleep-related hypoventilation, Comorbid sleep-related hypoventilation
G47.37	Central sleep apnea comorbid with opioid use
G47.411	Narcolepsy with cataplexy but without hypocretin deficiency
G47.419	Autosomal dominant cerebellar ataxia, deafness, and narcolepsy
G47.419	Autosomal dominant narcolepsy, obesity, and type 2 diabetes
G47.419	Narcolepsy without cataplexy but with hypocretin deficiency
G47.429	Narcolepsy secondary to another medical condition
G47.52	Rapid eye movement sleep behavior disorder
G47.8	Other specified sleep-wake disorder
G47.9	Unspecified sleep-wake disorder
L98.1	Excoriation (skin-picking) disorder
N39.498	Other specified elimination disorder, With urinary symptoms
N94.3	Premenstrual dysphoric disorder
R06.3	Central sleep apnea, Cheyne-Stokes breathing
R15.9	Other specified elimination disorder, With fecal symptoms
R15.9	Unspecified elimination disorder, With fecal symptoms
R32	Unspecified elimination disorder, With urinary symptoms
R41.0	Other specified delirium
R41.0	Unspecified delirium
R41.83	Borderline intellectual functioning
R41.9	Unspecified neurocognitive disorder
T43.205A	Antidepressant discontinuation syndrome, Initial encounter
T43.205D	Antidepressant discontinuation syndrome, Subsequent encounter
T43.205S	Antidepressant discontinuation syndrome, Sequelae
T50.905A	Other adverse effect of medication, Initial encounter
T50.905D	Other adverse effect of medication, Subsequent encounter
T50.905S	Other adverse effect of medication, Sequelae
T74.01XA	Spouse or partner neglect, Confirmed, Initial encounter
T74.01XD	Spouse or partner neglect, Confirmed, Subsequent encounter
T74.02XA	Child neglect, Confirmed, Initial encounter
T74.02XD	Child neglect, Confirmed, Subsequent encounter
T74.11XA	Adult physical abuse by nonspouse or nonpartner, Confirmed, Initial encounter
T74.11XA	Spouse or partner violence, Physical, Confirmed, Initial encounter
T74.11XD	Adult physical abuse by nonspouse or nonpartner, Confirmed, Subsequent encounter
T74.11XD	Spouse or partner violence, Physical, Confirmed, Subsequent encounter
T74.12XA	Child physical abuse, Confirmed, Initial encounter
T74.12XD	Child physical abuse, Confirmed, Subsequent encounter
T74.21XA	Adult sexual abuse by nonspouse or nonpartner, Confirmed, Initial encounter
T74.21XA	Spouse or partner violence, Sexual, Confirmed, Initial encounter
T74.21XD	Adult sexual abuse by nonspouse or nonpartner, Confirmed, Subsequent encounter

ICD-10-CM	Disorder, condition, or problem
T74.21XD	Spouse or partner violence, Sexual, Confirmed, Subsequent encounter
T74.22XA	Child sexual abuse, Confirmed, Initial encounter
T74.22XD	Child sexual abuse, Confirmed, Subsequent encounter
T74.31XA	Adult psychological abuse by nonspouse or nonpartner, Confirmed, Initial encounter
T74.31XA	Spouse or partner abuse, Psychological, Confirmed, Initial encounter
T74.31XD	Adult psychological abuse by nonspouse or nonpartner, Confirmed, Subsequent encounter
T74.31XD	Spouse or partner abuse, Psychological, Confirmed, Subsequent encounter
T74.32XA	Child psychological abuse, Confirmed, Initial encounter
T74.32XD	Child psychological abuse, Confirmed, Subsequent encounter
T76.01XA	Spouse or partner neglect, Suspected, Initial encounter
T76.01XD	Spouse or partner neglect, Suspected, Subsequent encounter
T76.02XA	Child neglect, Suspected, Initial encounter
T76.02XD	Child neglect, Suspected, Subsequent encounter
T76.11XA	Adult physical abuse by nonspouse or nonpartner, Suspected, Initial encounter
T76.11XA	Spouse or partner violence, Physical, Suspected, Initial encounter
T76.11XD	Adult physical abuse by nonspouse or nonpartner, Suspected, Subsequent encounter
T76.11XD	Spouse or partner violence, Physical, Suspected, Subsequent encounter
T76.12XA	Child physical abuse, Suspected, Initial encounter
T76.12XD	Child physical abuse, Suspected, Subsequent encounter
T76.21XA	Adult sexual abuse by nonspouse or nonpartner, Suspected, Initial encounter
T76.21XA	Spouse or partner violence, Sexual, Suspected, Initial encounter
T76.21XD	Adult sexual abuse by nonspouse or nonpartner, Suspected, Subsequent encounter
T76.21XD	Spouse or partner violence, Sexual, Suspected, Subsequent encounter
T76.22XA	Child sexual abuse, Suspected, Initial encounter
T76.22XD	Child sexual abuse, Suspected, Subsequent encounter
T76.31XA	Adult psychological abuse by nonspouse or nonpartner, Suspected, Initial encounter
T76.31XA	Spouse or partner abuse, Psychological, Suspected, Initial encounter
T76.31XD	Adult psychological abuse by nonspouse or nonpartner, Suspected, Subsequent encounter
T76.31XD	Spouse or partner abuse, Psychological, Suspected, Subsequent encounter
T76.32XA	Child psychological abuse, Suspected, Initial encounter
T76.32XD	Child psychological abuse, Suspected, Subsequent encounter
Z55.9	Academic or educational problem
Z56.82	Problem related to current military deployment status
Z56.9	Other problem related to employment
Z59.0	Homelessness
Z59.1	Inadequate housing
Z59.2	Discord with neighbor, lodger, or landlord
Z59.3	Problem related to living in a residential institution
Z59.4	Lack of adequate food or safe drinking water
Z59.5	Extreme poverty

ICD-10-CM	Disorder, condition, or problem
Z59.6	Low income
Z59.7	Insufficient social insurance or welfare support
Z59.9	Unspecified housing or economic problem
Z60.0	Phase of life problem
Z60.2	Problem related to living alone
Z60.3	Acculturation difficulty
Z60.4	Social exclusion or rejection
Z60.5	Target of (perceived) adverse discrimination or persecution
Z60.9	Unspecified problem related to social environment
Z62.29	Upbringing away from parents
Z62.810	Personal history (past history) of physical abuse in childhood
Z62.810	Personal history (past history) of sexual abuse in childhood
Z62.811	Personal history (past history) of psychological abuse in childhood
Z62.812	Personal history (past history) of neglect in childhood
Z62.820	Parent-child relational problem
Z62.891	Sibling relational problem
Z62.898	Child affected by parental relationship distress
Z63.0	Relationship distress with spouse or intimate partner
Z63.4	Uncomplicated bereavement
Z63.5	Disruption of family by separation or divorce
Z63.8	High expressed emotion level within family
Z64.0	Problems related to unwanted pregnancy
Z64.1	Problems related to multiparity
Z64.4	Discord with social service provider, including probation officer, case manager, or social services worker
Z65.0	Conviction in civil or criminal proceedings without imprisonment
Z65.1	Imprisonment or other incarceration
Z65.2	Problems related to release from prison
Z65.3	Problems related to other legal circumstances
Z65.4	Victim of crime
Z65.4	Victim of terrorism or torture
Z65.5	Exposure to disaster, war, or other hostilities
Z65.8	Other problem related to psychosocial circumstances
Z65.8	Religious or spiritual problem
Z65.9	Unspecified problem related to unspecified psychosocial circumstances
Z69.010	Encounter for mental health services for victim of child abuse by parent
Z69.010	Encounter for mental health services for victim of child neglect by parent
Z69.010	Encounter for mental health services for victim of child psychological abuse by parent
Z69.010	Encounter for mental health services for victim of child sexual abuse by parent
Z69.011	Encounter for mental health services for perpetrator of parental child abuse
Z69.011	Encounter for mental health services for perpetrator of parental child neglect
Z69.011	Encounter for mental health services for perpetrator of parental child psychological abuse
Z69.011	Encounter for mental health services for perpetrator of parental child sexual abuse
Z69.020	Encounter for mental health services for victim of nonparental child abuse

ICD-10-CM	Disorder, condition, or problem
Z69.020	Encounter for mental health services for victim of nonparental child neglect
Z69.020	Encounter for mental health services for victim of nonparental child psychological abuse
Z69.020	Encounter for mental health services for victim of nonparental child sexual abuse
Z69.021	Encounter for mental health services for perpetrator of nonparental child abuse
Z69.021	Encounter for mental health services for perpetrator of nonparental child neglect
Z69.021	Encounter for mental health services for perpetrator of nonparental child psychological abuse
Z69.021	Encounter for mental health services for perpetrator of nonparental child sexual abuse
Z69.11	Encounter for mental health services for victim of spouse or partner neglect
Z69.11	Encounter for mental health services for victim of spouse or partner psychological abuse
Z69.11	Encounter for mental health services for victim of spouse or partner violence, Physical
Z69.12	Encounter for mental health services for perpetrator of spouse or partner neglect
Z69.12	Encounter for mental health services for perpetrator of spouse or partner psychological abuse
Z69.12	Encounter for mental health services for perpetrator of spouse or partner violence, Physical
Z69.12	Encounter for mental health services for perpetrator of spouse or partner violence, Sexual
Z69.81	Encounter for mental health services for victim of nonspousal adult abuse
Z69.81	Encounter for mental health services for victim of spouse or partner violence, Sexual
Z69.82	Encounter for mental health services for perpetrator of nonspousal adult abuse
Z70.9	Sex counseling
Z71.9	Other counseling or consultation
Z72.0	Tobacco use disorder, mild
Z72.810	Child or adolescent antisocial behavior
Z72.811	Adult antisocial behavior
Z72.9	Problem related to lifestyle
Z75.3	Unavailability or inaccessibility of health care facilities
Z75.4	Unavailability or inaccessibility of other helping agencies
Z76.5	Malingering
Z91.19	Nonadherence to medical treatment
Z91.410	Personal history (past history) of spouse or partner violence, Physical
Z91.410	Personal history (past history) of spouse or partner violence, Sexual
Z91.411	Personal history (past history) of spouse or partner psychological abuse
Z91.412	Personal history (past history) of spouse or partner neglect
Z91.49	Other personal history of psychological trauma
Z91.5	Personal history of self-harm
Z91.82	Personal history of military deployment
Z91.83	Wandering associated with a mental disorder
Z91.89	Other personal risk factors

DSM-5 Advisors and Other Contributors

APA Board of Trustees DSM-5 Review Committees

Scientific Review Committee (SRC)

Kenneth S. Kendler, M.D. (Chair)
Robert Freedman, M.D. (Co-chair)
Dan G. Blazer, M.D., Ph.D., M.P.H.
David Brent, M.D. (2011–)
Ellen Leibenluft, M.D.
Sir Michael Rutter, M.D. (–2011)
Paul S. Summergrad, M.D.
Robert J. Ursano, M.D. (–2011)
Myrna Weissman, Ph.D. (2011–)
Joel Yager, M.D.
Jill L. Opalesky M.S. (Administrative Support)

Clinical and Public Health Review Committee (CPHC)

John S. McIntyre, M.D. (Chair)
Joel Yager, M.D. (Co-chair)
Anita Everett M.D.
Cathryn A. Galanter, M.D.
Jeffrey M. Lyness, M.D.
James E. Niner, M.D.
Victor I. Reus, M.D.
Michael J. Vergare, M.D.
Ann Miller (Administrative Support)

Oversight Committee

Carolyn Robinowitz, M.D. (Chair)
Mary Badaracco, M.D.
Ronald Burd, M.D.
Robert Freedman, M.D.
Jeffrey A. Lieberman, M.D.
Kyla Pope, M.D.
Victor I. Reus, M.D.
Daniel K. Winstead, M.D.
Joel Yager, M.D.

APA Assembly DSM-5 Review Committee

Glenn A. Martin, M.D. (Chair)
R. Scott Benson, M.D. (Speaker of the Assembly)
William Cardasis, M.D.
John M. de Figueiredo, M.D.
Lawrence S. Gross, M.D.
Brian S. Hart, M.D.

Stephen A. McLeod Bryant, M.D.
Gregory A. Miller, M.D.
Roger Peele, M.D.
Charles S. Price, M.D.
Deepika Sastry, M.D.
John P.D. Shemo, M.D.
Eliot Sorel, M.D.

DSM-5 Summit Group

Dilip V. Jeste, M.D. (Chair)
R. Scott Benson, M.D.
Kenneth S. Kendler, M.D.
Helena C. Kraemer, Ph.D.
David J. Kupfer, M.D.
Jeffrey A. Lieberman, M.D.
Glenn A. Martin, M.D.
John S. McIntyre, M.D.
John M. Oldham, M.D.
Roger Peele, M.D.
Darrel A. Regier, M.D., M.P.H.
James H. Scully Jr., M.D.
Joel Yager, M.D.
Paul S. Appelbaum, M.D. (Consultant)
Michael B. First, M.D. (Consultant)

DSM-5 Field Trials Review

Robert D. Gibbons, Ph.D.
Craig Nelson, M.D.

DSM-5 Forensic Review

Paul S. Appelbaum, M.D.
Lama Bazzi, M.D.
Alec W. Buchanan, M.D., Ph.D.
Carissa Cabán Alemán, M.D.
Michael Champion, M.D.
Jeffrey C. Eisen, M.D.
Elizabeth Ford, M.D.
Daniel T. Hackman, M.D.
Mark Hauser, M.D.
Steven K. Hoge, M.D., M.B.A.
Debra A. Pinals, M.D.
Guillermo Portillo, M.D.
Patricia Recupero, M.D., J.D.
Robert Weinstock, M.D.
Cheryl Wills, M.D.
Howard V. Zonana, M.D.

Past DSM-5 APA Staff

Erin J. Dalder-Alpher
Kristin Edwards
Leah I. Engel

Lenna Jawdat
Elizabeth C. Martin
Rocio J. Salvador

Work Group Advisors

ADHD and Disruptive Behavior Disorders

Emil F. Coccaro, M.D.
Deborah Dabrick, Ph.D.
Prudence W. Fisher, Ph.D.
Benjamin B. Lahey, Ph.D.
Salvatore Mannuzza, Ph.D.
Mary Solanto, Ph.D.
J. Blake Turner, Ph.D.
Eric Youngstrom, Ph.D.

Anxiety, Obsessive-Compulsive Spectrum, Posttraumatic, and Dissociative Disorders

Lynn E. Alden, Ph.D.
David B. Arciniegas, M.D.
David H. Barlow, Ph.D.
Katja Beesdo-Baum, Ph.D.
Chris R. Brewin, Ph.D.
Richard J. Brown, Ph.D.
Timothy A. Brown, Ph.D.
Richard A. Bryant, Ph.D.
Joan M. Cook, Ph.D.
Joop de Jong, M.D., Ph.D.
Paul F. Dell, Ph.D.
Damiaan Denys, M.D.
Bruce P. Dohrenwend, Ph.D.
Brian A. Fallon, M.D., M.P.H.
Edna B. Foa, Ph.D.
Martin E. Franklin, Ph.D.
Wayne K. Goodman, M.D.
Jon E. Grant, J.D., M.D.
Bonnie L. Green, Ph.D.
Richard G. Heimberg, Ph.D.
Judith L. Herman, M.D.
Devon E. Hinton, M.D., Ph.D.
Stefan G. Hofmann, Ph.D.
Charles W. Hoge, M.D.
Terence M. Keane, Ph.D.
Nancy J. Keuthen, Ph.D.
Dean G. Kilpatrick, Ph.D.
Katharina Kircanski, Ph.D.
Laurence J. Kirmayer, M.D.
Donald F. Klein, M.D., D.Sc.
Amaro J. Laria, Ph.D.
Richard T. LeBeau, M.A.
Richard J. Loewenstein, M.D.
David Mataix-Cols, Ph.D.
Thomas W. McAllister, M.D.

Harrison G. Pope, M.D., M.P.H.
Ronald M. Rapee, Ph.D.
Steven A. Rasmussen, M.D.
Patricia A. Resick, Ph.D.
Vedat Sar, M.D.
Sanjaya Saxena, M.D.
Paula P. Schnurr, Ph.D.
M. Katherine Shear, M.D.
Daphne Simeon, M.D.
Harvey S. Singer, M.D.
Melinda A. Stanley, Ph.D.
James J. Strain, M.D.
Kate Wolitzky Taylor, Ph.D.
Onno van der Hart, Ph.D.
Eric Vermetten, M.D., Ph.D.
John T. Walkup, M.D.
Sabine Wilhelm, Ph.D.
Douglas W. Woods, Ph.D.
Richard E. Zinbarg, Ph.D.
Joseph Zohar, M.D.

Childhood and Adolescent Disorders

Adrian Angold, Ph.D.
Deborah Beidel, Ph.D.
David Brent, M.D.
John Campo, M.D.
Gabrielle Carlson, M.D.
Prudence W. Fisher, Ph.D.
David Klonsky, Ph.D.
Matthew Nock, Ph.D.
J. Blake Turner, Ph.D.

Eating Disorders

Michael J. Devlin, M.D.
Denise E. Wilfley, Ph.D.
Susan Z. Yanovski, M.D.

Mood Disorders

Boris Birmaher, M.D.
Yeates Conwell, M.D.
Ellen B. Denney, Ph.D.
S. Ann Hartlage, Ph.D.
Jack M. Hettema, M.D., Ph.D.
Michael C. Neale, Ph.D.
Gordon B. Parker, M.D., Ph.D., D.Sc.
Roy H. Perlis, M.D. M.Sc.
Holly G. Prigerson, Ph.D.
Norman E. Rosenthal, M.D.
Peter J. Schmidt, M.D.

Mort M. Silverman, M.D.
 Meir Steiner, M.D., Ph.D.
 Mauricio Tohen, M.D., Dr.P.H., M.B.A.
 Sidney Zisook, M.D.

Neurocognitive Disorders

Jiska Cohen-Mansfield, Ph.D.
 Vladimir Hachinski, M.D., C.M., D.Sc.
 Sharon Inouye, M.D., M.P.H.
 Grant Iverson, Ph.D.
 Laura Marsh, M.D.
 Bruce Miller, M.D.
 Jacobo Mintzer, M.D., M.B.A.
 Bruce Pollock, M.D., Ph.D.
 George Prigatano, Ph.D.
 Ron Ruff, Ph.D.
 Ingmar Skoog, M.D., Ph.D.
 Robert Sweet, M.D.
 Paula Trzepacz, M.D.

Neurodevelopmental Disorders

Ari Ne'eman
 Nickola Nelson, Ph.D.
 Diane Paul, Ph.D.
 Eva Petrova, Ph.D.
 Andrew Pickles, Ph.D.
 Jan Piek, Ph.D.
 Helene Polatajko, Ph.D.
 Alya Reeve, M.D.
 Mabel Rice, Ph.D.
 Joseph Sergeant, Ph.D.
 Bennett Shaywitz, M.D.
 Sally Shaywitz, M.D.
 Audrey Thurm, Ph.D.
 Keith Widaman, Ph.D.
 Warren Zigman, Ph.D.

Personality and Personality Disorders

Eran Chemerinski, M.D.
 Thomas N. Crawford, Ph.D.
 Harold W. Koenigsberg, M.D.
 Kristian E. Markon, Ph.D.
 Rebecca L. Shiner, Ph.D.
 Kenneth R. Silk, M.D.
 Jennifer L. Tackett, Ph.D.
 David Watson, Ph.D.

Psychotic Disorders

Kamaldeep Bhui, M.D.
 Manuel J. Cuesta, M.D., Ph.D.
 Richard Douyon, M.D.
 Paolo Fusar-Poli, Ph.D.
 John H. Krystal, M.D.
 Thomas H. McGlashan, M.D.
 Victor Peralta, M.D., Ph.D.
 Anita Riecher-Rössler, M.D.
 Mary V. Seeman, M.D.

Sexual and Gender Identity Disorders

Stan E. Althof, Ph.D.
 Richard Balon, M.D.
 John H.J. Bancroft, M.D., M.A., D.P.M.
 Howard E. Barbaree, Ph.D., M.A.
 Rosemary J. Basson, M.D.
 Sophie Bergeron, Ph.D.
 Anita L. Clayton, M.D.
 David L. Delmonico, Ph.D.
 Domenico Di Ceglie, M.D.
 Esther Gomez-Gil, M.D.
 Jamison Green, Ph.D.
 Richard Green, M.D., J.D.
 R. Karl Hanson, Ph.D.
 Lawrence Hartmann, M.D.
 Stephen J. Hucker, M.B.
 Eric S. Janus, J.D.
 Patrick M. Jern, Ph.D.
 Megan S. Kaplan, Ph.D.
 Raymond A. Knight, Ph.D.
 Ellen T.M. Laan, Ph.D.
 Stephen B. Levine, M.D.
 Christopher G. McMahon, M.B.
 Marta Meana, Ph.D.
 Michael H. Miner, Ph.D., M.A.
 William T. O'Donohue, Ph.D.
 Michael A. Perelman, Ph.D.
 Caroline F. Pukall, Ph.D.
 Robert E. Pyke, M.D., Ph.D.
 Vernon L. Quinsey, Ph.D. M.Sc.
 David L. Rowland, Ph.D., M.A.
 Michael Sand, Ph.D., M.P.H.
 Leslie R. Schover, Ph.D., M.A.
 Paul Stern, B.S., J.D.
 David Thornton, Ph.D.
 Leonore Tiefer, Ph.D.
 Douglas E. Tucker, M.D.
 Jacques van Lankveld, Ph.D.
 Marcel D. Waldinger, M.D., Ph.D.

Sleep-Wake Disorders

Donald L. Bliwise, Ph.D.
 Daniel J. Buysse, M.D.
 Vishesh K. Kapur, M.D., M.P.H.
 Sanjeev V. Kothare, M.D.
 Kenneth L. Lichstein, Ph.D.
 Mark W. Mahowald, M.D.
 Rachel Manber, Ph.D.
 Emmanuel Mignot, M.D., Ph.D.
 Timothy H. Monk, Ph.D., D.Sc.
 Thomas C. Neylan, M.D.
 Maurice M. Ohayon, M.D., D.Sc., Ph.D.
 Judith Owens, M.D., M.P.H.
 Daniel L. Picchietti, M.D.
 Stuart F. Quan, M.D.
 Thomas Roth, Ph.D.
 Daniel Weintraub, M.D.

Theresa B. Young, Ph.D.
Phyllis C. Zee, M.D., Ph.D.

Somatic Symptom Disorders

Brenda Bursch, Ph.D.
Kurt Kroenke, M.D.
W. Curt LaFrance, Jr., M.D., M.P.H.
Jon Stone, M.B., Ch.B., Ph.D.
Lynn M. Wegner, M.D.

Substance-Related Disorders

Raymond F. Anton, Jr., M.D.
Deborah A. Dawson, Ph.D.
Roland R. Griffiths, Ph.D.
Dorothy K. Hatsukami, Ph.D.
John E. Helzer, M.D.
Marilyn A. Huestis, Ph.D.
John R. Hughes, M.D.
Laura M. Julianio, Ph.D.
Thomas R. Kosten, M.D.
Nora D. Volkow, M.D.

DSM-5 Study Group and Other DSM-5 Group Advisors

Lifespan Developmental Approaches

Christina Bryant, Ph.D.
Amber Gum, Ph.D.
Thomas Meeks, M.D.
Jan Mohlman, Ph.D.
Steven Thorp, Ph.D.
Julie Wetherell, Ph.D.

Gender and Cross-Cultural Issues

Neil K. Aggarwal, M.D., M.B.A., M.A.
Sofie Bäärnhielm, M.D., Ph.D.
José J. Bauermeister, Ph.D.
James Boehnlein, M.D., M.Sc.
Jaswant Guzder, M.D.
Alejandro Interian, Ph.D.
Sushrut S. Jadhav, M.B.B.S., M.D., Ph.D.
Laurence J. Kirmayer, M.D.
Alex J. Kopelowicz, M.D.
Amaro J. Laria, Ph.D.
Steven R. Lopez, Ph.D.
Kwame J. McKenzie, M.D.
John R. Peteet, M.D.

Hans (J.G.B.M.) Rohlhof, M.D.
Cecile Rousseau, M.D.
Mitchell G. Weiss, M.D., Ph.D.

Psychiatric/General Medical Interface

Daniel L. Coury, M.D.
Bernard P. Dreyer, M.D.
Danielle Laraque, M.D.
Lynn M. Wegner, M.D.

Impairment and Disability

Prudence W. Fisher, Ph.D.
Martin Prince, M.D., M.Sc.
Michael R. Von Korff, Sc.D.

Diagnostic Assessment Instruments

Prudence W. Fisher, Ph.D.
Robert D. Gibbons, Ph.D.
Ruben Gur, Ph.D.
John E. Helzer, M.D.
John Houston, M.D., Ph.D.
Kurt Kroenke, M.D.

Other Contributors/Consultants

ADHD and Disruptive Behavior Disorders

Patrick E. Shrout, Ph.D.
Erik Willcutt, Ph.D.

Anxiety, Obsessive-Compulsive Spectrum, Posttraumatic, and Dissociative Disorders

Etzel Cardeña, Ph.D.
Richard J. Castillo, Ph.D.
Eric Hollander, M.D.
Charlie Marmar, M.D.
Alfonso Martínez-Taboas, Ph.D.
Mark W. Miller, Ph.D.
Mark H. Pollack, M.D.
Heidi S. Resnick, Ph.D.

Childhood and Adolescent Disorders

Grace T. Baranek, Ph.D.
Colleen Jacobson, Ph.D.
Maria Oquendo, M.D.
Sir Michael Rutter, M.D.

Eating Disorders

Nancy L. Zucker, Ph.D.

Mood Disorders

Keith Hawton, M.D., Ph.D.
David A. Jobes, Ph.D.
Maria A. Oquendo, M.D.
Alan C. Swann, M.D.

Neurocognitive Disorders

J. Eric Ahlskog, M.D., Ph.D.
 Allen J. Aksamit, M.D.
 Marilyn Albert, Ph.D.
 Guy Mckhann, M.D.
 Bradley Boeve, M.D.
 Helena Chui, M.D.
 Sureyya Dikmen, Ph.D.
 Douglas Galasko, M.D.
 Harvey Levin, Ph.D.
 Mark Lovell, Ph.D.
 Jeffery Max, M.B.B.Ch.
 Ian McKeith, M.D.
 Cynthia Munro, Ph.D.
 Marlene Oscar-Berman, Ph.D.
 Alexander Troster, Ph.D.

Neurodevelopmental Disorders

Anna Barnett, Ph.D.
 Martha Denckla, M.D.
 Jack M. Fletcher, Ph.D.
 Dido Green, Ph.D.
 Stephen Greenspan, Ph.D.
 Bruce Pennington, Ph.D.
 Ruth Shalev, M.D.
 Larry B. Silver, M.D.
 Lauren Swineford, Ph.D.
 Michael Von Aster, M.D.

Personality and Personality Disorders

Patricia R. Cohen, Ph.D.
 Jaime L. Derringer, Ph.D.
 Lauren Helm, M.D.
 Christopher J. Patrick, Ph.D.
 Anthony Pinto, Ph.D.

Psychotic Disorders

Scott W. Woods, M.D.

Sexual and Gender Identity Disorders

Alan J. Riley, M.Sc.
 Ray C. Rosen, Ph.D.

Sleep-Wake Disorders

Jack D. Edinger, Ph.D.
 David Gozal, M.D.
 Hochang B. Lee, M.D.
 Tore A. Nielsen, Ph.D.
 Michael J. Sateia, M.D.
 Jamie M. Zeitzer, Ph.D.

Somatic Symptom Disorders

Chuck V. Ford, M.D.
 Patricia I. Rosebush, M.Sc.N., M.D.

Substance-Related Disorders

Sally M. Anderson, Ph.D.
 Julie A. Kable, Ph.D.
 Christopher Martin, Ph.D.
 Sarah N. Mattson, Ph.D.
 Edward V. Nunes, Jr., M.D.
 Mary J. O'Connor, Ph.D.
 Heather Carmichael Olson, Ph.D.
 Blair Paley, Ph.D.
 Edward P. Riley, Ph.D.
 Tulshi D. Saha, Ph.D.
 Wim van den Brink, M.D., Ph.D.
 George E. Woody, M.D.

Diagnostic Spectra and DSM/ICD Harmonization

Bruce Cuthbert, Ph.D.

Lifespan Developmental Approaches

Aartjan Beekman Ph.D.
 Alistair Flint, M.B.
 David Sultzer, M.D.
 Ellen Whyte, M.D.

Gender and Cross-Cultural Issues

Sergio Aguilar-Gaxiola, M.D., Ph.D.
 Kavos G. Bassiri, M.S.
 Venkataramana Bhat, M.D.
 Marit Boiler, M.P.H.
 Denise Canso, M.Sc.
 Smita N. Deshpande, M.D., D.P.M.
 Ravi DeSilva, M.D.
 Esperanza Diaz, M.D.
 Byron J. Good, Ph.D.
 Simon Groen, M.A.
 Ladson Hinton, M.D.
 Lincoln I. Khasakhala, Ph.D.
 Francis G. Lu, M.D.
 Athena Madan, M.A.
 Anne W. Mbwayero, Ph.D.
 Oanh Meyer, Ph.D.
 Victoria N. Mutiso, Ph.D., D.Sc.
 David M. Ndeti, M.D.
 Andel V. Nicasio, M.S.Ed.
 Vasudeo Paralikar, M.D., Ph.D.
 Kanak Patil, M.A.
 Filipa I. Santos, H.B.Sc.
 Sanjeev B. Sarmukaddam, Ph.D., M.Sc.
 Monica Z. Scalco, M.D., Ph.D.
 Katie Thompson, M.A.
 Hendry Ton, M.D., M.Sc.
 Rob C.J. van Dijk, M.Sc.
 William A. Vega, Ph.D.
 Johann M. Vega-Dienstmaier, M.D.
 Joseph Westermeyer, M.D., Ph.D.

Psychiatric/General Medical Interface

Daniel J. Balog, M.D.
Charles C. Engel, M.D., M.P.H.
Charles D. Motsinger, M.D.

Impairment and Disability

Cille Kennedy, Ph.D.

Diagnostic Assessment Instruments

Paul J. Piconis, Ph.D.

Other Conditions That May Be a Focus of Clinical Attention

William E. Narrow, M.D., M.P.H., *Chair*
Roger Peele, M.D.
Lawson R. Wulsin, M.D.
Charles H. Zeanah, M.D.
Prudence W. Fisher, Ph.D., *Advisor*
Stanley N. Caroff, M.D., *Contributor/Consultant*
James B. Lohr, M.D., *Contributor/Consultant*
Marianne Wambolt, Ph.D., *Contributor/Consultant*

DSM-5 Research Group

Allan Donner, Ph.D.

CPHC Peer Reviewers

Kenneth Altshuler, M.D.
Pedro G. Alvarenga, M.D.
Diana J. Antonacci, M.D.
Richard Balon, M.D.
David H. Barlow, Ph.D.
L. Jarrett Barnhill, M.D.
Katja Beesdo-Baum, Ph.D.
Marty Boman, Ed.D.
James Bourgeois, M.D.
David Braff, M.D.
Harry Brandt, M.D.
Kirk Brower, M.D.
Rachel Bryant-Waugh, Ph.D.
Jack D. Burke Jr., M.D., M.P.H.
Brenda Bursch, Ph.D.
Joseph Camilleri, M.D.
Patricia Casey, M.D.
F. Xavier Castellanos, M.D.
Eran Chemerinski, M.D.
Wai Chen, M.D.
Elie Cheniaux, M.D., D.Sc.
Cheryl Chessick, M.D.
J. Richard Ciccone, M.D.
Anita H. Clayton, M.D.
Tihalia J. Coleman, Ph.D.
John Csernansky, M.D.
Manuel J. Cuesta M.D., Ph.D.
Joanne L. Davis, M.D.
David L. Delmonico, Ph.D.
Ray J. DePaulo, M.D.
Dimitris Dikeos, M.D.
Ina E. Djonlagic, M.D.
C. Neill Epperson, M.D.
Javier I. Escobar, M.D., M.Sc.
Spencer Eth, M.D.
David Fassler, M.D.
Giovanni A. Fava, M.D.
Robert Feinstein, M.D.
Molly Finnerty, M.D.
Mark H. Fleisher, M.D.
Alessio Florentini, M.D.

Laura Fochtmann, M.D.
Marshal Forstein, M.D.
William French, M.D.
Maximillian Gahr, M.D.
Cynthia Geppert, M.D.
Ann Germaine, Ph.D.
Marcia Goin, M.D.
David A. Gorelick, M.D., Ph.D.
David Graeber, M.D.
Cynthia A. Graham, Ph.D.
Andreas Hartmann, M.D.
Victoria Hendrick, M.D.
Merrill Herman, M.D.
David Herzog, M.D.
Mardi Horowitz, M.D.
Ya-fen Huang, M.D.
Anthony Kales, M.D.
Niranjan S. Karnik, M.D., Ph.D.
Jeffrey Katzman, M.D.
Bryan King, M.D.
Cecilia Kjellgren, M.D.
Harold W. Koenigsberg, M.D.
Richard B. Krueger, M.D.
Steven Lamberti, M.D.
Ruth A. Lanius, M.D.
John Lauriello, M.D.
Anthony Lehman, M.D.
Michael Linden, M.D.
Mark W. Mahowald, M.D.
Marsha D. Marcus, Ph.D.
Stephen Marder, M.D.
Wendy Marsh, M.D.
Michael S. McCloskey, Ph.D.
Jeffrey Metzner, M.D.
Robert Michels, M.D.
Laura Miller, M.D.
Michael C. Miller, M.D.
Frederick Moeller, M.D.
Peter T. Morgan, M.D., Ph.D.
Madhav Muppa, M.D.
Philip Muskin, M.D.

Joachim Nitschke, M.D.
 Abraham Nussbaum, M.D.
 Ann Olincy, M.D.
 Mark Onslow, Ph.D.
 Sally Ozonoff, Ph.D.
 John R. Peteet, M.D.
 Ismene L. Petrakis, M.D.
 Christophe M. Pfeiffer, M.D.
 Karen Pierce, M.D.
 Belinda Plattner, M.D.
 Franklin Putnam, M.D.
 Stuart F. Quan, M.D.
 John Racy, M.D.
 Phillip Resnick, M.D.
 Michele Riba, M.D.
 Jerold Rosenbaum, M.D.
 Stephen Ross, M.D.
 Lawrence Scahill, M.S.N., Ph.D.
 Daniel Schechter, M.D.
 Mary V. Seeman, M.D.
 Alessandro Serretti, M.D.
 Jianhua Shen, M.D.

Ravi Kumar R. Singareddy, M.D.
 Ingmar Skoog, M.D., Ph.D.
 Gary Small, M.D.
 Paul Soloff, M.D.
 Christina Stadler, M.D., Ph.D.
 Nada Stotland, M.D.
 Neil Swerdlow, M.D.
 Kim Tillery, Ph.D.
 David Tolin, Ph.D.
 Jayne Trachman, M.D.
 Luke Tsai, M.D.
 Ming T. Tsuang, M.D., Ph.D.
 Richard Tuch, M.D.
 Johan Verhulst, M.D.
 B. Timothy Walsh, M.D.
 Michael Weissberg, M.D.
 Godehard Weniger, M.D.
 Keith Widaman, Ph.D.
 Thomas Wise, M.D.
 George E. Woods, M.D.
 Kimberly A. Yonkers, M.D.
 Alexander Young, M.D.

DSM-5 Field Trials in Academic Clinical Centers— Adult Samples

David Geffen School of Medicine, University of California, Los Angeles

Investigator

Helen Lavretsky, M.D., Principal Investigator

Referring and Interviewing Clinicians

Jessica Brommelhoff, Ph.D.
 Xavier Cagigas, Ph.D.
 Paul Cernin, Ph.D.
 Linda Ercoli, Ph.D.
 Randall Espinoza, M.D.

Helen Lavretsky, M.D.
 Jeanne Kim, Ph.D.
 David Merrill, M.D.
 Karen Miller, Ph.D.
 Christopher Nunez, Ph.D.

Research Coordinators

Natalie St. Cyr, M.A., Lead Research
 Coordinator
 Nora Nazarian, B.A.
 Colin Shinn, M.A.

Centre for Addiction and Mental Health, Toronto, Ontario, Canada

Investigators

Bruce G. Pollock, M.D., Ph.D., Lead Principal
 Investigator
 R. Michael Bagby, Ph.D., Principal Investigator
 Kwame J. McKenzie, M.D., Principal
 Investigator
 Tony P. George, M.D., Co-investigator
 Lena C. Quilty, Ph.D., Co-investigator
 Peter Voore, M.D., Co-investigator

Referring and Interviewing Clinicians

Donna E. Akman, Ph.D.
 R. Michael Bagby, Ph.D.
 Wayne C. V. Baici, M.D.
 Crystal Baluyut, M.D.

Eva W. C. Chow, M.D., J.D., M.P.H.
 Z. J. Daskalakis, M.D., Ph.D.
 Pablo Diaz-Hermosillo, M.D.
 George Foussias, M.Sc., M.D.
 Paul A. Frewen, Ph.D.
 Ariel Graff-Guerrero, M.D., M.Sc., Ph.D.
 Margaret K. Hahn, M.D.
 Lorena Hsu, Ph.D.
 Justine Joseph, Ph.D.
 Sean Kidd, Ph.D.
 Kwame J. McKenzie, M.D.
 Mahesh Menon, Ph.D.
 Romina Mizrahi, M.D., Ph.D.
 Daniel J. Mueller, M.D., Ph.D.
 Lena C. Quilty, Ph.D.
 Anthony C. Ruocco, Ph.D.

Jorge Soni, M.D.
 Aristotle N. Voineskos, M.D., Ph.D.
 George Voineskos, M.D.
 Peter Voore, Ph.D.
 Chris Watson, Ph.D.

Referring Clinicians

Ofer Agid, M.D.
 Ash Bender, M.D.
 Patricia Cavanagh, M.D.
 Sarah Colman, M.D.
 Vincenzo Deluca, M.D.
 Justin Geagea, M.D.
 David S. Goldbloom, M.D.
 Daniel Greben, M.D.
 Malati Gupta, M.D.
 Ken Harrison, M.D.
 Imraan Jeeva, M.D.
 Joel Jeffries, M.B.
 Judith Laposa, Ph.D.

Jan Malat, M.D.
 Shelley McMain, Ph.D.
 Bruce Pollock, M.D., Ph.D.
 Andriy V. Samokhvalov, M.D., Ph.D.
 Martin Strassnig, M.D.
 Albert H. C. Wong, M.D., Ph.D.

Research Coordinators

Gloria I. Leo, M.A., Lead Research Coordinator
 Anissa D. Bachan, B.A.
 Bahar Haji-Khamneh, M.A.
 Olga Likhodi, M.Sc.
 Eleanor J. Liu, Ph.D.
 Sarah A. McGee Ng, B.B.A.

Other Research Staff

Susan E. Dickens, M.A., Clinical Research
 Manager
 Sandy Richards, B.Sc.N., Schizophrenia
 Research Manager

Dallas VA Medical Center, Dallas, Texas

Investigators

Carol S. North, M.D., M.P.E., Principal
 Investigator
 Alina Suris, Ph.D., A.B.P.P., Principal
 Investigator

Referring and Interviewing Clinicians

Barry Ardolf, Psy.D.
 Abila Awan, M.D.
 Joel Baskin, M.D.
 John Black, Ph.D.
 Jeffrey Dodds, Ph.D.
 Gloria Emmett, Ph.D.
 Karma Hudson, M.D.
 Jamylah Jackson, Ph.D., A.B.P.P.
 Lynda Kirkland-Culp, Ph.D., A.B.P.P.
 Heidi Koehler, Ph.D., A.B.P.P.
 Elizabeth Lewis, Psy.D.
 Aashish Parikh, M.D.
 Reed Robinson, Ph.D.
 Jheel Shah, M.D.
 Geetha Shivakumar, M.D.
 Sarah Spain, Ph.D., A.B.P.P.

Lisa Thoman, Ph.D.
 Lia Thomas, M.D.
 Jamie Zabukovec, Psy.D.
 Mustafa Zaidi, M.D.
 Andrea Zartman, Ph.D.

General Referral Sources

Robert Blake, L.M.S.W.
 Evelyn Gibbs, L.M.S.W.
 Michelle King-Thompson, L.M.S.W.

Research Coordinators

Jeannie B. Whitman, Ph.D., Lead Research
 Coordinator
 Sunday Adewuyi, M.D.
 Elizabeth Anderson, B.A.
 Solaleh Azimipour, B.S.
 Carissa Barney, B.S.
 Kristie Cavazos, B.A.
 Robert Devereaux, B.S.
 Dana Downs, M.S., M.S.W.
 Sharjeel Farooqui, M.D.
 Julia Smith, Psy.D.
 Kun-Ying H. Sung, B.S.

School of Medicine, The University of Texas San Antonio,
 San Antonio, Texas

Investigator

Mauricio Tohen, M.D., Dr.P.H., M.B.A.,
 Principal Investigator

Referring and Interviewing Clinicians

Suman Baddam, Psy.D.
 Charles L. Bowden, M.D.

Nancy Diazgranados, M.D., M.S.
 Craig A. Dike, Psy.D.
 Dianne E. Dunn, Psy.D., M.P.H.
 Elena Gherman, M.D.
 Jodi M. Gonzalez, Ph.D.
 Pablo Gonzalez, M.D.
 Phillip Lai, Psy.D.

Natalie Maples-Aguilar, M.A., L.P.A.
 Marlon P. Quinones, M.D.
 Jeslina J. Raj, Psy.D.
 David L. Roberts, Ph.D.
 Nancy Sandusky, R.N., F.P.M.H.N.P.-B.C.,
 D.N.P.-C.
 Donna S. Stutes, M.S., L.P.C.
 Mauricio Tohen, M.D., Dr.PH, M.B.A.
 Dawn I. Velligan, Ph.D.
 Weiran Wu, M.D., Ph.D.

Referring Clinicians

Albana Dassori, M.D.
 Megan Frederick, M.A.

Robert Gonzalez, M.D.
 Uma Kasinath, M.D.
 Camis Milam, M.D.
 Vivek Singh, M.D.
 Peter Thompson, M.D.

Research Coordinators

Melissa Hernandez, B.A., Lead Research
 Coordinator
 Fermin Alejandro Carrizales, B.A.
 Martha Dahl, R.N., B.S.N.
 Patrick M. Smith, B.A.
 Nicole B. Watson, M.A.

Michael E. DeBakey VA Medical Center and the Menninger Clinic,
 Houston, Texas (Joint Study Site)

Michael E. DeBakey VA Medical Center

Investigator

Laura Marsh, M.D., Principal Investigator

Referring and Interviewing Clinicians

Shalini Aggarwal, M.D.
 Su Bailey, Ph.D.
 Minnete (Helen) Beckner, Ph.D.
 Crystal Clark, M.D.
 Charles DeJohn, M.D.
 Robert Garza, M.D.
 Aruna Gottumakkla, M.D.
 Janet Hickey, M.D.
 James Ireland, M.D.
 Mary Lois Lacey, A.P.R.N.
 Wendy Leopoulos, M.D.
 Laura Marsh, M.D.
 Deleene Menefee, Ph.D.
 Brian I. Miller, Ph.D.
 Candy Smith, Ph.D.
 Avila Steele, Ph.D.
 Jill Wanner, Ph.D.
 Rachel Wells, Ph.D.
 Kaki York-Ward, Ph.D.

Referring Clinicians

Sara Allison, M.D.
 Leonard Denney, L.C.S.W.
 Catherine Flores, L.C.S.W.
 Nathalie Marie, M.D.
 Christopher Martin, M.D.
 Sanjay Mathew, M.D.
 Erica Montgomery, M.D.
 Gregory Scholl, P.A.
 Jocelyn Ulanday, M.D., M.P.H.

Research Coordinators

Sarah Neely Torres, B.S., Lead Research
 Coordinator
 Kathleen Grout, M.A.
 Lea Kiefer, M.P.H.
 Jana Tran, M.A.

Volunteer Research Assistants

Catherine Clark
 Linh Hoang

Menninger Clinic

Investigator

Efrain Bleiberg, M.D., Principal Investigator

Referring and Interviewing Clinicians

Jennifer Baumgardner, Ph.D.
 Elizabeth Dodd Conaway, L.C.S.W., B.C.D.
 Warren Christianson, D.O.
 Wesley Clayton, L.M.S.W.
 J. Christopher Fowler, Ph.D.
 Michael Groat, Ph.D.
 Edythe Harvey, M.D.
 Denise Kagan, Ph.D.
 Hans Meyer, L.C.S.W.

Segundo Robert-Ibarra, M.D.
 Sandhya Trivedi, M.D.
 Rebecca Wagner, Ph.D.
 Harrell Woodson, Ph.D.
 Amanda Yoder, L.C.S.W.

Referring Clinicians

James Flack, M.D.
 David Ness, M.D.

Research Coordinators

Steve Herrera, B.S., M.T., Lead Research
 Coordinator
 Allison Kalpakci, B.A.

Mayo Clinic, Rochester, Minnesota

Investigators

Mark A. Frye, M.D., Principal Investigator
 Glenn E. Smith, Ph.D., Principal Investigator
 Jeffrey P. Staab M.D., M.S., Principal Investigator

Referring and Interviewing Clinicians

Osama Abulseoud, M.D.
 Jane Cerhan, Ph.D.
 Julie Fields, Ph.D.
 Mark A. Frye, M.D.
 Manuel Fuentes, M.D.
 Yonas Geda, M.D.
 Maria Harmandayan, M.D.
 Reba King, M.D.
 Simon Kung, M.D.
 Mary Machuda, Ph.D.
 Donald McAlpine, M.D.
 Alastair McKean, M.D.
 Juliana Moraes, M.D.
 Teresa Rummans, M.D.

James R. Rundell, M.D.
 Richard Seime, Ph.D.
 Glenn E. Smith, Ph.D.
 Christopher Sola, D.O.
 Jeffrey P. Staab M.D., M.S.
 Marin Veldic, M.D.
 Mark D. Williams, M.D.
 Maya Yustis, Ph.D.

Research Coordinators

Lisa Seymour, B.S., Lead Research Coordinator
 Scott Feeder, M.S.
 Lee Gunderson, B.S.
 Sherrie Hanna, M.A., L.P.
 Kelly Harper, B.A.
 Katie Mingo, B.A.
 Cynthia Stoppel, A.S.

Other Study Staff

Anna Frye
 Andrea Hogan

Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania

Investigators

Mahendra T. Bhati, M.D., Principal Investigator
 Marna S. Barrett, Ph.D., Co-investigator
 Michael E. Thase, M.D., Co-investigator

Referring and Interviewing Clinicians

Peter B. Bloom, M.D.
 Nicole K Chalmers L.C.S.W.
 Torrey A. Creed, Ph.D.
 Mario Cristancho, M.D.
 Amy Cunningham, Psy.D.
 John P. Dennis, Ph.D.
 Josephine Elia, M.D.
 Peter Gariti, Ph.D., L.C.S.W.
 Philip Gehrman, Ph.D.
 Laurie Gray, M.D.
 Emily A.P. Haigh, Ph.D.
 Nora J. Johnson, M.B.A., M.S., Psy.D.
 Paulo Knapp, M.D.
 Yong-Tong Li, M.D.
 Bill Mace, Ph.D.
 Kevin S. McCarthy, Ph.D.
 Dimitri Perivoliotis, Ph.D.
 Luke Schultz, Ph.D.
 Tracy Steen, Ph.D.
 Chris Tjoa, M.D.
 Nancy A. Wintering, L.C.S.W.

Referring Clinicians

Eleanor Ainslie, M.D.
 Kelly C. Allison, Ph.D.

Rebecca Aspden, M.D.
 Claudia F. Baldassano, M.D.
 Vijayta Bansal, M.D.
 Rachel A. Bennett, M.D.
 Richard Bollinger, Ph.D.
 Andrea Bowen, M.D.
 Karla Campanella, M.D.
 Anthony Carlino, M.D.
 Noah Carroll, M.S.S.
 Alysia Cirona, M.D.
 Samuel Collier, M.D.
 Andreea Crauciuc, L.C.S.W.
 Pilar Cristancho, M.D.
 Traci D'Almeida, M.D.
 Kathleen Diller, M.D.
 Benoit Dubé, M.D.
 Jon Dukes, M.S.W.
 Lauren Elliott, M.D.
 Mira Elwell, B.A.
 Mia Everett, M.D.
 Lucy F. Faulconbridge, Ph.D.
 Patricia Furlan, Ph.D.
 Joanna Goldstein, L.C.S.W.
 Paul Grant, Ph.D.
 Jillian Graves, L.C.S.W.
 Tamar Gur, M.D., Ph.D.
 Alisa Gutman, M.D., Ph.D.
 Nora Hymowitz, M.D.
 Sofia Jensen, M.D.
 Tiffany King, M.S.W.
 Katherine Levine, M.D.

Alice Li, M.D.
 Janet Light, L.C.S.W.
 John Listerud, M.D., Ph.D.
 Emily Malcoun, Ph.D.
 Donovan Maust, M.D.
 Adam Meadows, M.D.
 Michelle Moyer, M.D.
 Rebecca Naugle, L.C.S.W.
 Cory Newman, Ph.D.
 John Northrop, M.D., Ph.D.
 Elizabeth A. Ellis Ohr, Psy.D.
 John O'Reardon, M.D.
 Abraham Pachikara, M.D.
 Andrea Perelman, M.S.W.
 Diana Perez, M.S.W.
 Bianca Previdi, M.D.
 J. Russell Ramsay, Ph.D.
 Jorge Rivera-Colon, M.D.
 Jan Smedley, L.C.S.W.
 Katie Struble, M.S.W.
 Aita Susi, M.D.
 Yekaterina Tatarchuk, M.D.
 Ellen Tarves, M.A.
 Allison Tweedie, M.D.
 Holly Valerio, M.D.

Thomas A. Wadden, Ph.D.
 Joseph Wright, Ph.D.
 Yan Xuan, M.D.
 David Yusko, Psy.D.

Research Coordinators

Jordan A. Coello, B.A., Lead Research
 Coordinator
 Eric Wang, B.S.E.

Volunteer Research Assistants/ Interns

Jeannine Barker, M.A., A.T.R.
 Jacqueline Baron
 Kelsey Bogue
 Alexandra Ciomek
 Martekuor Dodoo, B.A.
 Julian Domanico
 Laura Heller, B.A.
 Leah Hull-Rawson, B.A.
 Jacquelyn Klehm, B.A.
 Christina Lam
 Dante Proetto, B.S.
 Molly Roy
 Casey Shannon

Stanford University School of Medicine, Stanford, California

Investigators

Carl Feinstein, M.D., Principal Investigator
 Debra Safer, M.D., Principal Investigator

Referring and Interviewing Clinicians

Kari Berquist, Ph.D.
 Eric Clausell, Ph.D.
 Danielle Colborn, Ph.D.
 Whitney Daniels, M.D.
 Alison Darcy, Ph.D.
 Krista Fielding, M.D.
 Mina Fisher, M.D.
 Kara Fitzpatrick, Ph.D.
 Wendy Froehlich, M.D.
 Grace Gengoux, Ph.D.
 Anna Cassandra Golding, Ph.D.
 Lisa Groesz, Ph.D.
 Kyle Hinman, M.D.
 Rob Holaway, Ph.D.
 Matthew Holve, M.D.
 Rex Huang, M.D.
 Nina Kirz, M.D.
 Megan Klabunde, Ph.D.
 John Leckie, Ph.D.
 Naomi Leslie, M.D.
 Adrienne Lona, M.D.
 Ranvinder Rai, M.D.
 Rebecca Rialon, Ph.D.
 Beverly Rodriguez, M.D., Ph.D.
 Debra Safer, M.D.
 Mary Sanders, Ph.D.

Jamie Scaletta, Ph.D.
 Norah Simpson, Ph.D.
 Manpreet Singh, M.D.
 Maria-Christina Stewart, Ph.D.
 Melissa Vallas, M.D.
 Patrick Whalen, Ph.D.
 Sanno Zack, Ph.D.

Referring Clinicians

Robin Apple, Ph.D.
 Victor Carrion, M.D.
 Carl Feinstein, M.D.
 Christine Gray, Ph.D.
 Antonio Hardan, M.D.
 Megan Jones, Psy.D.
 Linda Lotspeich, M.D.
 Lauren Mikula, Psy.D.
 Brandyn Street, Ph.D.
 Violeta Tan, M.D.
 Heather Taylor, Ph.D.
 Jacob Towery, M.D.
 Sharon Williams, Ph.D.

Research Coordinators

Kate Arnow, B.A., Lead Research Coordinator
 Nandini Datta, B.S.
 Stephanie Manasse, B.A.

Volunteer Research Assistants/ Interns

Arianna Martin, M.S.
 Adriana Nevado, B.A.

Children's Hospital Colorado, Aurora, Colorado

Investigator

Marianne Wamboldt, M.D., Principal Investigator

Referring and Interviewing Clinicians

Galia Abadi, M.D.
 Steven Behling, Ph.D.
 Jamie Blume, Ph.D.
 Adam Burstein, M.D.
 Debbie Carter, M.D.
 Kelly Caywood, Ph.D.
 Meredith Chapman, M.D.
 Paulette Christian, A.P.P.M.H.N.
 Mary Cook, M.D.
 Anthony Cordaro, M.D.
 Audrey Dumas, M.D.
 Guido Frank, M.D.
 Karen Frankel, Ph.D.
 Darryl Graham, Ph.D.
 Yael Granader, Ph.D.
 Isabelle Guillemet, M.D.
 Patrece Hairston, Ph.D.
 Charles Harrison, Ph.D.
 Tammy Herckner, L.C.S.W.
 Cassie Karlsson, M.D.
 Kimberly Kelsay, M.D.
 David Kieval, Ph.D.
 Megan Klabunde, Ph.D.
 Jaimelyn Kost, L.C.S.W.
 Harrison Levine, M.D.
 Raven Lipmanson, M.D.
 Susan Lurie, M.D.
 Asa Marokus, M.D.
 Idalia Massa, Ph.D.
 Christine McDunn, Ph.D.
 Scot McKay, M.D.
 Marissa Murgolo, L.C.S.W.
 Alyssa Oland, Ph.D.
 Lina Patel, Ph.D.
 Rheena Pineda, Ph.D.
 Gautam Rajendran, M.D.
 Diane Reichmuth, Ph.D.
 Michael Rollin, M.D.

Marlena Romero, L.C.S.W.
 Michelle Roy, Ph.D.
 Celeste St. John-Larkin, M.D.
 Elise Sannar, Ph.D.
 Daniel Savin, M.D.
 Claire Dean Sinclair, Ph.D.
 Ashley Smith, L.C.S.W.
 Mindy Solomon, Ph.D.
 Sally Tarbell, Ph.D.
 Helen Thilly, L.C.S.W.
 Sara Tlustos-Carter, Ph.D.
 Holly Vause, A.P.P.M.H.N.
 Marianne Wamboldt, M.D.
 Angela Ward, L.C.S.W.
 Jason Williams, Ph.D.
 Jason Willoughby, Ph.D.
 Brennan Young, Ph.D.

Referring Clinicians

Kelly Bhatnagar, Ph.D.
 Jeffery Dolgan, Ph.D.
 Jennifer Eichberg, L.C.S.W.
 Jennifer Hagman, M.D.
 James Masterson, L.C.S.W.
 Hy Gia Park, M.D.
 Tami Roblek, Ph.D.
 Wendy Smith, Ph.D.
 David Williams, M.D.

Research Coordinators

Laurie Burnside, M.S.M., C.C.R.C., Lead Research Coordinator
 Darci Anderson, B.A., C.C.R.C.
 Heather Kennedy, M.P.H.
 Amanda Millar, B.A.
 Vanessa Waruinge, B.S.
 Elizabeth Wallace, B.A.

Volunteer Research Assistants/Interns

Wisdom Amouzou
 Ashley Anderson
 Michael Richards
 Mateya Whyte

Baystate Medical Center, Springfield, Massachusetts

Investigators

Bruce Waslick, M.D., Principal Investigator
 Cheryl Bonica, Ph.D., Co-investigator
 John Fanton, M.D., Co-investigator
 Barry Sarvet, M.D., Co-investigator

Referring and Interviewing Clinicians

Julie Bermant, R.N., M.S.N., N.P.
 Cheryl Bonica, Ph.D.
 Jodi Devine, L.I.C.S.W.
 William Fahey, Ph.D.
 John Fanton, M.D.

Stephane Jacobus, Ph.D.
 Barry Sarvet, M.D.
 Peter Thunfors, Ph.D.
 Bruce Waslick, M.D.
 Vicki Weld, L.I.C.S.W.
 Sara Wiener, L.I.C.S.W.
 Shadi Zaghoul, M.D.

Referring Clinicians

Sarah Detenber, L.I.C.S.W.
 Gordon Garrison, L.I.C.S.W.
 Jacqueline Humpreys, L.I.C.S.W.
 Noreen McGirr, L.I.C.S.W.

Sarah Marcotte, L.C.S.W.
 Patricia Rogowski, R.N., C.N.S.

Research Coordinators

Julie Kingsbury, C.C.R.P., Lead Research
 Coordinator
 Brenda Martin, B.A.

Volunteer Research Assistant/ Intern

Liza Detenber

New York State Psychiatric Institute, New York, N.Y., Weill Cornell
 Medical College, Payne Whitney and Westchester Divisions, New York
 and White Plains, N.Y., and North Shore Child and Family Guidance
 Center, Roslyn Heights, N.Y. (Joint Study Site)

Investigator

Prudence W. Fisher, Ph.D., Principal
 Investigator

Research Coordinators

Julia K. Carmody, B.A., Lead Research
 Coordinator
 Zvi R. Shapiro, B.A., Lead Research
 Coordinator

Volunteers

Preeya Desai
 Samantha Keller
 Jeremy Litfin, M.A.
 Sarah L. Pearlstein, B.A.
 Cedilla Sacher

New York State Psychiatric Institute

Referring and Interviewing Clinicians

Michele Cohen, L.C.S.W.
 Eduvigis Cruz-Arrieta, Ph.D.
 Miriam Ehrensaft, Ph.D.
 Laurence Greenhill, M.D.
 Schuyler Henderson, M.D., M.P.H.
 Sharlene Jackson, Ph.D.
 Lindsay Moskowitz, M.D.
 Sweeney C. Oscar, Ph.D.
 Xenia Protopopescu, M.D.
 James Rodriguez, Ph.D.
 Gregory Tau, M.D.
 Melissa Tebbs, L.C.S.W.
 Carolina Velez-Grau, L.C.S.W.
 Khadijah Booth Watkins, M.D.

Referring Clinicians

George Alvarado, M.D.
 Alison Baker, M.D.
 Elena Baron, Psy.D.
 Lincoln Bickford, M.D., Ph.D.
 Zachary Blumkin, Psy.D.
 Colleen Cullen, L.C.S.W.
 Chyristianne DeAlmeida, Ph.D.
 Matthew Ehrlich, M.D.

Eve Friedl, M.D.
 Clare Gaskins, Ph.D.
 Alice Greenfield, L.C.S.W.
 Liora Hoffman, M.D.
 Kathleen Jung, M.D.
 Karimi Mailutha, M.D., M.P.H.
 Valentina Nikulina, Ph.D.
 Tal Reis, Ph.D.
 Moira Rynn, M.D.
 Jasmine Sawhney, M.D.
 Sarajbit Singh, M.D.
 Katherine Stratigos, M.D.
 Oliver Stroeh, M.D.
 Russell Tobe, M.D.
 Meghan Tomb, Ph.D.
 Michelle Tricamo, M.D.

Research Coordinators

Angel A. Caraballo, M.D.
 Erica M. Chin, Ph.D.
 Daniel T. Chrzanowski, M.D.
 Tess Dougherty, B.A.
 Stephanie Hundt, M.A.
 Moira A. Rynn, M.D.
 Deborah Stedje, R.N.

Weill Cornell Medical College, Payne Whitney and Westchester Divisions

Referring and Interviewing Clinicians

Archana Basu, Ph.D.
 Shannon M. Bennett, M.D.
 Maria De Pena-Nowak, M.D.
 Jill Feldman, L.M.S.W.
 Dennis Gee, M.D.
 Jo R. Hariton, Ph.D.
 Lakshmi P. Reddy, M.D.
 Margaret Yoon, M.D.

Referring Clinicians

Margo Benjamin, M.D.
 Vanessa Bobb, M.D.
 Elizabeth Bochtler, M.D.
 Katie Cave, L.C.S.W.
 Maalobeeka Gangopadhyay, M.D.

Jodi Gold, M.D.
 Tejal Kaur, M.D.
 Aaron Krasner, M.D.
 Amy Miranda, L.C.S.W.
 Cynthia Pfeffer, M.D.
 James Rebeta, Ph.D.
 Sharon Skariah, M.D.
 Jeremy Stone, Ph.D.
 Dirk Winter, M.D.

Research Coordinators

Alex Eve Keller, B.S., Lead Research Coordinator
 Nomi Bodner (volunteer)
 Barbara L. Flye, Ph.D.
 Jamie S. Neiman (volunteer)
 Rebecca L. Rendleman, M.D.

North Shore Child and Family Guidance Center

Referring and Interviewing Clinicians

Casye Brachfeld-Launer, L.C.S.W.
 Susan Klein Cohen, Ph.D.
 Amy Gelb, L.C.S.W.-R.
 Jodi Glasser, L.C.S.W.
 Elizabeth Goulding-Tag, L.C.S.W.
 Deborah B. Kassimir, L.C.S.W.
 Margo Posillico Messina, L.C.S.W.
 Andréa Moullin-Heddle, L.M.S.W.
 Lisa Pineda, L.C.S.W.
 Elissa Smilowitz, L.C.S.W.

Referring Clinicians

Regina Barros-Rivera, L.C.S.W.-R. Assistant
 Executive Director
 Maria Christiansen, B.S.
 Amy Davies-Hollander, L.M.S.W.
 Eartha Hackett, M.S.Ed., M.Sc., B.Sc.

Bruce Kaufstein, L.C.S.W.-R, Director of
 Clinical Services
 Kathy Knaust, L.C.S.W.
 John Levinson, L.C.S.W.-R, B.C.D.
 Andrew Maleckoff, L.C.S.W., Executive
 Director/CEO
 Sarah Rosen, L.C.S.W.-R, A.C.S.W.
 Abigail Rothenberg, L.M.S.W.
 Christine Scotten, A.C.S.W.
 Michelle Spatano, L.C.S.W.-R.
 Diane Straneri, M.S., R.N., C.S.
 Rosara Torrisi, L.M.S.W.
 Rob Vichnis, L.C.S.W.

Research Coordinators

Toni Kolb-Papetti, L.C.S.W.
 Sheena M. Dauro (volunteer)

**DSM-5 Field Trials Pilot Study,
 Johns Hopkins Medical Institution, Baltimore, Maryland**

Adult Sample

Community Psychiatry Outpatient Program, Department of Psychiatry
 and Behavioral Sciences Main Campus

Investigators

Bernadette Cullen, M.B., B.Ch., B.A.O.,
 Principal Investigator
 Holly C. Wilcox, Ph.D., Principal Investigator

**Referring and Interviewing
 Clinicians**

Bernadette Cullen, M.B., B.Ch., B.A.O.
 Shane Grant, L.C.S.W.-C.
 Charee Green, L.C.P.C.

Emily Lorensen, L.C.S.W.-C.
 Kathleen Malloy, L.C.P.C.
 Gary Pilarchik, L.C.S.W.-C
 Holly Slater, L.C.P.C.
 Stanislav Spivak, M.D.
 Tarcia Spencer Turner, L.C.P.C.
 Nicholas Seldes Windt, L.C.S.W.-C.

Research Coordinators

Mellisha McKitty, B.A.
 Alison Newcomer, M.H.S.

Pediatric Sample

Child and Adolescent Outpatient Program, Department of Psychiatry and
Behavioral Sciences Bayview Medical Center

Investigators

Joan P. Gerring, M.D., Principal Investigator
Leslie Miller, M.D., Principal Investigator
Holly C. Wilcox, Ph.D., Co-investigator

Referring and Interviewing

Clinicians

Shannon Barnett, M.D.
Gwen Condon, L.C.P.C.
Brijan Fellows, L.C.S.W.-C.
Heather Garner, L.C.S.W.-C.
Joan P. Gerring, M.D.

Anna Gonzaga, M.D.
Debra Jenkins, L.C.S.W.-C.
Paige N. Johnston, L.C.P.C.
Brenda Memel, D.N.P., R.N.
Leslie Miller, M.D.
Ryan Moore, L.C.S.W.-C.
Shauna Reinblatt, M.D.
Monique Vardi, L.C.P.C.

Research Coordinators

Mellisha McKitty, B.A.
Alison Newcomer, M.H.S.

DSM-5 Field Trials in Routine Clinical Practice Settings: Collaborating Investigators

Archil Abashidze, M.D.
Francis R. Abueg, Ph.D.
Jennifer Louise Accuardi, M.S.
Balkozar S. Adam, M.D.
Miriam E. Adams, Sc.D., M.S.W., L.I.C.S.W.
Suzanna C. Adams, M.A.
Lawrence Adler, M.D.
Rownak Afroz, M.D.
Khalid I. Afzal, M.D.
Joseph Alimasuya, M.D.
Emily Allen, M.S.
Katherine A. Allen, L.M.F.T., M.A.
William D. Allen, M.S.
Jafar AlMashat, M.D.
Anthony T. Alonzo, D.M.F.T.
Guillermo Alvarez, B.A., M.A.
Angela Amoia-Lutz, L.M.F.T.
Krista A. Anderson, M.A., L.M.F.T.
Lisa R. Anderson, M.Ed., L.C.P.C.
Pamela M. Anderson, L.M.F.T.
Shannon N. Anderson, M.A., L.P.C., N.C.C.
Eric S. Andrews, M.A.
Vicki Arbuckle, M.S., Nursing(N.P.)
Namita K. Arora, M.D.
Darryl Arrington, M.A.
Bearlyn Y. Ash, M.S.
Wylie J. Bagley, Ph.D.
Kumar D. Bahl, M.D.
Deborah C. Bailey, M.A., M.S., Ph.D.
Carolyn Baird, D.N.P., M.B.A., R.N.-B.C.,
C.A.R.N.-A.P., I.C.C.D.P.D.
Joelle Bangsund M.S.W.
Maria Baratta, M.S.W., Ph.D.
Stan Barnard, M.S.W.
Deborah Barnes, M.S.

Margaret L. Barnes, Ph.D.
David Barnum, Ph.D.
Raymond M. Baum, M.D.
Edward Wescott Beal, M.D.
Michelle Beaudoin, M.A.
Ernest E. Beckham, Ph.D.
Lori L. Beckwith, M.Ed
Emmet Bellville, M.A.
Randall E. Bennett, M.A.
Lynn Benson, Ph.D.
Robert Scott Benson, M.D.
Linda Benton, M.S.W.
Ditza D. Berger, Ph.D.
Louise I. Bertman, Ph.D.
Robin Bieber, M.S., L.M.F.T.
Diana M. Bigham, M.A.
David R. Blackburn, Ph.D.
Kelley Blackwell, L.M.F.T.
Lancia Blatchley, B.A., L.M.F.T.
Stacey L. Block, L.M.S.W., A.C.S.W.
Karen J. Bloodworth, M.S., N.C.C., L.P.C.
Lester Bloomenstiel, M.S.
Christine M. Blue, D.O.
Marina Bluvshstein, Ph.D.
Callie Gray Bobbitt, M.S.W., L.C.S.W.
Moses L. Boone, Jr., L.M.S.W., B.C.D.
Steffanie Boudreau-Thomas, M.A.-L.P.C.
Jay L. Boulter, M.A.
Aaron Daniel Bourne, M.A.
Helen F. Bowden, Ph.D.
Aryn Bowley-Safranek, B.S., M.S.
Elizabeth Boyajian, Ph.D.
Beth K. Boyarsky, M.D.
Gail M. Boyd, Ph.D.
Jeffrey M. Brandler, Ed.S., C.A.S., S.A.P.

- Sandra L. Branton, Ed.D.
 Karen J. Brocco-Kish, M.D.
 Kristin Brooks, P.M.H.N.P.
 Ann Marie Brown, M.S.W.
 Philip Brown, M.S.W.
 Kellie Buckner, Ed.S.
 Richard Bunt, M.D.
 Neil F. Buono, D.Min.
 Janice Bureau, M.S.W., L.C.S.W.
 Kimlee Butterfield, M.S.W.
 Claudia Byrne, Ph.D.
 Quinn Callicott, M.S.W., L.C.S.W.
 Alvaro Camacho, M.D., M.P.H.
 Sandra Cambra, Ph.D.
 Heather Campbell, M.A.
 Nancy Campbell, Ph.D., M.S.W.
 Karen Ranees Canada, L.M.F.T.
 Joseph P. Cannavo, M.D.
 Catherine F. Caporale, Ph.D.
 Frederick Capps, Ph.D., M.S.
 Rebecca J. Carney, M.B.A., M.A., L.M.H.C.
 Kelly J. Carroll, M.S.W.
 Richard W. Carroll, Ph.D., L.P.C., A.C.S.
 Sherry Casper, Ph.D.
 Joseph A. Catania, L.I.S.W.S., L.C.D.C. III
 Manisha P. Cavendish, Ph.D.
 Kenneth M. Certa, M.D.
 Shambhavi Chandraiah, M.D.
 Calvin Chatlos, M.D.
 Daniel C. Chen, M.D.
 Darlene Cheryl, M.S.W.
 Matthew R. Chirman, M.S.
 Carole A. Chisholm, M.S.W.
 Shobha A. Chottera, M.D.
 Joseph Logue Christenson, M.D.
 Pamela Christy, Psy.D.
 Sharon M. Freeman Clevenger, Ph.D.,
 P.M.H.C.N.S.-B.C.
 Mary Ann Cohen, M.D.
 Mitchell J. Cohen, M.D.
 Diego L. Coira, M.D.
 Melinda A. Lawless Coker, Psy.D.
 Carol Cole, M.S.W., L.C.S.W.
 Caron Collins, M.A., L.M.F.T.
 Wanda Collins, M.S.N.
 Linda Cook Cason, M.A.
 Ayanna Cooke-Chen, M.D., Ph.D.
 Heidi B. Cooperstein, D.O.
 Ileana Corbelle, M.S.W.
 Kimberly Corbett, Psy.D.
 Angelina Cordova, M.A.Ed.
 Jennifer Carol Cox, L.P.C.
 Sheree Cox, M.A., R.N., N.C.C., D.C.C.,
 L.M.H.C.
 William Frederick Cox, M.D.
 Sally M. Cox, M.S.Ed.
 Debbie Herman Crane, M.S.W.
 Arthur Ray Crawford, III, Ph.D.
 Roula Creighton, M.D.
 John R. Crossfield, L.M.H.C.
 Sue Cutbirth, R.N., M.S.N., C.S., P.M.H.N.P.
 Marco Antonio Cuyar, M.S.
 Rebecca Susan Daily, M.D.
 Lori S. Danenberg, Ph.D.
 Chan Dang-Vu, M.D.
 Mary Hynes Danielak, Psy.D.
 Cynthia A. Darby, M.Ed., Ed.S.
 Douglas Darnall, Ph.D.
 Christopher Davidson, M.D.
 Doreen Davis, Ph.D., L.C.S.W.
 Sandra Davis, Ph.D., L.M.H.C., N.C.C.
 Walter Pitts Davis, M.Th.
 Christian J. Dean, Ph.D.
 Kent Dean, Ph.D.
 Elizabeth Dear, M.A.
 Shelby DeBause, M.A.
 Rebecca B. DeLaney, M.S.S.W., L.C.S.W., B.C.D.
 John R. Delatorre, M.A.
 Frank DeLaurentis, M.D.
 Eric Denner, M.A., M.B.A.
 Mary Dennihan, L.M.F.T.
 Kenny Dennis, M.A.
 Pamela L. Detrick, Ph.D., M.S., F.N.P.-B.C.,
 P.M.H.N.P.-B.C., R.N.-B.C., C.A.P.,
 G.C.A.C.
 Robert Detrinis, M.D.
 Daniel A. Deutschman, M.D.
 Tania Diaz, Psy.D.
 Sharon Dobbs, M.S.W., L.C.S.W.
 David Doreau, M.Ed.
 Gayle L. Doshier, M.A.
 D'Ann Downey, Ph.D., M.S.W.
 Beth Doyle, M.A.
 Amy J. Driskill, M.S., L.C.M.F.T.
 James Drury, M.D.
 Brenda-Lee Duarte, M.Ed.
 Shane E. Dulemba, M.S.N.
 Nancy R. G. Dunbar, M.D.
 Cathy Duncan, M.A.
 Rebecca S. Dunn, M.S.N., A.R.N.P.
 Debbie Earnshaw, M.A.
 Shawna Eddy-Kissell, M.A.
 Momen El Nesr, M.D.
 Jeffrey Bruce Elliott, Psy.D.
 Leslie Ellis, Ph.D.
 Donna M. Emfield, L.C.P.C.
 Gretchen S. Enright, M.D.
 John C. Espy, Ph.D.
 Renuka Evani, M.B.B.S., M.D.
 Heather Evans, M.S.Ed, L.P.C.N.C.C.
 Cesar A. Fabiani, M.D.
 Fahim Fahim, M.D.
 Samuel Fam, M.D.
 Edward H. Fankhanel, Ph.D., Ed.D.
 Tamara Farmer, M.S.N., A.R.N.P.
 Farida Farzana, M.D.

- Philip Fast, M.S.
 Patricia Feltrup-Exum, M.A.M.F.T.
 Hector J. Fernandez-Barillas, Ph.D.
 Julie Ferry, M.S.W., L.I.C.S.W.
 Jane Fink, Ph.D., M.S.S.A.
 Kathy Finkle, L.P.C.M.H.
 Steven Finlay, Ph.D.
 Rik Fire, M.S.W., L.C.S.W.
 Ann Flood, Ph.D.
 Jeanine Lee Foreman, M.S.
 Thyra Fossum, Ph.D.
 Karen S. Franklin, L.I.C.S.W.
 Sherre K. Franklin, M.A.
 Helen R. Frey, M.A., E.D.
 Michael L. Freytag, B.S., M.A.
 Beth Gagnon, M.S.W.
 Patrice L.R. Gallagher, Ph.D.
 Angela J. Gallien, M.A.
 Robert Gallo, M.S.W.
 Mario Galvarino, M.D.
 Vladimir I. Gasca, M.D.
 Joshua Gates, Ph.D.
 Anthony Gaudio, Ph.D.
 Michelle S. Gauthier, A.P.R.N., M.S.N.,
 P.M.H.N.P.-B.C.
 Rachel E. Gearhart, L.C.S.W.
 Stephen D. Gelfond, M.D.
 Nancy S. Gerow, M.S.
 Michael J. Gerson, Ph.D.
 Susan M. A. Geyer, L.M.S.W.
 Lorrie Gfeller-Strouts, Ph.D.
 Shubu Ghosh, M.D.
 Richard Dorsey Gillespie, M.Div.
 Stuart A. Gitlin, M.S.S.A.
 Jeannette E. Given, Ph.D.
 Frances Gizzi, L.C.S.W.
 Stephen I. Glicksman, Ph.D.
 Martha Glisky, Ph.D.
 Sonia Godbole, M.D.
 Howard M. Goldfischer, Psy.D.
 Mary Jane Gonzalez-Huss, Ph.D.
 Michael I. Good, M.D.
 Dawn Goodman-Martin, M.A.-L.M.H.C.
 Robert Gorkin, Ph.D., M.D.
 Jeff Gorski, M.S.W.
 Linda O. Graf, M.Ed., L.C.P.C.
 Ona Graham, Psy.D.
 Aubrie M. Graves, L.M.S.W., C.A.S.A.C.
 Howard S. Green, M.D.
 Karen Torry Green, M.S.W.
 Gary Greenberg, Ph.D.
 Marjorie Greenhut, M.A.
 James L. Greenstone, Ed.D., J.D.
 Raymond A. Griffin, Ph.D.
 Joseph Grillo, Ph.D.
 Janeane M. Grisez, A.A., B.A.
 Lawrence S. Gross, M.D.
 Robert J. Gross, M.D.
 Sally J. Grosscup, Ph.D.
 Philip A. Grossi, M.D.
 Gabrielle Guedet, Ph.D.
 Nicholas Guenzel, B.A., B.S., M.S.N.
 Mary G. Hales, M.A.
 Tara C. Haley, M.S., L.M.F.T.
 John D. Hall, M.D.
 Amy Hammer, M.S.W.
 Michael S. Hanau, M.D.
 Linda K.W. Hansen, M.A., L.P.
 Genevieve R. Hansler, M.S.W.
 Mary T. Harrington, L.C.S.W.
 Lois Hartman, Ph.D.
 Steven Lee Hartsock, Ph.D., M.S.W.
 Victoria Ann Harwood, M.S.W., L.C.S.W.
 Rossi A. Hassad, Ph.D., M.P.H.
 Erin V. Hatcher, M.S.N.
 Richard L. Hauger, M.D.
 Kimberly M. Haverly, M.A.
 Gale Eisner Heater, M.S., M.F.T.
 Katlin Hecox, M.A.
 Brenda Heideman, M.S.W.
 Melinda Heinen, M.Sc.
 Marie-Therese Heitkamp, M.S.
 Melissa B. Held, M.A.
 Jessica Hellings, M.D.
 Bonnie Helmick-O'Brien, M.A., L.M.F.T.
 MaLinda T. Henderson, M.S.N, F.P.M.H.N.P.
 Gwenn Herman, M.S.W.
 Martha W. Hernandez, M.S.N, A.P.R.N.,
 P.M.H.C.N.S.
 Robin L. Hewitt, M.S.
 Kenneth Hoffman, Ph.D.
 Patricia E. Hogan, D.O.
 Peggy Holcomb, Ph.D.
 Garland H. Holloman, Jr., M.D.
 Kimberly Huegel, M.S.W., L.C.S.W.
 Jason Hughes, L.P.C.-S., N.C.C.
 Jennifer C. Hughes, Ph.D., M.S.W., L.I.S.W.-S.
 Michelle K. Humke, M.A.
 Judith G. Hunt, L.M.F.T.
 Tasneem Hussainee, M.D.
 Sharlene J. Hutchinson, M.S.N.
 Muhammad Ikram, M.D.
 Sunday Ilechukwu, M.D., D.Psy. Cli.
 Douglas H. Ingram, M.D.
 Marilynne Irvine, Ph.D.
 Marjorie Isaacs, Psy.D.
 Raymond Isackila, Ed.S., P.C.C.-S., L.I.C.D.C.
 Mohammed A. Issa, M.D.
 John L. Jankord, M.A.
 Barbara P. Jannah, L.C.S.W.
 C. Stuart Johnson, M.S.
 Dawn M. Johnson, M.A.
 Deanna V. Johnson, M.S., A.P.R.N., B.C.
 Eric C. Johnson, M.F.T.
 Joy Johnson, Ph.D., L.C.S.W.
 Willard Johnson, Ph.D.

- Xenia Johnson-Bhembe, M.D.
 Vann S. Joines, Ph.D.
 Margaret Jones, Psy.D.
 Patricia Jorgenson, M.S.W.
 Steven M. Joseph, M.D.
 Taylere Joseph, M.A.
 Jeanette M. Joyner-Craddock, M.S.S.W.
 Melissa Kachapis, M.A.
 Charles T. Kaelber, M.D.
 Aimee C. Kaempf, M.D.
 Peter Andrew Kahn, M.D.
 Robert P. Kahn-Rose, M.D.
 Maher Karam-Hage, M.D.
 Todd H. Kasdan, M.D.
 Karen Kaufman, M.S., L.M.F.T.
 Rhesa Kaulia, M.A., M.F.T.
 Debbie Lynn Kelly, M.S.N, P.M.H.N.P.-B.C.
 W. Stephen Kelly, Ph.D.
 Selena Kennedy, M.A.
 Judith A. Kenney, M.S., L.P.C.
 Mark Patrick Kerekes, M.D.
 Alyse Kerr, M.S., N.C.C., N.A.D.D.-C.C., L.P.C.
 Karen L. Kerschmann, L.C.S.W.
 Marcia Kesner, M.S.
 Ashan Khan, Ph.D.
 Shaukat Khan, M.D.
 Audrey Khatchikian, Ph.D.
 Laurie B. Kimmel, M.S.W.
 Jason H. King, Ph.D.
 Nancy Leigh King, M.S.W., L.C.S.W., L.C.A.S.
 Kyle Kinne, M.S.C
 Cassandra M. Klyman, M.D.
 David R. Knapp, L.C.S.W.
 Margaret Knerr, M.S.
 Michael R. Knox, Ph.D.
 Carolyn Koblin, M.S.
 Valerie Kolbert, M.S., A.R.N.P.-B.C.
 Heather Koontz, M.S.W.
 Faye Koop, Ph.D., L.C.M.F.T.
 Fern M. Kopakin, M.S.W., L.C.S.W.
 Joel Kotin, M.D.
 Sharlene K. Kraemer, M.S.E.
 Marjorie Vego Krausz, M.A., Ed.D.
 Nancy J. Krell, M.S.W.
 Mindy E. Kronenberg, Ph.D.
 Dwayne Kruse, M.S., M.F.T.
 Ajay S. Kuchibhatla, M.D.
 Shubha N. Kumar, M.D.
 Helen H. Kyomen, M.D., M.S.
 Rebecca M. Lachut, M.Ed., Ed.S.
 Alexis Lake, M.S.S.
 Ramaswamy Lakshmanan, M.D.
 Brigitta Lalone, L.C.S.W.-R
 John W. Lancaster, Ph.D.
 Patience R. Land, L.I.C.S.W., M.S.W., M.P.A.
 Amber Lange, M.A., Ph.D.
 Jeff K. Larsen, M.A.
 Nathan E. Lavid, M.D.
 Michelle Leader, Ph.D.
 Stephen E. Lee, M.D.
 Cathryn L. Leff, Ph.D., L.M.F.T.
 Rachael Kollar Leombruno, L.M.F.T.
 Arlene I. Lev, M.S.W., L.C.S.W.-R
 Gregory K. Lewis, M.A.-L.M.F.T.
 Jane Hart Lewis, M.S.
 Melissa S. Lewis, M.S.W., L.I.C.S.W.
 Norman Gerald Lewis, F.R.A.N.Z.C.P.
 Robin Joy Lewis, Ph.D.
 Ryan Michael Ley, M.D.
 Tammy R. Lias, M.A.
 Russell F. Lim, M.D.
 Jana Lincoln, M.D.
 Ted Lindberg, L.M.S.W., L.M.F.T., M.S.W.
 Peggy Solow Liss, M.S.W.
 Andrea Loeb, Psy.D.
 William David Lohr, M.D.
 Mary L. Ludy, M.A., L.M.H.C., L.M.F.T.
 Nathan Lundin, M.A., L.P.C.
 Veena Luthra, M.D.
 Patti Lyerly, L.C.S.W.
 Denise E. Maas, M.A.
 Silvia MacAllister, L.M.F.T.
 Nicola MacCallum, M.S., M.F.C. Therapy
 Colin N. MacKenzie, M.D.
 Cynthia Mack-Ernsdorff, Ph.D.
 John R. Madsen-Bibeau, M.S., M.Div
 Christopher J. Maglio, Ph.D.
 Deepak Mahajan, M.D.
 Debra Majewski, M.A.
 Harish Kumar Malhotra, M.D.
 Pamela Marcus, R.N., M.S.
 Mary P. Marshall, Ph.D.
 Flora Lynne Martin, M.A., L.P.C., A.D.C.
 Robert S. Martin, M.D.
 Jennifer L. Martinez, M.S.
 Ninfa Martinez-Aguilar, M.A., M.F.T.
 Emily Martinsen, M.S.W.
 Farhan A. Matin, M.D.
 Janus Maybee, P.M.H.N.P.
 Karen Mazarin-Stanek, M.A.
 Eben L. McClenahan, M.D., M.S.
 Jerlyn C. McCleod, M.D.
 Susan E. McCue, M.S.W., L.C.S.W.
 Kent D. McDonald, M.S.N.
 Daniel McDonnell, M.S.N, P.M.H.-N.P.
 Robert McElhose, Ph.D.
 Lisa D. McGrath, Ph.D.
 Mark McGrosky, M.S.W.
 Katherine M. McKay, Ph.D.
 Darren D. McKinnis, M.S.W.
 Mona McNelis-Broadley, M.S.W., L.C.S.W.
 Rick McQuestion, Ph.D.
 Susan Joy Mendelsohn, Psy.D.
 Barbara S. Menninga, M.Ed.
 Hindi Mermelstein, M.D., F.A.P.M.
 Rachel B. Michaelsen, M.S.W.

- Thomas F. Micka, M.D.
 Tonya Miles, Psy.D.
 Matthew Miller, M.S.
 Michael E. Miller, M.D.
 Noel Miller, L.M.S.W., M.B.A., M.P.S.
 Kalpana Miriyala, M.D.
 Sandra Moenssens, M.S.
 Erin Mokhtar, M.A.
 Robert E. Montgomery, M.Ed.
 Susan Moon, M.A.
 Theresa K. Moon, M.D.
 David B. Moore, B.A., M.Div., M.S.S.W., Ph.D.
 Joanne M. Moore, M.S.
 Peter I. M. Moran, M.B.B.Ch.
 Anna Moriarty, M.P.S., L.P.C., L.M.H.C.
 Richard Dean Morris, M.A.
 Michael M. Morrison, M.A.
 Carlton E. Munson, Ph.D.
 Timothy A. Murphy, M.D.
 Beth L. Murphy, Psy.D.
 Melissa A. Myers, M.D.
 Stefan Nawab, M.D.
 Allyson Matney Neal, D.N.P.
 Steven Nicholas, M.A.
 Aurelian N. Niculescu, M.D.
 Earl S. Nielsen, Ph.D.
 Terry Oleson, Ph.D.
 Julianne R. Oliver, B.S., M.S., Ph.D.
 Robert O. Olsen, M.D.
 Amy O'Neill, M.D.
 Oscar H. Oo, Psy.D., A.B.P.P.
 Laurie Orlando, J.D., M.A.
 Jill Osborne, M.S., Ed.S.
 Kimberly Overlie, M.S.
 L. Kola Oyewumi, Ph.D.
 Zachary J. Pacha, M.S.W.
 Suzette R. Papadakis, M.S.
 Amanda C. Parsons, M.A., L.P.C.C.
 Lee R. Pate, B.A., M.A.
 Eric L. Patterson, L.P.C.
 Sherri Paulson, M.Ed., L.S.C.W.
 Peter Dennis Pautz, B.A., M.S.W.
 Malinda J. Perkins, M.S.W., L.C.S.W.
 Eleanor F. Perlman, M.S.W.
 Deborah K. Perry, M.S.W.
 Amanda Peterman, L.M.F.T.
 Shawn Pflugardt, Psy.D.
 Robert J. Dean Phillips, M.S.
 Laura Pieper, M.S.W., L.C.S.W.
 Lori D. Pink, M.S.W., B.C.D.
 Michael G. Pipich, M.S., L.M.F.T.
 Cynthia G. Pizzulli, M.S.W., Ph.D.
 Kathy C. Points, M.A.
 Marya E. Pollack, M.D., M.P.H.
 Sanford E. Pomerantz, M.D.
 Eva Ponder, M.S.W., Psy.D.
 Ernest Poortinga, M.D.
 David Post, M.D.
 Laura L. Post, M.D., Ph.D., J.D.
 Patrick W. Powell, Ed.D.
 Beth M. Prewett, Psy.D.
 Robert Price, D.C.C., M.Ed.
 John Pruett, M.D.
 Aneita S. Radov, M.A.
 Dawn M. Raffa, Ph.D.
 Kavitha Raja, M.D.
 Ranjit Ram, M.D.
 Mohamed Ibrahim Ramadan, M.D., M.S.
 Christopher S. Randolph, M.D.
 Nancy Rappaport, M.Ed.
 John Moir Rauenhurst, M.D.
 Laurel Jean Rebenstock, L.M.S.W.
 Edwin Renaud, Ph.D.
 Heather J. Rhodes, M.A.
 Jennifer S. Ritchie-Goodline, Psy.D.
 Daniel G. Roberts, M.A.
 Brenda Rohren, M.A., M.F.S., L.I.M.H.P.,
 L.A.D.C., M.A.C.
 Donna G. Rolin-Kenny, Ph.D., A.P.R.N.,
 P.M.H.C.N.S.-B.C.
 Sylvia E. Rosario, M.Ed.
 Mindy S. Rosenbloom, M.D.
 Harvey A. Rosenstock, M.D.
 Thalia Ross, M.S.S.W.
 Fernando Rosso, M.D.
 Barry H. Roth, M.D.
 Thomas S. Rue, M.A., L.M.H.C.
 Elizabeth Ruegg, L.C.S.W.
 Diane Rullo, Ph.D.
 Angie Rumaldo, Ph.D.
 Eric Rutberg, M.A., D.H.Ed.
 Joseph A. Sabella, L.M.H.C.
 Kemal Sagduyu, M.D.
 Adam H. Saltz, M.S.W.
 Jennifer A. Samardak, L.I.S.W.-S.
 George R. Samuels, M.A., M.S.W.
 Carmen Sanjurjo, M.A.
 John S. Saroyan, Ed.D.
 Brigid Kathleen Sboto, M.A., M.F.T.
 Lori Cluff Schade, M.S.
 Joan E. Schaper, M.S.N.
 Rae J. Schilling, Ph.D.
 Larry Schor, Ph.D.
 Donna J. Schwartz, M.S.W., L.I.C.S.W.
 Amy J. Schwarzenbart, P.M.H.-C.N.S., B.C.,
 A.P.N.P.
 John V. Scialli, M.D.
 Chad Scott, Ph.D., L.P.C.C.
 Sabine Sell, M.F.T.
 Minal Shah, N.S., N.C.C., L.P.C.
 Lynn Shell, M.S.N.
 Dharmesh Navin Sheth, M.D.
 S. Christopher Shim, M.D.
 Marta M. Shinn, Ph.D.
 Andreas Sidiropoulos, M.D., Ph.D.
 Michael Siegel, M.D.

Michael G. Simonds, Psy.D.
 Gagandeep Singh, M.D.
 Melissa Rae Skrzypchak, M.S.S.W., L.C.S.W.
 Paula Slater, M.D.
 William Bill Slaughter, M.D., M.A.
 Aki Smith, Ph.D.
 Deborah L. Smith, Ed.M.
 Diane E. Smith, M.A., L.M.F.T.
 James S. Sommer, M.S.
 J. Richard Spatafora, M.D.
 Judy Splittergerber, M.S.N., C.S., N.P.
 Thiruneermalai T.G. Sriram, M.D.
 Martha W. St. John, M.D.
 Sybil Stafford, Ph.D.
 Timothy Stambaugh, M.A.
 Laura A. Stamboni, M.S.W.
 Carol L. R. Stark, M.D.
 Stephanie Steinman, M.S.
 Claudia M. Stevens, M.S.W.
 Jennifer Boyer Stevens, Psy.D.
 Dominique Stevens-Young, M.S.W., L.C.S.W.
 Kenneth Stewart, Ph.D.
 Daniel Storch, M.D.
 Suzanne Straebler, A.P.R.N.
 Dawn Stremel, M.A., L.M.F.T.
 Emel Stroup, Psy.D.
 John W. Stump, M.S., L.M.F.T.
 Thomas G. Suk, M.A.
 Elizabeth Sunzeri, M.S.
 Linnea Swanson, M.A., Psy.D.
 Patricia Swanson, M.A.
 Fereidoon Taghizadeh, M.D.
 Bonnie L. Tardif, L.M.H.C., N.C.C., B.C.P.C.C.
 Joan Tavares, M.S.W.
 Ann Taylor, M.S.W.
 Dawn O'Dwyer Taylor, Ph.D.
 Chanel V. Tazza, L.M.H.C.
 Martha H. Teater, M.A.
 Clark D. Terrell, M.D.
 Mark R. Thelen, Psy.D.
 Norman E. Thibault, M.S., Ph.D.
 Tojuana L. Thomason, Ph.D.
 Paula Thomson, Psy.D.
 D. Chadwick Thompson, M.A.
 Susan Thorne-Devin, A.M.
 Jean Eva Thumm, M.A.P.C., M.A.T., L.M.F.T., B.C.C.
 James E. Tille, Ph.D., D.Min.
 Jacalyn G. Tippey, Ph.D.
 Saraswathi Tirumalasetty, M.D.
 Jacqueline A. Torrance, M.S.
 Terrence Trobaugh, M.S.
 Louisa V. Troemel, Psy.D., L.M.F.T.

Susan Ullman, M.S.W.
 Jennifer M. Underwood, M.S.W., L.C.S.W.
 Rodney Dale Veldhuizen, M.A.
 Michelle Voegels, B.S.N., M.S.N., B.C.
 Wess Vogt, M.D.
 R. Christopher Votolato, Psy.D.
 John W. Waid, Ph.D.
 Christa A. Wallis, M.A.
 Dominique Walmsley, M.A.
 Bhupinder Singh Waraich, M.D.
 Joseph Ward, N.C.C., L.P.C. M.Ed.
 Robert Ward, M.S.W.
 Marilee L. M. Wasell, Ph.D.
 Gannon J. Watts, L.P.C.-S., L.A.C., N.C.C., N.C.S.C., A.A.D.C., I.C.A.A.D.C.
 Sheila R. Webster, M.A., M.S.S.A.
 Burton Weiss, M.D.
 Dennis V. Weiss, M.D.
 Jonathan S. Weiss, M.D.
 Richard Wendel, Ph.D.
 Paul L. West, Ed.D.
 Kris Sandra Wheatley, M.A., L.P.C., N.C.C.
 Leneigh White, M.A.
 Danny R. Whitehead, L.I.C.S.W.
 Jean Whiting, M.A.
 Peter D. Wilk, M.D.
 Vanessa Wilkinson, L.P.C.
 Tim F. Willia, M.S., M.A.Ed., L.P.C.
 Cathy E. Willis, M.A., L.M.F.T., C.A.D.C.
 Jeffery John Wilson, M.D.
 Jacquie Wilson, M.Ed.
 David D. Wines, M.S.W.
 Barbara A. Wirebaugh, M.S.W.
 Daniel L. Wise, Ph.D.
 Christina Wong, M.S.W., L.C.S.W.
 Susanna Wood, M.S.W., L.C.S.W.
 Linda L. Woodall, M.D.
 Leoneen Woodard-Faust, M.D.
 Sheryl E. Woodhouse, L.M.F.T.
 Gregory J. Worthington, Psy.D.
 Tanya Wozniak, M.D.
 Kimberly Isaac Wright, M.A.
 Peter Yamamoto, M.D.
 Maria Ruiza Ang Yee, M.D.
 Michael B. Zafrani, M.D.
 Jafet E. Gonzalez Zakarchenco, M.D.
 John Zibert, Ph.D.
 Karen Zilberstein, M.S.W.
 Cathi Zillmann, C.P.N.P., N.P.P.
 Gerald A. Zimmerman, Ph.D.
 Michele Zimmerman, M.A., P.M.H.C.N.S.-B.C.
 Judith A. Zink, M.A.

Vanderbilt University REDCap Team

Paul Harris, Ph.D.
 Sudah Kashyap, B.E.
 Brenda Minor

Jon Scherdin, M.A.
 Rob Taylor, M.A.
 Janey Wang, M.S.

Index

Page numbers printed in **boldface type** refer to tables.

- Abuse and neglect, 22, 717–722
 - adult maltreatment and neglect problems, 720–722
 - child maltreatment and neglect problems, 717–719
- Access to medical and other health care, problems related to, 726
- Acute dissociative reactions to stressful events, 306–307
- Acute stress disorder, 265, 280–286
 - associated features supporting diagnosis of, 283–284
 - culture-related diagnostic issues in, 285
 - development and course of, 284
 - diagnostic criteria for, 280–281
 - diagnostic features of, 281–283
 - differential diagnosis of, 285–286
 - functional consequences of, 285
 - gender-related diagnostic issues in, 285
 - prevalence of, 284
 - risk and prognostic factors for, 284–285
- Addiction. *See* Substance-related and addictive disorders
- ADHD. *See* Attention-deficit/hyperactivity disorder
- Adjustment disorders, 265, 286–289
 - comorbidity with, 289
 - culture-related diagnostic issues in, 288
 - development and course of, 287
 - diagnostic criteria for, 286–287
 - diagnostic features of, 287
 - differential diagnosis of, 288–289
 - functional consequences of, 288
 - prevalence of, 287
 - risk and prognostic factors for, 288
- Adjustment-like disorders, 289
- Adult maltreatment and neglect problems, 720–722
 - adult abuse by nonspouse or nonpartner, 722
 - spouse or partner abuse, psychological, 721–722
 - spouse or partner neglect, 721
 - spouse or partner violence, physical, 720
 - spouse or partner violence, sexual, 720
- Agoraphobia, 190, 217–221
 - associated features supporting diagnosis of, 219
 - comorbidity with, 221
 - development and course of, 219–220
 - diagnostic criteria for, 217–218
 - diagnostic features of, 218–219
 - differential diagnosis of, 220–221
 - functional consequences of, 220
 - gender-related diagnostic issues in, 220
 - prevalence of, 219
 - risk and prognostic factors for, 220
- Akathisia, medication-induced, 22
 - acute, 711
 - tardive, 712
- Alcohol intoxication, 497–499
 - associated features supporting diagnosis of, 497–498
 - comorbidity with, 499
 - culture-related diagnostic issues in, 498
 - development and course of, 498
 - diagnostic criteria for, 497
 - diagnostic features of, 497
 - diagnostic markers for, 499
 - differential diagnosis of, 499
 - functional consequences of, 499
 - gender-related diagnostic issues in, 498
 - prevalence of, 498
 - risk and prognostic factors for, 498
- Alcohol-related disorders, 481, 490–503
 - alcohol intoxication, 497–499
 - alcohol use disorder, 490–497
 - alcohol withdrawal, 484, 499–501
 - diagnoses associated with, **482**
 - other alcohol-induced disorders, 502–503
 - development and course of, 502–503
 - features of, 502
 - unspecified alcohol-related disorder, 503
- Alcohol use disorder, 490–497
 - associated features supporting diagnosis of, 492–493
 - comorbidity with, 496–497
 - culture-related diagnostic issues in, 494–495
 - development and course of, 493–494

- Alcohol use disorder (*continued*)
 - diagnostic criteria for, 490–491
 - diagnostic features of, 492
 - diagnostic markers for, 495–496
 - differential diagnosis of, 496
 - functional consequences of, 496
 - prevalence of, 493
 - risk and prognostic factors for, 494
 - specifiers for, 492
- Alcohol withdrawal, 499–501
 - associated features supporting diagnosis of, 500
 - comorbidity with, 501
 - development and course of, 501
 - diagnostic criteria for, 499–500
 - diagnostic features of, 500
 - diagnostic markers for, 501
 - differential diagnosis of, 501
 - functional consequences of, 501
 - prevalence of, 501
 - risk and prognostic factors for, 501
 - specifiers for, 500
- Alzheimer's disease, major or mild
 - neurocognitive disorder due to, 591, **603**, 611–614
 - associated features supporting diagnosis of, 612
 - comorbidity with, 614
 - culture-related diagnostic issues in, 613
 - development and course of, 612–613
 - diagnostic criteria for, 611–612
 - diagnostic features of, 612
 - diagnostic markers for, 613
 - differential diagnosis of, 614
 - functional consequences of, 614
 - prevalence of, 612
 - risk and prognostic factors for, 613
- American Psychiatric Association (APA), 5–7
- Anorexia nervosa, 329, 338–345
 - associated features supporting diagnosis of, 341
 - atypical, 353
 - comorbidity with, 344–345
 - culture-related diagnostic issues in, 342
 - development and course of, 341–342
 - diagnostic criteria for, 338–339
 - diagnostic features of, 339–340
 - diagnostic markers for, 342–343
 - differential diagnosis of, 344
 - functional consequences of, 343
 - prevalence of, 341
 - risk and prognostic factors for, 342
 - subtypes of, 339
 - suicide risk in, 343
- Antidepressant discontinuation syndrome, 22, 712–714
 - comorbidity with, 714
 - course and development of, 713
 - diagnostic features of, 713
 - differential diagnosis of, 713–714
 - prevalence of, 713
- Antisocial personality disorder, 461, 476, 645, 646, 659–663
 - associated features supporting diagnosis of, 660–661
 - culture-related diagnostic issues in, 662
 - development and course of, 661
 - diagnostic criteria for, 659
 - diagnostic features of, 659–660
 - differential diagnosis of, 662–663
 - features and criteria in alternative DSM-5 model for personality disorders, 763, 764–765
 - gender-related diagnostic issues in, 662
 - prevalence of, 661
 - risk and prognostic factors for, 661–662
- Anxiety disorder due to another medical condition, 190, 230–232
 - associated features supporting diagnosis of, 231
 - development and course of, 231
 - diagnostic criteria for, 230
 - diagnostic features of, 230–231
 - diagnostic markers for, 231
 - differential diagnosis of, 231–232
 - prevalence of, 231
- Anxiety disorders, 189–264
 - agoraphobia, 190, 217–221
 - anxiety disorder due to another medical condition, 190, 230–232
 - generalized anxiety disorder, 190, 222–226
 - highlights of changes from DSM-IV to DSM-5, 811
 - other specified anxiety disorder, 233
 - panic attack specifier, 214–217
 - panic disorder, 190, 208–214
 - selective mutism, 189, 195–197
 - separation anxiety disorder, 189, 190–195
 - social anxiety disorder (social phobia), 190, 202–208
 - specific phobia, 189–190, 197–202
 - substance/medication-induced anxiety disorder, 190, 226–230
 - unspecified anxiety disorder, 233
- APA (American Psychiatric Association), 5–7
- Assessment measures, 23–24, 733–748
 - cross-cutting symptom measures, 733–741
 - DSM-5 Level 1 Cross-Cutting Symptom Measure, 734–736, 738–741
 - DSM-5 Level 2 Cross-Cutting Symptom Measures, 734, 735, 736, 737
 - frequency of use of, 737
 - severity measures, 733, 742

- Clinician-Rated Dimensions of Psychosis
 - Symptom Severity, 742–744
 - frequency of use of, 742
 - scoring and interpretation of, 742
- WHO Disability Assessment Schedule (WHODAS), 16, 21, 734, 745–748
- Ataque de nervios*, 14, 211–212, 233, 833
- Attention-deficit/hyperactivity disorder (ADHD), 11, 32, 59–66
 - associated features supporting diagnosis of, 61
 - comorbidity with, 65
 - culture-related diagnostic issues in, 62
 - development and course of, 61
 - diagnostic criteria for, 59–61
 - diagnostic features of, 61
 - differential diagnosis of, 63–65
 - functional consequences of, 63
 - gender-related diagnostic issues in, 63
 - medication-induced symptoms of, 65
 - other specified attention-deficit/hyperactivity disorder, 65–66
 - prevalence of, 61
 - risk and prognostic factors for, 62
 - unspecified attention-deficit/hyperactivity disorder, 66
- Attenuated psychosis syndrome, 122, 783–786
 - associated features supporting diagnosis of, 784
 - comorbidity with, 786
 - development and course of, 785
 - diagnostic features of, 783–784
 - differential diagnosis of, 785–786
 - functional consequences of, 785
 - prevalence of, 784–785
 - proposed criteria for, 783
 - risk and prognostic factors for, 785
- Autism spectrum disorder, 31–32, 50–59
 - associated features supporting diagnosis of, 55
 - comorbidity with, 58–59
 - culture-related diagnostic issues in, 57
 - development and course of, 55–56
 - diagnostic criteria for, 50–51
 - diagnostic features of, 53–55
 - differential diagnosis of, 57–58
 - functional consequences of, 57
 - gender-related diagnostic issues in, 57
 - prevalence of, 55
 - recording procedures for, 51
 - risk and prognostic factors for, 56–57
 - specifiers for, 51–53, 52
- Avoidant personality disorder, 645, 646, 672–675
 - associated features supporting diagnosis of, 673–674
 - culture-related diagnostic issues in, 674
 - development and course of, 674
 - diagnostic criteria for, 672–673
 - diagnostic features of, 673
 - differential diagnosis of, 674–675
 - features and criteria in alternative DSM-5 model for personality disorders, 763, 765–766
 - gender-related diagnostic issues in, 674
 - prevalence of, 674
- Avoidant/restrictive food intake disorder, 329, 334–338
 - associated features supporting diagnosis of, 335
 - comorbidity with, 338
 - culture-related diagnostic issues in, 336
 - development and course of, 335–336
 - diagnostic criteria for, 334
 - diagnostic features of, 334–335
 - diagnostic markers for, 336
 - differential diagnosis of, 336–338
 - functional consequences of, 336
 - gender-related diagnostic issues in, 336
 - risk and prognostic factors for, 336
- Bereavement, 125–126, 134, 155, 161, 194
 - persistent complex, 289, 789–792
- Binge-eating disorder, 329, 350–353
 - associated features supporting diagnosis of, 351
 - comorbidity with, 353
 - culture-related diagnostic issues in, 352
 - development and course of, 352
 - diagnostic criteria for, 350
 - diagnostic features of, 350–351
 - differential diagnosis of, 352–353
 - functional consequences of, 352
 - of low frequency and/or limited duration, 353
 - prevalence of, 351
 - risk and prognostic factors for, 352
- Bipolar I disorder, 123–132
 - associated features supporting diagnosis of, 129
 - comorbidity with, 132
 - culture-related diagnostic issues in, 130
 - development and course of, 130
 - diagnostic criteria for, 123–127
 - diagnostic features of, 127–129
 - differential diagnosis of, 131–132
 - functional consequences of, 131
 - gender-related diagnostic issues in, 130
 - prevalence of, 130
 - risk and prognostic factors for, 130
 - suicide risk and, 131
- Bipolar II disorder, 123, 132–139
 - associated features supporting diagnosis of, 136
 - comorbidity with, 139
 - development and course of, 136–137
 - diagnostic criteria for, 132–135
 - diagnostic features of, 135–136
 - differential diagnosis of, 138–139

- Bipolar II disorder (*continued*)
 - functional consequences of, 138
 - gender-related diagnostic issues in, 137
 - prevalence of, 136
 - risk and prognostic factors for, 137
 - suicide risk in, 138
- Bipolar and related disorder due to another
 - medical condition, 123, 145–147
 - associated features supporting diagnosis of, 146
 - comorbidity with, 147
 - culture-related diagnostic issues in, 147
 - development and course of, 146–147
 - diagnostic criteria for, 145–146
 - diagnostic features of, 146
 - diagnostic markers for, 147
 - differential diagnosis of, 147
 - functional consequences of, 147
 - gender-related diagnostic issues in, 147
- Bipolar and related disorders, 123–154
 - bipolar I disorder, 123–132
 - bipolar II disorder, 123, 132–139
 - bipolar and related disorder due to another
 - medical condition, 123, 145–147
 - cyclothymic disorder, 123, 139–141
 - highlights of changes from DSM-IV to DSM-5, 810
 - other specified bipolar and related disorder, 123, 148
 - specifiers for, 149–154
 - substance/medication-induced bipolar and related disorder, 123, 142–145
 - unspecified bipolar and related disorder, 149
- Body dysmorphic disorder, 235, 236, 242–247
 - associated features supporting diagnosis of, 244
 - comorbidity with, 247
 - culture-related diagnostic issues in, 245
 - development and course of, 244
 - diagnostic criteria for, 242–243
 - diagnostic features of, 243–244
 - differential diagnosis of, 245–247
 - functional consequences of, 245
 - gender-related diagnostic issues in, 245
 - prevalence of, 244
 - risk and prognostic factors for, 245
 - suicide risk and, 245
- Body dysmorphic-like disorder with actual flaws, 263
- Body dysmorphic-like disorder without repetitive behaviors, 263
- Body-focused repetitive behavior disorder, 235, 263–264
- Borderline personality disorder, 645, 646, 663–666
 - associated features supporting diagnosis of, 665
 - culture-related diagnostic issues in, 665–666
 - development and course of, 665
 - diagnostic criteria for, 663
 - diagnostic features of, 663–664
 - differential diagnosis of, 666
 - features and criteria in alternative DSM-5 model for personality disorders, 763, 766–767
 - gender-related diagnostic issues in, 666
 - prevalence of, 665
 - risk and prognostic factors for, 665
- Breathing-related sleep disorders, 361, 378–390
 - central sleep apnea, 383–386
 - obstructive sleep apnea hypopnea, 378–383
 - sleep-related hypoventilation, 387–390
- Brief illness anxiety disorder, 327
- Brief psychotic disorder, 94–96
 - associated features supporting diagnosis of, 95
 - culture-related diagnostic issues in, 95
 - development and course of, 95
 - diagnostic criteria for, 94
 - diagnostic features of, 94–95
 - differential diagnosis of, 96
 - duration of, 89, 94, 99
 - functional consequences of, 95
 - prevalence of, 95
 - risk and prognostic factors for, 95
- Brief somatic symptom disorder, 327
- Bulimia nervosa, 329, 345–350
 - associated features supporting diagnosis of, 347
 - comorbidity with, 349–350
 - culture-related diagnostic issues in, 348
 - development and course of, 347–348
 - diagnostic criteria for, 345
 - diagnostic features of, 345–347
 - diagnostic markers for, 348
 - differential diagnosis of, 349
 - functional consequences of, 349
 - gender-related diagnostic issues in, 348
 - of low frequency and/or limited duration, 353
 - prevalence of, 347
 - risk and prognostic factors for, 348
 - suicide risk in, 349
- Caffeine intoxication, 503–506
 - associated features supporting diagnosis of, 504
 - comorbidity with, 506
 - development and course of, 505
 - diagnostic criteria for, 503–504
 - diagnostic features of, 504
 - differential diagnosis of, 505
 - functional consequences of, 505
 - prevalence of, 505
 - risk and prognostic factors for, 505
- Caffeine-related disorders, 481, 503–509
 - caffeine intoxication, 503–506
 - caffeine withdrawal, 506–508

- diagnoses associated with, 482
 - other caffeine-induced disorders, 508
 - unspecified caffeine-related disorder, 509
- Caffeine use disorder, 792–795
 - comorbidity with, 795
 - development and course of, 794
 - diagnostic features of, 793–794
 - differential diagnosis of, 795
 - functional consequences of, 794–795
 - prevalence of, 794
 - proposed criteria for, 792–793
 - risk and prognostic factors for, 794
- Caffeine withdrawal, 506–508
 - associated features supporting diagnosis of, 507
 - comorbidity with, 508
 - culture-related diagnostic issues in, 508
 - development and course of, 507
 - diagnostic criteria for, 506
 - diagnostic features of, 506–507
 - differential diagnosis of, 508
 - functional consequences of, 508
 - prevalence of, 507
 - risk and prognostic factors for, 507–508
- Cannabis intoxication, 516–517
 - diagnostic criteria for, 516
 - diagnostic features of, 516–517
 - differential diagnosis of, 517
 - functional consequences of, 517
 - prevalence of, 517
 - specifiers for, 516
- Cannabis-related disorders, 481, 509–519
 - cannabis intoxication, 516–517
 - cannabis use disorder, 509–516
 - cannabis withdrawal, 484, 517–519
 - diagnoses associated with, 482
 - other cannabis-induced disorders, 519
 - unspecified cannabis-related disorder, 519
- Cannabis use disorder, 509–516
 - associated features supporting diagnosis of, 512
 - comorbidity with, 515–516
 - culture-related diagnostic issues in, 514
 - development and course of, 513
 - diagnostic criteria for, 509–510
 - diagnostic features of, 510–512
 - diagnostic markers for, 514
 - functional consequences of, 514–515
 - prevalence of, 512
 - risk and prognostic factors for, 513–514
 - specifiers for, 510
- Cannabis withdrawal, 517–519
 - development and course of, 518
 - diagnostic criteria for, 517–518
 - diagnostic features of, 518
 - differential diagnosis of, 519
 - risk and prognostic factors for, 519
- Case formulation, 19–20
 - cultural, 749–759 (*See also* Cultural formulation)
- Catatonia, 89, 119–121
 - associated with another mental disorder (catatonia specifier), 119–120
 - diagnostic criteria for, 119–120
 - diagnostic features of, 120
 - unspecified, 89, 121
- Catatonic disorder due to another medical condition, 120–121
 - associated features supporting diagnosis of, 121
 - diagnostic criteria for, 120–121
 - diagnostic features of, 121
 - differential diagnosis of, 121
- Central sleep apnea, 383–386
 - associated features supporting diagnosis of, 385
 - comorbidity with, 386
 - development and course of, 385
 - diagnostic criteria for, 383–384
 - diagnostic features of, 384–385
 - diagnostic markers for, 385
 - differential diagnosis of, 386
 - functional consequences of, 386
 - prevalence of, 385
 - risk and prognostic factors for, 385
 - specifiers for, 384
 - subtypes of, 384
- CFI. *See* Cultural Formulation Interview
- Cheyne-Stokes breathing, 383–386. *See also* Central sleep apnea
- Childhood-onset fluency disorder (stuttering), 31, 45–47
 - associated features supporting diagnosis of, 46
 - development and course of, 46–47
 - diagnostic criteria for, 45–46
 - diagnostic features of, 46
 - differential diagnosis of, 47
 - functional consequences of, 47
 - risk and prognostic factors for, 47
- Child maltreatment and neglect problems, 717–719
 - child neglect, 718–719
 - child physical abuse, 717–718
 - child psychological abuse, 719
 - child sexual abuse, 718
- Circadian rhythm sleep-wake disorders, 361, 390–398
 - advanced sleep phase type, 393–394
 - associated features supporting diagnosis of, 393
 - comorbidity with, 394
 - culture-related diagnostic issues in, 394
 - development and course of, 393
 - diagnostic features of, 393
 - diagnostic markers for, 394

- Circadian rhythm sleep-wake disorders
(*continued*)
- advanced sleep phase type (*continued*)
 - differential diagnosis of, 394
 - functional consequences of, 394
 - prevalence of, 393
 - risk and prognostic factors for, 394
 - specifiers for, 393
 - delayed sleep phase type, 391–392
 - associated features supporting diagnosis of, 391
 - comorbidity with, 392
 - development and course of, 391
 - diagnostic features of, 391
 - diagnostic markers for, 392
 - differential diagnosis of, 392
 - functional consequences of, 392
 - prevalence of, 391
 - risk and prognostic factors for, 392
 - diagnostic criteria for, 390–391
 - irregular sleep-wake type, 394–396
 - associated features supporting diagnosis of, 395
 - comorbidity with, 396
 - development and course of, 395
 - diagnostic features of, 394–395
 - diagnostic markers for, 395
 - differential diagnosis of, 395
 - functional consequences of, 395
 - prevalence of, 395
 - risk and prognostic factors for, 395
 - non-24-hour sleep-wake type, 396–397
 - associated features supporting diagnosis of, 396
 - comorbidity with, 397
 - development and course of, 396
 - diagnostic features of, 396
 - diagnostic markers for, 397
 - differential diagnosis of, 397
 - functional consequences of, 397
 - prevalence of, 396
 - risk and prognostic factors for, 396–397
 - relationship to *International Classification of Sleep Disorders*, 398
 - shift work type, 397–398
 - comorbidity with, 398
 - development and course of, 398
 - diagnostic features of, 397
 - diagnostic markers for, 398
 - differential diagnosis of, 398
 - functional consequences of, 398
 - prevalence of, 397
 - risk and prognostic factors for, 398
- Clinician-Rated Dimensions of Psychosis Symptom Severity, 742–744
- Coding and reporting procedures, 12, 16, 22, 23, 29
- Cognitive disorders. *See* Neurocognitive disorders
- Communication disorders, 31, 41–49
 - childhood-onset fluency disorder (stuttering), 45–47
 - language disorder, 42–44
 - social (pragmatic) communication disorder, 47–49
 - speech sound disorder, 44–45
 - unspecified communication disorder, 49
- Comorbidity, 5
- Compulsions, 235–236, 239. *See also* Obsessive-compulsive and related disorders
- Conditions for further study, 7, 11, 24, 783–806
 - attenuated psychosis syndrome, 783–786
 - caffeine use disorder, 792–795
 - depressive episodes with short-duration hypomania, 786–789
 - Internet gaming disorder, 795–798
 - neurobehavioral disorder associated with prenatal alcohol exposure, 798–801
 - nonsuicidal self-injury, 803–805
 - persistent complex bereavement disorder, 789–792
 - suicidal behavior disorder, 801–803
- Conduct disorder, 32, 461, 469–475
 - associated features supporting diagnosis of, 472–473
 - comorbidity with, 475
 - culture-related diagnostic issues in, 474
 - development and course of, 473
 - diagnostic criteria for, 469–471
 - diagnostic features of, 472
 - differential diagnosis of, 474–475
 - functional consequences of, 474
 - gender-related diagnostic issues in, 474
 - prevalence of, 473
 - risk and prognostic factors for, 473–474
 - specifiers for, 471–472
 - subtypes of, 471
- Conversion disorder (functional neurological symptom disorder), 309, 310, 318–321
 - associated features supporting diagnosis of, 319–320
 - comorbidity with, 321
 - culture-related diagnostic issues in, 320
 - development and course of, 320
 - diagnostic criteria for, 318–319
 - diagnostic features of, 319
 - differential diagnosis of, 321
 - functional consequences of, 321
 - gender-related diagnostic issues in, 320
 - prevalence of, 320
 - risk and prognostic factors for, 320

- Creutzfeldt-Jakob disease. *See* Prion disease, major or mild neurocognitive disorder due to
- Crime or interaction with the legal system, problems related to, 725
- Criterion for clinical significance, 21
- Cross-cutting symptom measures, 733–741
 DSM-5 Level 1 Cross-Cutting Symptom Measure, 734–736, 738–741
 DSM-5 Level 2 Cross-Cutting Symptom Measures, 734, 735, 736, 737
 frequency of use of, 737
- Cultural concepts of distress, 750, 758, 759, 833–837
- Cultural explanations or perceived causes, 14, 758
- Cultural formulation, 749–759
 definitions related to, 749
 diagnostic importance of, 758–759
 outline for, 749–750
 relationship to DSM-5 nosology, 758
- Cultural Formulation Interview (CFI), 17, 24, 749, 750–757
 domains of assessment, 751
 indications for, 751
 Informant Version, 755–757
 supplementary modules of, 751
- Cultural idioms of distress, 14, 758
- Cultural issues, 14–15, 749–759
 in anxiety disorders
 generalized anxiety disorder, 224
 panic attacks, 216
 panic disorder, 211–212
 selective mutism, 196
 separation anxiety disorder, 193
 social anxiety disorder (social phobia), 205–206
 specific phobia, 201
 in bipolar and related disorders
 bipolar I disorder, 130
 bipolar and related disorder due to another medical condition, 147
 in depressive disorders
 major depressive disorder, 166
 premenstrual dysphoric disorder, 173
 in disruptive, impulse-control, and conduct disorders
 conduct disorder, 474
 intermittent explosive disorder, 468
 oppositional defiant disorder, 465
 in dissociative disorders
 depersonalization/derealization disorder, 304
 dissociative amnesia, 300
 dissociative identity disorder, 295
 in enuresis, 357
 in feeding and eating disorders
 anorexia nervosa, 342
 avoidant/restrictive food intake disorder, 336
 binge-eating disorder, 352
 bulimia nervosa, 348
 pica, 331
 in fetishistic disorder, 701
 in gender dysphoria, 457
 in neurocognitive disorders, 609
 due to Alzheimer's disease, 613
 in neurodevelopmental disorders
 attention-deficit/hyperactivity disorder, 62
 autism spectrum disorder, 57
 developmental coordination disorder, 76
 intellectual disability (intellectual developmental disorder), 39
 specific learning disorder, 72–73
 stereotypic movement disorder, 79
 tic disorders, 83
 in obsessive-compulsive and related disorders
 body dysmorphic disorder, 245
 hoarding disorder, 250
 obsessive-compulsive disorder, 240
 trichotillomania (hair-pulling disorder), 253
 in personality disorders, 648
 antisocial personality disorder, 662
 avoidant personality disorder, 674
 borderline personality disorder, 665–666
 dependent personality disorder, 677
 histrionic personality disorder, 668
 obsessive-compulsive personality disorder, 681
 paranoid personality disorder, 651
 schizoid personality disorder, 654
 schizotypal personality disorder, 657
 in schizophrenia spectrum and other psychotic disorders
 brief psychotic disorder, 95
 delusional disorder, 93
 schizoaffective disorder, 108–109
 schizophrenia, 103
 in sexual dysfunctions, 423
 delayed ejaculation, 425
 erectile disorder, 428
 female orgasmic disorder, 432
 female sexual interest/arousal disorder, 435–436
 genito-pelvic pain/penetration disorder, 439
 male hypoactive sexual desire disorder, 442
 premature (early) ejaculation, 445
 substance/medication-induced sexual dysfunction, 449

Cultural issues (*continued*)

- in sleep-wake disorders
 - central sleep apnea hypopnea, 381
 - circadian rhythm sleep-wake disorders,
 - advanced sleep phase type, 394
 - narcolepsy, 376
 - nightmare disorder, 406
 - substance/medication-induced sleep disorder, 418
- in somatic symptoms and related disorders
 - conversion disorder (functional neurological symptom disorder), 320
 - illness anxiety disorder, 317
 - psychological factors affecting other medical conditions, 323
 - somatic symptom disorder, 313
- in substance-related and addictive disorders
 - alcohol intoxication, 498
 - alcohol use disorder, 495
 - caffeine withdrawal, 508
 - cannabis use disorder, 514
 - gambling disorder, 588
 - inhalant use disorder, 536
 - opioid use disorder, 544
 - other hallucinogen use disorder, 526
 - other (or unknown) substance use disorder, 580
 - other (or unknown) substance withdrawal, 580
 - phencyclidine use disorder, 522
 - sedative, hypnotic, or anxiolytic use disorder, 554
 - stimulant use disorder, 565
 - tobacco use disorder, 574
- in suicidal behavior disorder, 802
- in trauma- and stressor-related disorders
 - acute stress disorder, 285
 - adjustment disorders, 288
 - posttraumatic stress disorder, 278
 - reactive attachment disorder, 267

Cultural syndromes, 14, 758

Culture-bound syndromes, 14, 758

Cyclothymic disorder, 123, 139–141

- comorbidity with, 141
- development and course of, 140–141
- diagnostic criteria for, 139–140
- diagnostic features of, 140
- differential diagnosis of, 141
- prevalence of, 140
- risk and prognostic factors for, 141

Definition of a mental disorder, 20

Delayed ejaculation, 423, 424–426

- associated features supporting diagnosis of, 424–425

- comorbidity with, 426
- culture-related diagnostic issues in, 425
- development and course of, 425
- diagnostic criteria for, 424
- diagnostic features of, 424
- differential diagnosis of, 425–426
- functional consequences of, 425
- prevalence of, 425
- risk and prognostic factors for, 425

Delirium, 591, 596–602

- due to another medical condition, 597
- associated features supporting diagnosis of, 600
- development and course of, 600–601
- diagnostic criteria for, 596–598
- diagnostic features of, 599–600
- diagnostic markers for, 601
- differential diagnosis of, 601
- functional consequences of, 601
- medication-induced, 597, 599
- due to multiple etiologies, 597
- other specified, 602
- prevalence of, 600
- recording procedures for, 598–599
- risk and prognostic factors for, 601
- specifiers for, 599
- substance intoxication, 596–597, 598
- substance withdrawal, 597, 598–599
- unspecified, 602

Delusional disorder, 89, 90–93

- associated features supporting diagnosis of, 92
- culture-related diagnostic issues in, 93
- delusional symptoms in partner of individual with, 122
- development and course of, 92–93
- diagnostic criteria for, 90–91
- diagnostic features of, 92
- functional consequences of, 93
- prevalence of, 92
- subtypes of, 91–92

Delusions, 87, 89, 90–93

- bizarre, 87, 91
- of control, 87
- erotomanic, 87, 90
- grandiose, 87, 90
- jealous, 90, 91
- mixed type, 91
- nihilistic, 87
- nonbizarre, 87
- persecutory, 87, 90–91
- referential, 87
- with significant overlapping mood episodes, 122
- somatic, 87, 90, 92
- unspecified type, 91

Dementia, 591. *See also* Neurocognitive disorders

- Dependent personality disorder, 645, 646, 675–678
 - associated features supporting diagnosis of, 677
 - culture-related diagnostic issues in, 677
 - development and course of, 677
 - diagnostic criteria for, 675
 - diagnostic features of, 675–677
 - differential diagnosis of, 677–678
 - gender-related diagnostic issues in, 677
 - prevalence of, 677
- Depersonalization/derealization disorder, 291, 302–306
 - associated features supporting diagnosis of, 303
 - comorbidity with, 306
 - culture-related diagnostic issues in, 304
 - development and course of, 303–304
 - diagnostic criteria for, 302
 - diagnostic features of, 302–303
 - differential diagnosis of, 305–306
 - functional consequences of, 304–305
 - prevalence of, 303
 - risk and prognostic factors for, 304
- Depressive disorder due to another medical condition, 155, 180–183
 - associated features supporting diagnosis of, 181
 - comorbidity with, 183
 - development and course of, 181–182
 - diagnostic criteria for, 180–181
 - diagnostic features of, 181
 - diagnostic markers for, 182
 - differential diagnosis of, 182–183
 - functional consequences of, 182
 - gender-related diagnostic issues in, 182
 - risk and prognostic factors for, 182
 - suicide risk in, 182
- Depressive disorders, 155–188
 - depressive disorder due to another medical condition, 155, 180–183
 - disruptive mood dysregulation disorder, 155, 156–160
 - highlights of changes from DSM-IV to DSM-5, 810–811
 - major depressive disorder, 155, 160–168
 - other specified depressive disorder, 155, 183–184
 - persistent depressive disorder (dysthymia), 155, 168–171
 - premenstrual dysphoric disorder, 155, 171–175
 - specifiers for, 184–188
 - substance/medication-induced depressive disorder, 155, 175–180
 - unspecified depressive disorder, 155, 184
- Depressive episode or symptoms in bipolar and related disorders
 - bipolar I disorder, 125–126, 129
 - bipolar II disorder, 133–134, 135–136
 - cyclothymic disorder, 139, 140
 - other specified bipolar and related disorder, 148
- Depressive episodes with short-duration hypomania, 786–789
 - associated features supporting diagnosis of, 788
 - comorbidity with, 789
 - diagnostic features of, 788
 - differential diagnosis of, 788–789
 - functional consequences of, 788
 - prevalence of, 788
 - proposed criteria for, 786–787
 - risk and prognostic factors for, 788
 - suicide risk in, 788
- Developmental coordination disorder, 32, 74–77
 - associated features supporting diagnosis of, 75
 - comorbidity with, 76
 - culture-related diagnostic issues in, 76
 - development and course of, 75–76
 - diagnostic criteria for, 74
 - diagnostic features of, 74–75
 - differential diagnosis of, 76–77
 - functional consequences of, 76
 - prevalence of, 75
 - risk and prognostic factors for, 76
- Dhat syndrome*, 833–834
- Diagnosis, 5–6
 - assessment and monitoring measures for, 23–24, 733–748
 - categorical, 5, 8, 12, 13, 19, 20
 - clinical utility of, 20
 - coding and reporting procedures for, 12, 16, 22, 23, 29
 - criterion for clinical significance, 21
 - culture and, 14–15, 749–759
 - definition of a mental disorder, 20
 - diagnostic criteria and descriptors, 21
 - dimensional approach to, 5, 8, 9, 12–13, 17
 - elements of, 21–24
 - in forensic settings, 25
 - of medication-induced movement disorders, 20, 22, 29, 709–714
 - of other conditions that may be a focus of clinical attention, 20, 22, 29, 715–727
 - principal, 22–23
 - provisional, 23
- Diagnostic criteria, 21, 29
 - case formulation and, 19
 - proposed criteria for conditions for further study, 11, 783
 - revisions of, 6–10
 - subtypes and specifiers for, 21–22
 - validators for, 5, 9, 11, 12, 20
- Diagnostic spectra, 6, 9, 12

- Disinhibited social engagement disorder, 265, 268–270
 - associated features supporting diagnosis of, 269
 - development and course of, 269–270
 - diagnostic criteria for, 268–269
 - diagnostic features of, 269
 - differential diagnosis of, 270
 - functional consequences of, 270
 - prevalence of, 269
 - risk and prognostic factors for, 270
- Disorganized thinking (speech), 88
- Disruptive, impulse-control, and conduct disorders, 461–480
 - antisocial personality disorder, 461, 476, 645, 646, 659–663
 - conduct disorder, 461, 469–475
 - highlights of changes from DSM-IV to DSM-5, 815
 - intermittent explosive disorder, 461, 466–469
 - kleptomania, 461, 478–479
 - oppositional defiant disorder, 461, 462–466
 - other specified disruptive, impulse-control, and conduct disorder, 461, 479
 - pyromania, 461, 476–477
 - unspecified disruptive, impulse-control, and conduct disorder, 480
- Disruptive mood dysregulation disorder, 155, 156–160
 - comorbidity with, 160
 - development and course of, 157
 - diagnostic criteria for, 156
 - diagnostic features of, 156–157
 - differential diagnosis of, 158–160
 - functional consequences of, 158
 - gender-related diagnostic issues in, 158
 - prevalence of, 157
 - risk and prognostic factors for, 157–158
 - suicide risk in, 158
- Dissociative amnesia, 291, 298–302
 - associated features supporting diagnosis of, 299
 - comorbidity with, 302
 - culture-related diagnostic issues in, 300
 - development and course of, 299
 - diagnostic criteria for, 298
 - diagnostic features of, 298–299
 - differential diagnosis of, 300–302
 - functional consequences of, 300
 - prevalence of, 299
 - risk and prognostic factors for, 299–300
 - suicide risk in, 300
- Dissociative disorders, 291–307
 - depersonalization/derealization disorder, 291, 302–306
 - dissociative amnesia, 291, 298–302
 - dissociative identity disorder, 291–298
 - highlights of changes from DSM-IV to DSM-5, 812
 - other specified dissociative disorder, 292, 306–307
 - unspecified dissociative disorder, 307
- Dissociative identity disorder, 291–298
 - associated features supporting diagnosis of, 294
 - comorbidity with, 297–298
 - culture-related diagnostic issues in, 295
 - development and course of, 294
 - diagnostic criteria for, 292
 - diagnostic features of, 292–294
 - differential diagnosis of, 296–297
 - functional consequences of, 295–296
 - gender-related diagnostic issues in, 295
 - prevalence of, 294
 - risk and prognostic factors for, 294–295
 - suicide risk in, 295
- Dissociative reactions to stressful events, acute, 306–307
- Dissociative stupor or coma, 292
- Dissociative trance, 292, 307
- Down syndrome, 38, 40, 44, 53
- DSM, history of, 5, 6
- DSM-5
 - cultural issues in, 14–15, 749–759
 - developmental and lifespan considerations in, 13
 - forensic use of, 25
 - gender differences in, 15
 - glossary of technical terms in, 817–831
 - harmonization with ICD-11, 11–12
 - highlights of changes from DSM-IV to, 809–817
 - anxiety disorders, 811
 - bipolar and related disorders, 810
 - depressive disorders, 810–811
 - disruptive, impulse-control, and conduct disorders, 815
 - dissociative disorders, 812
 - elimination disorders, 813
 - feeding and eating disorders, 813
 - gender dysphoria, 814–815
 - neurodevelopmental disorders, 809–810
 - obsessive-compulsive and related disorders, 811–812
 - paraphilic disorders, 816
 - personality disorders, 816
 - schizophrenia spectrum and other psychotic disorders, 810
 - sexual dysfunctions, 814
 - sleep-wake disorders, 814
 - somatic symptom and related disorders, 812–813

- substance-related and addictive disorders, 815–816
- trauma- and stressor-related disorders, 812
- multiaxial system and, 16
- online enhancements of, 17
- organizational structure of, 10–11, 13
- other specified and unspecified mental disorders in, 15–16, 19–20, 707–708
- revision process for, 5, 6–10
 - expert review, 8–10
 - field trials, 7–8
 - proposals for revisions, 7
 - public and professional review, 8
- use of, 19–24
 - assessment and monitoring tools, 23–24, 733–748
 - case formulation, 19–20
 - coding and reporting procedures, 12, 16, 22, 23, 29
 - definition of a mental disorder, 20–21
 - elements of a diagnosis, 21–24
- DSM-5 Level 1 Cross-Cutting Symptom Measure, 734–736
 - adult self-rated version, 734, 735, 738–739
 - parent/guardian-rated version, 734, 736, 740–741
 - scoring and interpretation of, 734–736
- DSM-5 Level 2 Cross-Cutting Symptom Measures, 734, 735, 736, 737
- Dysthymia. *See* Persistent depressive disorder (dysthymia)
- Dystonia, medication-induced, 22
 - acute, 711
 - tardive, 712
- Eating disorders. *See* Feeding and eating disorders
- Economic problems, 724
- Educational problems, 723
- Ejaculation
 - delayed, 423, 424–426
 - premature (early), 423, 443–446
- Elements of diagnosis, 21–24
- Elimination disorders, 355–360
 - encopresis, 355, 357–359
 - enuresis, 355–357
 - highlights of changes from DSM-IV to DSM-5, 813
 - other specified elimination disorder, 359
 - unspecified elimination disorder, 360
- Encopresis, 355, 357–359
 - associated features supporting diagnosis of, 358
 - comorbidity with, 359
 - development and course of, 359
 - diagnostic criteria for, 357–358
 - diagnostic features of, 358
 - diagnostic markers for, 359
 - differential diagnosis of, 359
 - prevalence of, 359
 - risk and prognostic factors for, 359
 - subtypes of, 358
- Enuresis, 355–357
 - associated features supporting diagnosis of, 356
 - comorbidity with, 356
 - culture-related diagnostic issues in, 356
 - development and course of, 356
 - diagnostic criteria for, 355
 - diagnostic features of, 355–356
 - differential diagnosis of, 356
 - functional consequences of, 356
 - gender-related diagnostic issues in, 356
 - prevalence of, 356
 - risk and prognostic factors for, 356
 - subtypes of, 355
- Erectile disorder, 423, 426–429
 - associated features supporting diagnosis of, 427
 - comorbidity with, 429
 - culture-related diagnostic issues in, 428
 - development and course of, 427–428
 - diagnostic criteria for, 426–427
 - diagnostic features of, 427
 - diagnostic markers for, 428
 - differential diagnosis of, 428–429
 - functional consequences of, 428
 - prevalence of, 427
 - risk and prognostic factors for, 428
- Excoriation (skin-picking) disorder, 235, 236, 254–257
 - associated features supporting diagnosis of, 255
 - comorbidity with, 257
 - development and course of, 255
 - diagnostic criteria for, 254
 - diagnostic features of, 254–255
 - diagnostic markers for, 255
 - differential diagnosis of, 256
 - functional consequences of, 256
 - prevalence of, 255
 - risk and prognostic factors for, 255
- Exhibitionistic disorder, 685, 689–691
 - comorbidity with, 691
 - development and course of, 690
 - diagnostic criteria for, 689
 - diagnostic features of, 689–690
 - differential diagnosis of, 691
 - functional consequences of, 691
 - gender-related diagnostic issues in, 691
 - prevalence of, 690
 - risk and prognostic factors for, 690–691
 - specifiers for, 689
 - subtypes of, 689
- Externalizing disorders, 13

- Factitious disorder, 309, 310, 324–326
 associated features supporting diagnosis of, 325–326
 development and course of, 326
 diagnostic criteria for, 324–325
 diagnostic features of, 325
 differential diagnosis of, 326
 imposed on another, 310, 325–325, 338
 prevalence of, 326
 recording procedures for, 325
- Family upbringing, problems related to, 715–716
- Feeding and eating disorders, 329–354
 anorexia nervosa, 329, 338–345
 avoidant/restrictive food intake disorder, 329, 334–338
 binge-eating disorder, 329, 350–353
 bulimia nervosa, 329, 345–350
 highlights of changes from DSM-IV to DSM-5, 813
 other specified feeding or eating disorder, 353–354
 pica, 329–331
 rumination disorder, 329, 332–333
 unspecified feeding or eating disorder, 354
- Female orgasmic disorder, 423, 429–432
 associated features supporting diagnosis of, 430–431
 comorbidity with, 432
 culture-related diagnostic issues in, 432
 development and course of, 431
 diagnostic criteria for, 429–430
 diagnostic features of, 430
 diagnostic markers for, 432
 differential diagnosis of, 432
 functional consequences of, 432
 prevalence of, 431
 risk and prognostic factors for, 431–432
- Female sexual interest/arousal disorder, 423, 433–437
 associated features supporting diagnosis of, 434–435
 comorbidity with, 436–437
 culture-related diagnostic issues in, 435–436
 development and course of, 435
 diagnostic criteria for, 433
 diagnostic features of, 433–434
 differential diagnosis of, 436
 functional consequences of, 436
 gender-related diagnostic issues in, 436
 prevalence of, 435
 risk and prognostic factors for, 435
- Fetishistic disorder, 685, 700–702
 associated features supporting diagnosis of, 701
 comorbidity with, 702
 culture-related diagnostic issues in, 701
 development and course of, 701
 diagnostic criteria for, 700
 diagnostic features of, 701
 differential diagnosis of, 702
 functional consequences of, 701–702
 gender-related diagnostic issues in, 701
 specifiers for, 701
- Forensic settings, 25
- Formal thought disorder, 88
- Frontotemporal neurocognitive disorder, major or mild, 591, **603**, 614–618
 associated features supporting diagnosis of, 616
 development and course of, 616
 diagnostic criteria for, 614–615
 diagnostic features of, 615–616
 diagnostic markers for, 616–617
 differential diagnosis of, 617–618
 functional consequences of, 617
 prevalence of, 616
 risk and prognostic factors for, 616
- Frotteuristic disorder, 685, 691–694
 comorbidity with, 693–694
 development and course of, 693
 diagnostic criteria for, 691–692
 diagnostic features of, 692
 differential diagnosis of, 693
 gender-related diagnostic issues in, 693
 prevalence of, 692–693
 risk and prognostic factors for, 693
 specifiers for, 692
- Functional neurological symptom disorder. *See* Conversion disorder
- GAF (Global Assessment of Functioning) scale, 16
- Gambling disorder, 481, 585–589
 associated features supporting diagnosis of, 587
 comorbidity with, 589
 culture-related diagnostic issues in, 588
 development and course of, 587–588
 diagnostic criteria for, 585–586
 diagnostic features of, 586–587
 differential diagnosis of, 589
 functional consequences of, 589
 gender-related diagnostic issues in, 588
 prevalence of, 587
 risk and prognostic factors for, 588
 specifiers for, 586
- Gender differences, 15
- Gender dysphoria, 451–459
 associated features supporting diagnosis of, 454
 comorbidity with, 458–459
 culture-related diagnostic issues in, 457

- development and course of, 454–456
 - in association with a disorder of sex development, 456
 - without a disorder of sex development, 455–456
 - diagnostic criteria for, 452–453
 - diagnostic features of, 453–454
 - diagnostic markers for, 457
 - differential diagnosis of, 458
 - functional consequences of, 457–458
 - highlights of changes from DSM-IV to DSM-5, 814–815
 - other specified, 459
 - prevalence of, 454
 - risk and prognostic factors for, 456–457
 - specifiers for, 453
 - unspecified, 459
- Generalized anxiety disorder, 190, 222–226
- associated features supporting diagnosis of, 223
 - comorbidity with, 226
 - culture-related diagnostic issues in, 224
 - development and course of, 223–224
 - diagnostic criteria for, 222
 - diagnostic features of, 222–223
 - differential diagnosis of, 225–226
 - functional consequences of, 225
 - gender-related diagnostic issues in, 224–225
 - prevalence of, 223
 - risk and prognostic factors for, 224
- Genito-pelvic pain/penetration disorder, 423, 437–440
- associated features supporting diagnosis of, 438
 - comorbidity with, 440
 - culture-related diagnostic issues in, 439
 - development and course of, 439
 - diagnostic criteria for, 437
 - diagnostic features of, 437–438
 - differential diagnosis of, 440
 - functional consequences of, 439
 - gender-related diagnostic issues in, 439
 - prevalence of, 438
 - risk and prognostic factors for, 439
- Global Assessment of Functioning (GAF) scale, 16
- Global developmental delay, 31, 41
- Glossary of technical terms, 817–831
- Hair pulling. *See* Trichotillomania (hair-pulling disorder)
- Hallucinations, 87–88
- auditory, 87, 103, 116, 122
 - gustatory, 116
 - hypnagogic, 87
 - hypnopompic, 88
 - olfactory, 116, 118
 - tactile, 116
 - visual, 102, 103, 104, 116, 118
- Hallucinogen persisting perception disorder, 531–532
- associated features supporting diagnosis of, 531
 - comorbidity with, 532
 - development and course of, 532
 - diagnostic criteria for, 531
 - diagnostic features of, 531
 - differential diagnosis of, 532
 - functional consequences of, 532
 - prevalence of, 531
 - risk and prognostic factors for, 532
- Hallucinogen-related disorders, 481, 520–533
- diagnoses associated with, **482**
 - hallucinogen persisting perception disorder, 531–532
 - other hallucinogen-induced disorders, 532–533
 - other hallucinogen intoxication, 529–530
 - other hallucinogen use disorder, 523–527
 - other phencyclidine-induced disorders, 532
 - phencyclidine intoxication, 527–529
 - phencyclidine use disorder, 520–523
 - unspecified hallucinogen-related disorder, 533
 - unspecified phencyclidine-related disorder, 533
- Histrionic personality disorder, 645, 646, 667–669
- associated features supporting diagnosis of, 668
 - culture-related diagnostic issues in, 668
 - diagnostic criteria for, 667
 - diagnostic features of, 667–668
 - differential diagnosis of, 669
 - gender-related diagnostic issues in, 668
 - prevalence of, 668
- HIV infection, major or mild neurocognitive disorder due to, 591, **604**, 632–634
- associated features supporting diagnosis of, 633
 - comorbidity with, 634
 - development and course of, 633
 - diagnostic criteria for, 632
 - diagnostic features of, 632
 - diagnostic markers for, 634
 - differential diagnosis of, 634
 - functional consequences of, 634
 - prevalence of, 633
 - risk and prognostic factors for, 633
- Hoarding disorder, 235, 236, 247–251
- associated features supporting diagnosis of, 249
 - comorbidity with, 251
 - culture-related diagnostic issues in, 250
 - development and course of, 249
 - diagnostic criteria for, 247
 - diagnostic features of, 248–249
 - differential diagnosis of, 250–251

- Hoarding disorder (*continued*)
 functional consequences of, 250
 gender-related diagnostic issues in, 250
 prevalence of, 249
 risk and prognostic factors for, 249
 specifiers for, 248
- Housing problems, 723–724
- Huntington's disease, 81, 117, 181, 182
 major or mild neurocognitive disorder due to,
 591, **604**, 638–641
 associated features supporting diagnosis
 of, 639
 development and course of, 639–640
 diagnostic criteria for, 638–639
 diagnostic features of, 639
 diagnostic markers for, 640
 differential diagnosis of, 640–641
 functional consequences of, 640
 prevalence of, 639
 risk and prognostic factors for, 640
- Hypersomnolence disorder, 361, 368–372
 associated features supporting diagnosis of,
 370
 comorbidity with, 372
 development and course of, 370
 diagnostic criteria for, 368–369
 diagnostic features of, 369–370
 diagnostic markers for, 371
 differential diagnosis of, 371–372
 functional consequences of, 371
 other specified, 421
 prevalence of, 370
 relationship to *International Classification of
 Sleep Disorders*, 372
 risk and prognostic factors for, 370–371
 unspecified, 421
- Hypochondriasis, 310, 315–316, 318. *See also*
 Illness anxiety disorder
- Hypomanic episode or symptoms in bipolar and
 related disorders
 bipolar I disorder, 124–125, 129
 bipolar II disorder, 132–133, 135–136
 bipolar and related disorder due to another
 medical condition, 146
 cyclothymic disorder, 139, 140
 depressive episodes with short-duration
 hypomania, 786–789
 other specified bipolar and related disorder,
 148
- ICD. *See International Classification of Diseases*
- ICF (International Classification of Functioning,
 Disability and Health), 21, 734
- ICSD-2. *See International Classification of Sleep
 Disorders*, 2nd Edition
- Identity disturbance due to prolonged and intense
 coercive persuasion, 306
- Illness anxiety disorder, 309, 310, 315–318
 associated features supporting diagnosis of, 316
 brief, 327
 comorbidity with, 318
 culture-related diagnostic issues in, 317
 diagnostic criteria for, 315
 diagnostic features of, 315–316
 differential diagnosis of, 317–318
 functional consequences of, 317
 prevalence of, 316
 risk and prognostic factors for, 316–317
 without excessive health-related behaviors,
 327
- Inhalant intoxication, 538–540
 associated features supporting diagnosis of,
 539
 diagnostic criteria for, 538
 diagnostic features of, 538
 differential diagnosis of, 539–540
 functional consequences of, 539
 gender-related diagnostic issues in, 539
 prevalence of, 539
- Inhalant-related disorders, 481, 533–540
 diagnoses associated with, **482**
 inhalant intoxication, 538–540
 inhalant use disorder, 533–538
 other inhalant-induced disorders, 540
 unspecified inhalant-related disorder, 540
- Inhalant use disorder, 533–538
 associated features supporting diagnosis of,
 535
 comorbidity with, 538
 culture-related diagnostic issues in, 536
 development and course of, 536
 diagnostic criteria for, 533–534
 diagnostic features of, 535
 diagnostic markers for, 536–537
 differential diagnosis of, 537
 functional consequences of, 537
 gender-related diagnostic issues in, 536
 prevalence of, 535–536
 risk and prognostic factors for, 536
 specifiers for, 535
- Insomnia disorder, 361, 362–368
 associated features supporting diagnosis of,
 364
 brief, 420
 comorbidity with, 368
 development and course of, 365
 diagnostic criteria for, 362–363
 diagnostic features of, 363–364
 diagnostic markers for, 366–367
 differential diagnosis of, 367–368

- functional consequences of, 367
- gender-related diagnostic issues in, 366
- other specified, 420
- prevalence of, 364–365
- relationship to *International Classification of Sleep Disorders*, 368
- restricted to nonrestorative sleep, 420
- risk and protective factors for, 366
- unspecified, 420–421
- Intellectual disability (intellectual developmental disorder), 31, 33–41
 - associated features supporting diagnosis of, 38
 - coding and reporting for, 33
 - comorbidity with, 40
 - culture-related diagnostic issues in, 39
 - development and course of, 38–39
 - diagnostic criteria for, 33
 - diagnostic features of, 37–38
 - diagnostic markers for, 39
 - differential diagnosis of, 39–40
 - gender-related diagnostic issues in, 39
 - global developmental delay, 31, 41
 - prevalence of, 38
 - relationship to other classifications, 40–41
 - risk and prognostic factors for, 39
 - specifiers for levels of severity of, 33, **34–36**
 - unspecified intellectual disability, 41
- Intermittent explosive disorder, 461, 466–469
 - associated features supporting diagnosis of, 467
 - comorbidity with, 469
 - culture-related diagnostic issues in, 468
 - development and course of, 467
 - diagnostic criteria for, 466
 - diagnostic features of, 466–467
 - differential diagnosis of, 468–469
 - functional consequences of, 468
 - gender-related diagnostic issues in, 468
 - prevalence of, 467
 - risk and prognostic factors for, 467–468
- Internalizing disorders, 13
- International Classification of Diseases (ICD)*, 21
 - revision process for ICD-11, 6, 10, 11–12
 - use of ICD-9-CM and ICD-10 codes, 12, 16, 22, 23, 29
- International Classification of Functioning, Disability and Health (ICF)*, 21, 734
- International Classification of Sleep Disorders*, 2nd Edition (ICSD-2), relationship of DSM-5 to, 361–362
- circadian rhythm sleep-wake disorders, 398
- hypersomnolence disorder, 372
- insomnia disorder, 368
- narcolepsy, 378
- nightmare disorder, 407
- obstructive sleep apnea hypopnea, 383
- rapid eye movement sleep behavior disorder, 410
- restless legs syndrome, 413
- sleep-related hypoventilation, 390
- substance/medication-induced sleep disorder, 420
- Internet gaming disorder, 795–798
 - associated features supporting diagnosis of, 797
 - comorbidity with, 798
 - diagnostic features of, 796–797
 - differential diagnosis of, 797–798
 - functional consequences of, 797
 - prevalence of, 797
 - proposed criteria for, 795–796
 - risk and prognostic factors for, 797
 - subtypes of, 796
- Intoxication, 481, 485–487
 - alcohol, 497–499
 - associated with use of multiple substances, 486
 - caffeine, 503–506
 - cannabis, 516–517
 - delirium due to, 598
 - development and course of, 487
 - duration of effects and, 486
 - inhalant, 538–540
 - laboratory findings associated with, 486–487
 - opioid, 546–547
 - other hallucinogen, 529–530
 - other (or unknown) substance, 581–582
 - phencyclidine, 527–529
 - recording procedures for, 487
 - related to route of administration and speed of substance effects, 486
 - sedative, hypnotic, or anxiolytic, 556–557
 - stimulant, 567–569
- Jealousy, obsessional, 264
- Jikoshu-kyofu*, 264
- Khyâl cap*, 211, 212, 233, 834
- Kleptomania, 461, 478–479
 - associated features supporting diagnosis of, 478
 - comorbidity with, 478
 - development and course of, 478
 - diagnostic criteria for, 478
 - diagnostic features of, 478
 - differential diagnosis of, 478
 - functional consequences of, 478
 - prevalence of, 478
 - risk and prognostic factors for, 478
- Koro*, 264
- Kufungisisa*, 14, 834–835

- Language disorder, 31, 42–44
 associated features supporting diagnosis of, 43
 comorbidity with, 44
 development and course of, 43
 diagnostic criteria for, 42
 diagnostic features of, 42
 differential diagnosis of, 43
 risk and prognostic factors for, 43
- Learning disorder. *See* Specific learning disorder
- Level of Personality Functioning Scale (LPFS), 772, 775–778
- Lewy bodies, major or mild neurocognitive disorder with, 591, 603, 618–621
 associated features supporting diagnosis of, 619
 comorbidity with, 621
 development and course of, 619–620
 diagnostic criteria for, 618–619
 diagnostic features of, 619
 diagnostic markers for, 620
 differential diagnosis of, 620
 functional consequences of, 620
 prevalence of, 619
 risk and prognostic factors for, 620
- LPFS (Level of Personality Functioning Scale), 772, 775–778
- Major depressive disorder, 155, 160–168
 associated features supporting diagnosis of, 164–165
 comorbidity with, 168
 culture-related diagnostic issues in, 166
 development and course of, 165–166
 diagnostic criteria for, 160–162
 diagnostic features of, 162–164
 differential diagnosis of, 167–168
 functional consequences of, 167
 gender-related diagnostic issues in, 167
 prevalence of, 165
 risk and prognostic factors for, 166
 suicide risk in, 164, 167
- Major depressive episode in bipolar and related disorders
 bipolar I disorder, 125–126, 129
 bipolar II disorder, 133–134, 135–136
 other specified bipolar and related disorder, 148
- Maladi moun*, 14, 835
- Male hypoactive sexual desire disorder, 423, 440–443
 associated features supporting diagnosis of, 441–442
 comorbidity with, 443
 culture-related diagnostic issues in, 442
 development and course of, 442
 diagnostic criteria for, 440–441
 diagnostic features of, 441
 differential diagnosis of, 443
 gender-related diagnostic issues in, 442–443
 prevalence of, 442
 risk and prognostic factors for, 442
- Manic episode
 in bipolar I disorder, 124, 127–129
 in bipolar and related disorder due to another medical condition, 146
- Medication-induced delirium, 597, 599
- Medication-induced movement disorders and other adverse effects of medication, 20, 22, 29, 709–714
 antidepressant discontinuation syndrome, 22, 712–714
 medication-induced acute akathisia, 22, 711
 medication-induced acute dystonia, 711
 medication-induced postural tremor, 712
 neuroleptic-induced parkinsonism, 709
 neuroleptic malignant syndrome, 22, 709–711
 other adverse effect of medication, 712–714
 other medication-induced movement disorder, 712
 other medication-induced parkinsonism, 709
 tardive akathisia, 712
 tardive dyskinesia, 22, 712
 tardive dystonia, 712
- Mental disorder(s)
 culture and, 14–15, 749–759
 definition of, 20
 criterion for clinical significance, 21
 in forensic settings, 25
 gender and, 15
- Motor disorders, neurodevelopmental, 32, 74–85
 developmental coordination disorder, 74–77
 stereotypic movement disorder, 77–80
 tic disorders, 81–85
- Movement disorders, medication-induced. *See* Medication-induced movement disorders and other adverse effects of medication
- Muscle dysmorphia, 236, 243, 245
- Narcissistic personality disorder, 645, 646, 669–672
 associated features supporting diagnosis of, 671
 development and course of, 671
 diagnostic criteria for, 669–670
 diagnostic features of, 670–671
 differential diagnosis of, 671–672
 features and criteria in alternative DSM-5 model for personality disorders, 763, 767–768
 gender-related diagnostic issues in, 671
 prevalence of, 671

- Narcolepsy, 361, 372–378
 associated features supporting diagnosis of, 374–375
 comorbidity with, 377–378
 culture-related diagnostic issues in, 376
 development and course of, 375
 diagnostic criteria for, 372–373
 diagnostic features of, 374
 diagnostic markers for, 376
 differential diagnosis of, 376–377
 functional consequences of, 376
 prevalence of, 375
 relationship to *International Classification of Sleep Disorders*, 378
 risk and prognostic factors for, 375–376
 subtypes of, 373–374
- NCDs. *See* Neurocognitive disorders
- Neglect
 child, 718–719
 spouse or partner, 721
- Nervios*, 835
- Neurobehavioral disorder associated with
 prenatal alcohol exposure, 798–801
 associated features supporting diagnosis of, 799
 comorbidity with, 800–801
 development and course of, 800
 diagnostic features of, 799
 differential diagnosis of, 800
 functional consequences of, 800
 prevalence of, 800
 proposed criteria for, 798–799
 suicide risk in, 800
- Neurocognitive disorders (NCDs), 591–643
 delirium, 591, 596–602
 other specified delirium, 602
 unspecified delirium, 602
 highlights of changes from DSM-IV to DSM-5, 816
 major and mild neurocognitive disorders, 591, 602–611, 611–643
 associated features supporting diagnosis of, 608
 comorbidity with, 610–611
 culture-related diagnostic issues in, 609
 development and course of, 608–609
 diagnostic criteria for, 602–606
 diagnostic features of, 607–608
 diagnostic markers for, 609–610
 differential diagnosis of, 610
 functional consequences of, 610
 gender-related diagnostic issues in, 609
 prevalence of, 608
 risk and prognostic factors for, 609
 specifiers for, 606–607
 subtypes of, 591, **603–604**, 606, 611–643
 major or mild frontotemporal neurocognitive disorder, 591, **603**, 614–618
 major or mild neurocognitive disorder due to Alzheimer's disease, 591, **603**, 611–614
 major or mild neurocognitive disorder due to another medical condition, 591, **604**, 641–642
 major or mild neurocognitive disorder due to HIV infection, 591, **604**, 632–634
 major or mild neurocognitive disorder due to Huntington's disease, 591, **604**, 638–641
 major or mild neurocognitive disorder with Lewy bodies, 591, **603**, 618–621
 major or mild neurocognitive disorder due to multiple etiologies, 591, **604**, 642–643
 major or mild neurocognitive disorder due to Parkinson's disease, 591, **604**, 636–638
 major or mild neurocognitive disorder due to prion disease, 591, **604**, 634–636
 major or mild neurocognitive disorder due to traumatic brain injury, 591, **603**, 624–627, **626**
 major or mild substance/medication-induced neurocognitive disorder, 591, **603**, 627–632
 unspecified neurocognitive disorder, 591, **604**, 643
 vascular neurocognitive disorder, 591, **603**, 621–624
 neurocognitive domains, 592, **593–595**
- Neurodevelopmental disorders, 11, 13, 31–86
 attention-deficit/hyperactivity disorder, 11, 32, 59–66
 autism spectrum disorders, 31–32, 50–59
 communication disorders, 31, 41–49
 highlights of changes from DSM-IV to DSM-5, 809–810
 intellectual disabilities, 31, 33–41
 motor disorders, 32, 74–85
 other specified neurodevelopmental disorder, 86
 specific learning disorder, 32, 66–74
 specifiers for, 32–33
 tic disorders, 32, 81–85
 unspecified neurodevelopmental disorder, 86
- Neurodevelopmental motor disorders, 32, 74–85
 developmental coordination disorder, 74–77
 stereotypic movement disorder, 77–80
 tic disorders, 81–85

- Neuroleptic-induced parkinsonism, 709
- Neuroleptic malignant syndrome, 22, 709–711
 - development and course of, 710
 - diagnostic features of, 710
 - differential diagnosis of, 711
 - risk and prognostic factors for, 711
- Night eating syndrome, 354
- Nightmare disorder, 361, 404–407
 - associated features supporting diagnosis of, 405
 - comorbidity with, 407
 - culture-related diagnostic issues in, 406
 - development and course of, 405
 - diagnostic criteria for, 404
 - diagnostic features of, 404–405
 - diagnostic markers for, 406
 - differential diagnosis of, 406–407
 - functional consequences of, 406
 - gender-related diagnostic issues in, 406
 - prevalence of, 405
 - relationship to *International Classification of Sleep Disorders*, 407
 - risk and prognostic factors for, 405
- Nonadherence to medical treatment, 22, 726–727
- Non-rapid eye movement sleep arousal disorders, 361, 399–404
 - associated features supporting diagnosis of, 400–401
 - comorbidity with, 403
 - development and course of, 401
 - diagnostic criteria for, 399
 - diagnostic features of, 400
 - diagnostic markers for, 402
 - differential diagnosis of, 402–403
 - functional consequences of, 402
 - gender-related diagnostic issues in, 401
 - prevalence of, 401
 - relationship to *International Classification of Sleep Disorders*, 404
 - risk and prognostic factors for, 401
- Non-suicidal self-injury, 803–805
 - development and course of, 804
 - diagnostic features of, 804
 - differential diagnosis of, 805–806
 - functional consequences of, 805
 - proposed criteria for, 803
 - risk and prognostic factors for, 804
- Obesity, 22
 - feeding and eating disorders and, 329, 344, 348, 351–353
 - sleep-wake disorders and, 413
 - hypersomnia, 372, 373, 375, 376, 377
 - obstructive sleep apnea hypopnea, 379–380, 382
 - sleep-related hypoventilation, 387–388, 389
- Obsessional jealousy, 264
- Obsessive-compulsive disorder (OCD), 235–236, 237–242
 - associated features supporting diagnosis of, 238–239
 - comorbidity with, 243
 - culture-related diagnostic issues in, 240
 - development and course of, 239
 - diagnostic criteria for, 237
 - diagnostic features of, 238
 - differential diagnosis of, 242–243
 - functional consequences of, 241–242
 - gender-related diagnostic issues in, 239, 240
 - prevalence of, 239
 - risk and prognostic factors for, 239–240
 - specifiers for, 236, 238
 - suicide risk in, 240
- Obsessive-compulsive personality disorder, 645, 646, 678–682
 - associated features supporting diagnosis of, 680–681
 - culture-related diagnostic issues in, 681
 - diagnostic criteria for, 678–679
 - diagnostic features of, 679–680
 - differential diagnosis of, 681–682
 - features and criteria in alternative DSM-5 model for personality disorders, 764, 768–769
 - gender-related diagnostic issues in, 681
 - prevalence of, 681
- Obsessive-compulsive and related disorder due to another medical condition, 235, 236, 260–263
 - associated features supporting diagnosis of, 262
 - development and course of, 262
 - diagnostic criteria for, 260–261
 - diagnostic features of, 261–262
 - diagnostic markers for, 262
 - differential diagnosis of, 262–263
- Obsessive-compulsive and related disorders, 235–264
 - body dysmorphic disorder, 235, 236, 242–247
 - excoriation (skin-picking) disorder, 235, 236, 254–257
 - highlights of changes from DSM-IV to DSM-5, 811–812
 - hoarding disorder, 235, 236, 247–251
 - obsessions and compulsions in, 235–236, 239
 - obsessive-compulsive disorder, 235–236, 237–242
 - obsessive-compulsive and related disorder due to another medical condition, 235, 236, 260–263
 - other specified obsessive-compulsive and related disorder, 235, 236, 263–264

- substance/medication-induced obsessive-compulsive and related disorder, 235, 236, 257–260
- trichotillomania (hair-pulling disorder), 235, 236, 251–254
- unspecified obsessive-compulsive and related disorder, 235, 236
- Obstructive sleep apnea hypopnea, 378–383
 - associated features supporting diagnosis of, 379
 - comorbidity with, 383
 - culture-related diagnostic issues in, 381
 - development and course of, 379–380
 - diagnostic criteria for, 378
 - diagnostic features of, 379
 - diagnostic markers for, 381
 - differential diagnosis of, 381–383
 - functional consequences of, 381
 - gender-related diagnostic issues in, 381
 - prevalence of, 379
 - relationship to *International Classification of Sleep Disorders*, 383
 - risk and prognostic factors for, 380–381
 - specifiers for, 378–379
- Occupational problems, 723
- OCD. *See* Obsessive-compulsive disorder
- Olfactory reference syndrome, 246, 264, 837
- Online enhancements, 17
- Opioid intoxication, 546–547
 - diagnostic criteria for, 546–547
 - diagnostic features of, 547
 - differential diagnosis of, 547
 - specifiers for, 547
- Opioid-related disorders, 481, 540–550
 - diagnoses associated with, 482
 - opioid intoxication, 546–547
 - opioid use disorder, 541–546
 - opioid withdrawal, 484, 547–549
 - other opioid-induced disorders, 549
 - unspecified opioid-related disorder, 550
- Opioid use disorder, 541–546
 - associated features supporting diagnosis of, 543
 - comorbidity with, 546
 - culture-related diagnostic issues in, 544
 - development and course of, 543
 - diagnostic criteria for, 541–542
 - diagnostic features of, 542
 - diagnostic markers for, 544
 - differential diagnosis of, 545–546
 - functional consequences of, 544–545
 - gender-related diagnostic issues in, 544
 - prevalence of, 543
 - risk and prognostic factors for, 543–544
 - specifiers for, 542
 - suicide risk in, 544
- Opioid withdrawal, 484, 547–549
 - associated features supporting diagnosis of, 549
 - development and course of, 549
 - diagnostic criteria for, 547–548
 - diagnostic features of, 548
 - differential diagnosis of, 549
 - prevalence of, 549
- Oppositional defiant disorder, 32, 461, 462–466
 - associated features supporting diagnosis of, 464
 - comorbidity with, 466
 - culture-related diagnostic issues in, 465
 - development and course of, 464
 - diagnostic criteria for, 462–463
 - diagnostic features of, 463
 - differential diagnosis of, 465
 - functional consequences of, 465
 - prevalence of, 464
 - risk and prognostic factors for, 464
 - specifiers for, 463
- Other circumstances of personal history, 726
- Other conditions that may be a focus of clinical
 - attention, 20, 22, 29, 715–727
 - abuse and neglect, 717–722
 - adult maltreatment and neglect problems, 720–722
 - child maltreatment and neglect problems, 717–719
 - educational and occupational problems, 723
 - housing and economic problems, 723–724
 - nonadherence to medical treatment, 726–727
 - other circumstances of personal history, 726
 - other health service encounters for counseling and medical advice, 725
 - other problems related to the social environment, 724–725
 - problems related to access to medical and other health care, 726
 - problems related to crime or interaction with the legal system, 725
 - problems related to other psychosocial, personal, and environmental circumstances, 725
 - relational problems, 715–717
 - other problems related to primary support group, 716–717
 - problems related to family upbringing, 715–716
- Other hallucinogen intoxication, 529–530
 - diagnostic criteria for, 529
 - diagnostic features of, 529
 - differential diagnosis of, 530
 - functional consequences of, 530
 - prevalence of, 530
 - suicide risk in, 530

- Other hallucinogen use disorder, 523–527
 - associated features supporting diagnosis of, 525
 - comorbidity with, 527
 - culture-related diagnostic issues in, 526
 - development and course of, 525–526
 - diagnostic criteria for, 523–524
 - diagnostic features of, 524–525
 - diagnostic markers for, 526
 - differential diagnosis of, 527
 - functional consequences of, 527
 - gender-related diagnostic issues in, 526
 - prevalence of, 525
 - risk and prognostic factors for, 526
 - specifiers for, 524
- Other health service encounters for counseling and medical advice, 725
- Other mental disorders, 707–708
 - other specified mental disorder, 15–16, 19, 708
 - other specified mental disorder due to another medical condition, 707
 - unspecified mental disorder, 15–16, 19–20, 708
 - unspecified mental disorder due to another medical condition, 708
- Other problems related to primary support group, 716–717
- Other problems related to social environment, 724–725
- Other psychosocial, personal, and environmental circumstances, problems related to, 725
- Other specified mental disorder, 15–16, 19, 708
 - due to another medical condition, 707
- Other (or unknown) substance intoxication, 581–582
 - comorbidity with, 582
 - development and course of, 581–582
 - diagnostic criteria for, 581
 - diagnostic features of, 581
 - differential diagnosis of, 582
 - functional consequences of, 582
 - prevalence of, 581
- Other (or unknown) substance-related disorders, 577–585
 - diagnoses associated with, **482**
 - other (or unknown) substance-induced disorders, 584–585
 - other (or unknown) substance intoxication, 581–582
 - other (or unknown) substance use disorder, 577–580
 - other (or unknown) substance withdrawal, 583–584
 - unspecified other (or unknown) substance-related disorder, 585
- Other (or unknown) substance use disorder, 577–580
 - associated features supporting diagnosis of, 579
 - comorbidity with, 580
 - culture-related diagnostic issues in, 580
 - development and course of, 580
 - diagnostic criteria for, 577–578
 - diagnostic features of, 579
 - diagnostic markers for, 580
 - differential diagnosis of, 580
 - prevalence of, 579
 - risk and prognostic factors for, 580
 - specifiers for, 578
- Other (or unknown) substance withdrawal, 583–584
 - comorbidity with, 584
 - culture-related diagnostic issues in, 583
 - development and course of, 583
 - diagnostic criteria for, 583
 - diagnostic features of, 583
 - differential diagnosis of, 584
 - functional consequences of, 584
 - prevalence of, 583
- Panic attacks, 189, 190, 208–209, 214–217
 - associated features with, 215
 - comorbidity with, 217
 - culture-related diagnostic issues in, 216
 - development and course of, 215–216
 - diagnostic markers for, 216
 - differential diagnosis of, 217
 - expected vs. unexpected, 215
 - features of, 214–215
 - functional consequences of, 217
 - gender-related diagnostic issues in, 216
 - nocturnal, 209, 215
 - in older adults, 210–211, 215–216
 - prevalence of, 215
 - risk and prognostic factors for, 216
 - specifier for, 214–217
 - suicide risk and, 215
 - symptoms of, 214
- Panic disorder, 190, 208–214
 - associated features supporting diagnosis of, 210
 - culture-related diagnostic issues in, 211–212
 - development and course of, 210–211
 - diagnostic criteria for, 208–209
 - diagnostic features of, 209
 - diagnostic markers for, 212
 - differential diagnosis of, 212–213
 - functional consequences of, 212
 - gender-related diagnostic issues in, 210.212
 - prevalence of, 210
 - risk and prognostic factors for, 211
 - suicide risk in, 212

- Paranoid personality disorder, 645, 646, 649–652
 - associated features supporting diagnosis of, 650–651
 - culture-related diagnostic issues in, 651
 - development and course of, 651
 - diagnostic criteria for, 649
 - diagnostic features of, 649–650
 - differential diagnosis of, 652
 - prevalence of, 651
 - risk and prognostic factors for, 651
- Paraphilic disorders, 685–705
 - exhibitionistic disorder, 685, 689–691
 - fetishistic disorder, 685, 700–702
 - frotteuristic disorder, 685, 691–694
 - highlights of changes from DSM-IV to DSM-5, 816
 - other specified paraphilic disorder, 705
 - pedophilic disorder, 685, 697–700
 - sexual masochism disorder, 685, 694–695
 - sexual sadism disorder, 685, 695–697
 - transvestic disorder, 685, 702–704
 - unspecified paraphilic disorder, 705
 - voyeuristic disorder, 685, 686–688
- Parasomnias, 361, 399–410
 - nightmare disorder, 361, 404–407
 - non-rapid eye movement sleep arousal disorders, 361, 399–404
 - rapid eye movement sleep behavior disorder, 361, 407–410
- Parkinsonism
 - neuroleptic-induced, 709
 - other medication-induced, 709
- Parkinson's disease
 - anxiety disorders and, 203, 205, 207, 218, 221
 - depressive disorders and, 181, 182
 - major or mild neurocognitive disorder due to, 591, 604, 636–638
 - associated features supporting diagnosis of, 637
 - comorbidity with, 638
 - development and course of, 637
 - diagnostic criteria for, 636–637
 - diagnostic features of, 637
 - diagnostic markers for, 637–638
 - differential diagnosis of, 638
 - prevalence of, 637
 - risk and prognostic factors for, 637
 - sleep-wake disorders and, 372, 383, 395, 413, 421
 - REM sleep behavior disorder, 361, 408, 410
- Pedophilic disorder, 685, 697–700
 - associated features supporting diagnosis of, 698
 - comorbidity with, 700
 - development and course of, 699
 - diagnostic criteria for, 697–698
 - diagnostic features of, 698
 - diagnostic markers for, 699
 - differential diagnosis of, 700
 - gender-related diagnostic issues in, 699
 - prevalence of, 698
 - risk and prognostic factors for, 699
- Persistent complex bereavement disorder, 289, 789–792
 - associated features supporting diagnosis of, 791
 - comorbidity with, 792
 - culture-related diagnostic issues in, 791
 - development and course of, 791
 - diagnostic features of, 790–791
 - differential diagnosis of, 792
 - functional consequences of, 792
 - prevalence of, 791
 - proposed criteria for, 789–790
 - risk and prognostic factors for, 791
 - suicide risk in, 791
- Persistent depressive disorder (dysthymia), 155, 168–171
 - comorbidity with, 171
 - development and course of, 170
 - diagnostic criteria for, 168–169
 - diagnostic features of, 169–170
 - differential diagnosis of, 170–171
 - functional consequences of, 170
 - prevalence of, 170
 - risk and prognostic factors for, 170
- Personality change due to another medical condition, 645, 682–684
 - associated features supporting diagnosis of, 683
 - diagnostic criteria for, 682
 - diagnostic features of, 683
 - differential diagnosis of, 683–684
 - subtypes of, 683
- Personality disorders, 645–684
 - Cluster A, 646, 649–659
 - paranoid personality disorder, 645, 646, 649–652
 - schizoid personality disorder, 645, 646, 652–655
 - schizotypal personality disorder, 87, 89, 90, 645, 646, 655–659
 - Cluster B, 646, 659–672
 - antisocial personality disorder, 461, 476, 645, 646, 659–663
 - borderline personality disorder, 645, 646, 663–666
 - histrionic personality disorder, 645, 646, 667–669
 - narcissistic personality disorder, 645, 646, 669–672

Personality disorders (*continued*)

- Cluster C, 646, 672–682
 - avoidant personality disorder, 645, 646, 672–675
 - dependent personality disorder, 645, 646, 675–678
 - obsessive-compulsive personality disorder, 645, 646, 678–682
- general personality disorder, 646–649
 - criteria for, 646–647
 - culture-related diagnostic issues in, 648
 - development and course of, 647–648
 - diagnostic features of, 647
 - differential diagnosis of, 648–649
 - gender-related diagnostic issues in, 648
- highlights of changes from DSM-IV to DSM-5, 816
- other specified personality disorder, 645–646, 684
- personality change due to another medical condition, 645, 682–684
- unspecified personality disorder, 645–646, 684
- Personality disorders: alternative DSM-5 model, 761–781
 - diagnosis of, 771
 - general criteria for personality disorder, 761–763
 - Criterion A: level of personality functioning, 762, **762**
 - Criterion B: pathological personality traits, 762–763
 - Criteria C and D: pervasiveness and stability, 763
 - Criteria E, F, and G: alternative explanations for personality pathology, 763
 - level of personality functioning, 762, **762**, 771–772
 - Level of Personality Functioning Scale for rating of, 772, **775–778**
 - self-* and *interpersonal* functioning
 - dimensional definition, 772
 - personality traits, 772–774
 - assessment of Personality Trait Model, 774
 - clinical utility of multidimensional personality functioning and trait model, 774
 - definition and description of, 772–773
 - definitions of personality disorder trait domains and facets, **779–781**
 - dimensionality of, 772–773
 - distinguishing traits, symptoms, and specific behaviors, 773–774
 - hierarchical structure of personality, 773
 - Personality Trait Model, 773
 - scoring algorithms for, 771
 - specific personality disorders, 763–771
 - antisocial personality disorder, 763, 764–765
 - avoidant personality disorder, 763, 765–766
 - borderline personality disorder, 763, 766–767
 - narcissistic personality disorder, 763, 767–768
 - obsessive-compulsive personality disorder, 764, 768–769
 - personality disorder—trait specified, 761, 770–771
 - schizotypal personality disorder, 764, 769–770
- Phencyclidine intoxication, 527–529
 - diagnostic criteria for, 527–528
 - diagnostic features of, 528
 - diagnostic markers for, 528
 - differential diagnosis of, 528–529
 - functional consequences of, 528
 - prevalence of, 528
- Phencyclidine-related disorders, 481
 - diagnoses associated with, **482**
 - other phencyclidine-induced disorders, 532
 - phencyclidine intoxication, 527–529
 - phencyclidine use disorder, 520–523
 - unspecified phencyclidine-related disorder, 533
- Phencyclidine use disorder, 520–523
 - associated features supporting diagnosis of, 522
 - culture-related diagnostic issues in, 522
 - diagnostic criteria for, 520–521
 - diagnostic features of, 521–522
 - diagnostic markers for, 522
 - differential diagnosis of, 523
 - functional consequences of, 522
 - gender-related diagnostic issues in, 522
 - prevalence of, 522
 - risk and prognostic factors for, 522
 - specifiers for, 521
- Phobic disorders
 - agoraphobia, 190, 217–221
 - social anxiety disorder (social phobia), 190, 202–208
 - specific phobia, 189–190, 197–202
- Physical abuse
 - child, 717–718
 - nonspouse or nonpartner, 722
 - spouse or partner, 720
- Pica, 329–331
 - associated features supporting diagnosis of, 330
 - comorbidity with, 331
 - culture-related diagnostic issues in, 331
 - development and course of, 330
 - diagnostic criteria for, 329–330

- diagnostic features of, 330
- diagnostic markers for, 331
- differential diagnosis of, 331
- functional consequences of, 331
- gender-related diagnostic issues in, 331
- prevalence of, 330
- risk and prognostic factors for, 330
- Posttraumatic stress disorder (PTSD), 265, 271–280
 - associated features supporting diagnosis of, 276
 - comorbidity with, 280
 - culture-related diagnostic issues in, 278
 - development and course of, 276–277
 - diagnostic criteria for, 271–274
 - diagnostic features of, 274–276
 - differential diagnosis of, 279–280
 - functional consequences of, 278–279
 - gender-related diagnostic issues in, 278
 - prevalence of, 276
 - risk and prognostic factors for, 277–278
 - suicide risk in, 278
- Postural tremor, medication-induced, 712
- Premature (early) ejaculation, 423, 443–446
 - associated features supporting diagnosis of, 444
 - comorbidity with, 446
 - culture-related diagnostic issues in, 445
 - development and course of, 444–445
 - diagnostic criteria for, 443–444
 - diagnostic features of, 444
 - diagnostic markers for, 445
 - differential diagnosis of, 445–446
 - functional consequences of, 445
 - gender-related diagnostic issues in, 445
 - prevalence of, 444
 - risk and prognostic factors for, 445
- Premenstrual dysphoric disorder, 155, 171–175
 - associated features supporting diagnosis of, 173
 - comorbidity with, 175
 - culture-related diagnostic issues in, 173
 - development and course of, 173
 - diagnostic criteria for, 171–172
 - diagnostic features of, 172–173
 - diagnostic markers for, 173–174
 - differential diagnosis of, 174–175
 - functional consequences of, 174
 - prevalence of, 173
 - recording procedures for, 172
 - risk and prognostic factors for, 173
- Principal diagnosis, 22–23
- Prion disease, major or mild neurocognitive disorder due to, 591, 604, 634–636
 - development and course of, 635
 - diagnostic criteria for, 634–635
 - diagnostic features of, 635
 - diagnostic markers for, 636
 - differential diagnosis of, 636
 - prevalence of, 635
 - risk and prognostic factors for, 636
- Problems related to access to medical and other health care, 726
- Problems related to crime or interaction with the legal system, 725
- Problems related to family upbringing, 715–716
- Problems related to other psychosocial, personal, and environmental circumstances, 725
- Provisional diagnosis, 23
- Pseudocyesis, 310, 327
- Psychological abuse
 - child, 719
 - nonspouse or nonpartner, 722
 - spouse or partner abuse, 721–722
- Psychological factors affecting other medical conditions, 309, 310, 322–324
 - comorbidity with, 324
 - culture-related diagnostic issues in, 323
 - development and course of, 323
 - diagnostic criteria for, 322
 - diagnostic features of, 322–323
 - differential diagnosis of, 323–324
 - functional consequences of, 323
 - prevalence of, 323
- Psychotic disorder due to another medical condition, 89, 115–118
 - associated features supporting diagnosis of, 116
 - comorbidity with, 118
 - development and course of, 117
 - diagnostic criteria for, 115–116
 - diagnostic features of, 116
 - diagnostic markers for, 117
 - differential diagnosis of, 118
 - functional consequences of, 118
 - prevalence of, 116–117
 - risk and prognostic factors for, 117
 - specifiers for, 116
 - suicide risk in, 118
- Psychotic disorders. *See* Schizophrenia spectrum and other psychotic disorders
- PTSD. *See* Posttraumatic stress disorder
- Purging disorder, 353
- Pyromania, 461, 476–477
 - associated features supporting diagnosis of, 476–477
 - comorbidity with, 477
 - development and course of, 477
 - diagnostic criteria for, 476
 - diagnostic features of, 476
 - differential diagnosis of, 477
 - gender-related diagnostic issues in, 477
 - prevalence of, 477

- Rapid eye movement (REM) sleep behavior disorder, 361, 407–410
 associated features supporting diagnosis of, 408
 comorbidity with, 410
 development and course of, 408–409
 diagnostic criteria for, 407–408
 diagnostic features of, 408
 diagnostic markers for, 409
 differential diagnosis of, 409–410
 functional consequences of, 409
 prevalence of, 408
 relationship to *International Classification of Sleep Disorders*, 410
 risk and prognostic factors for, 409
- Reactive attachment disorder, 265–268
 associated features supporting diagnosis of, 266
 comorbidity with, 268
 culture-related diagnostic issues in, 267
 development and course of, 266
 diagnostic criteria for, 265–266
 diagnostic features of, 266
 differential diagnosis of, 267–268
 functional consequences of, 267
 prevalence of, 266
 risk and prognostic factors for, 267
- Recurrent brief depression, 183
- Relational problems, 22, 715–717
 other problems related to primary support group, 716–717
 problems related to family upbringing, 715–716
- REM sleep behavior disorder. *See* Rapid eye movement sleep behavior disorder
- Restless legs syndrome (RLS), 361, 410–413
 associated features supporting diagnosis of, 411
 comorbidity with, 413
 development and course of, 411–412
 diagnostic criteria for, 410
 diagnostic features of, 411
 diagnostic markers for, 412
 differential diagnosis of, 413
 functional consequences of, 412–413
 gender-related diagnostic issues in, 412
 prevalence of, 411
 relationship to *International Classification of Sleep Disorders*, 413
 risk and prognostic factors for, 412
- Rett syndrome, 33, 38, 51, 53, 56, 57, 79, 80
- RLS. *See* Restless legs syndrome
- Rumination disorder, 329, 332–333
 associated features supporting diagnosis of, 332–333
 comorbidity with, 333
 development and course of, 333
 diagnostic criteria for, 332
 diagnostic features of, 332
 differential diagnosis of, 333
 functional consequences of, 333
 prevalence of, 333
 risk and prognostic factors for, 333
- Schizoaffective disorder, 89–90, 105–110
 associated features supporting diagnosis of, 107
 comorbidity with, 110
 culture-related diagnostic issues in, 108–109
 development and course of, 108
 diagnostic criteria for, 105–106
 diagnostic features of, 106–107
 differential diagnosis of, 109–110
 functional consequences of, 109
 prevalence of, 107–108
 risk and prognostic factors for, 108
 suicide risk in, 109
- Schizoid personality disorder, 645, 646, 652–655
 associated features supporting diagnosis of, 653–654
 culture-related diagnostic issues in, 654
 development and course of, 654
 diagnostic criteria for, 652–653
 diagnostic features of, 653
 differential diagnosis of, 654–655
 gender-related diagnostic issues in, 654
 prevalence of, 654
 risk and prognostic factors for, 654
- Schizophrenia, 87, 99–105
 associated features supporting diagnosis of, 101–102
 with catatonia, 88, 100
 comorbidity with, 105
 culture-related diagnostic issues in, 103
 development and course of, 102–103
 diagnostic features of, 87–88, 100–101
 differential diagnosis of, 104–105
 functional consequences of, 104
 gender-related diagnostic issues in, 103–104
 prevalence of, 102
 risk and prognostic factors for, 103
 suicide risk in, 104
- Schizophrenia spectrum and other psychotic disorders, 87–122
 brief psychotic disorder, 89, 94–96
 catatonia, 88, 89, 119–121
 clinician-rated assessment of symptoms and related clinical phenomena in, 89–90
 delusional disorder, 89, 90–93
 highlights of changes from DSM-IV to DSM-5, 810
 key features of, 87–88
 delusions, 87
 disorganized thinking (speech), 88

- grossly disorganized or abnormal motor behavior (including catatonia), 88
- hallucinations, 87–88
- negative symptoms, 88
- other specified schizophrenia spectrum and other psychotic disorder, 122
- psychotic disorder due to another medical condition, 89, 115–118
- schizoaffective disorder, 89–90, 105–110
- schizophrenia, 87, 99–105
- schizophreniform disorder, 89, 96–99
- schizotypal (personality) disorder, 87, 89, 90
- substance/medication-induced psychotic disorder, 89, 110–115
- unspecified schizophrenia spectrum and other psychotic disorder, 122
- Schizophreniform disorder, 89, 96–99
 - associated features supporting diagnosis of, 98
 - development and course of, 98
 - diagnostic criteria for, 96–97
 - diagnostic features of, 97–98
 - differential diagnosis of, 98–99
 - functional consequences of, 98
 - prevalence of, 98
 - provisional diagnosis of, 97
 - risk and prognostic factors for, 98
- Schizotypal personality disorder, 87, 89, 90, 645, 646, 655–659
 - associated features supporting diagnosis of, 657
 - culture-related diagnostic issues in, 657
 - development and course of, 657
 - diagnostic criteria for, 655–656
 - diagnostic features of, 656–657
 - differential diagnosis of, 658–659
 - features and criteria in alternative DSM-5 model for personality disorders, 764, 769–770
 - gender-related diagnostic issues in, 658
 - prevalence of, 657
 - risk and prognostic factors for, 657
- Sedative, hypnotic, or anxiolytic intoxication, 556–557
 - associated features supporting diagnosis of, 557
 - diagnostic criteria for, 556
 - diagnostic features of, 556–557
 - differential diagnosis of, 557
 - prevalence of, 557
- Sedative-, hypnotic-, or anxiolytic-related disorders, 481, 550–560
 - diagnoses associated with, 482
 - other sedative-, hypnotic-, or anxiolytic-induced disorders, 560
 - sedative, hypnotic, or anxiolytic intoxication, 556–557
 - sedative, hypnotic, or anxiolytic use disorder, 550–556
 - sedative, hypnotic, or anxiolytic withdrawal, 484, 557–560
 - unspecified sedative-, hypnotic-, or anxiolytic-related disorder, 560
- Sedative, hypnotic, or anxiolytic use disorder, 550–556
 - associated features supporting diagnosis of, 553
 - comorbidity with, 555–556
 - culture-related diagnostic issues in, 554
 - development and course of, 553–554
 - diagnostic criteria for, 550–552
 - diagnostic features of, 552–553
 - diagnostic markers for, 554–555
 - differential diagnosis of, 555
 - functional consequences of, 555
 - gender-related diagnostic issues in, 554
 - prevalence of, 553
 - risk and prognostic factors for, 554
 - specifiers for, 552
- Sedative, hypnotic, or anxiolytic withdrawal, 484, 557–560
 - associated features supporting diagnosis of, 559
 - diagnostic criteria for, 557–558
 - diagnostic features of, 558
 - diagnostic markers for, 559
 - differential diagnosis of, 559–560
 - prevalence of, 559
- Selective mutism, 189, 195–197
 - associated features supporting diagnosis of, 195–196
 - comorbidity with, 197
 - culture-related diagnostic issues in, 196
 - development and course of, 196
 - diagnostic criteria for, 195
 - diagnostic features of, 195
 - differential diagnosis of, 197
 - functional consequences of, 196–197
 - prevalence of, 196
 - risk and prognostic factors for, 196
- Separation anxiety disorder, 189, 190–195
 - associated features supporting diagnosis of, 192
 - comorbidity with, 195
 - culture-related diagnostic issues in, 193
 - development and course of, 192–193
 - diagnostic criteria for, 190–191
 - diagnostic features of, 191–192
 - differential diagnosis of, 194–195
 - functional consequences of, 193–194
 - gender-related diagnostic issues in, 193
 - prevalence of, 192
 - risk and prognostic factors for, 193
 - suicide risk in, 193

- Severity measures, 733, 742
 Clinician-Rated Dimensions of Psychosis
 Symptom Severity, 742–744
 frequency of use of, 742
 scoring and interpretation of, 742
- Sexual abuse
 child, 718
 nonspouse or nonpartner, 722
 spouse or partner, 720
- Sexual dysfunctions, 423–450
 delayed ejaculation, 423, 424–426
 erectile disorder, 423, 426–429
 female orgasmic disorder, 423, 429–432
 female sexual interest/arousal disorder, 423, 433–437
 genito-pelvic pain/penetration disorder, 423, 437–440
 highlights of changes from DSM-IV to DSM-5, 814
 male hypoactive sexual desire disorder, 423, 440–443
 other specified sexual dysfunction, 423, 450
 premature (early) ejaculation, 423, 443–446
 substance/medication-induced sexual dysfunction, 423, 446–450
 subtypes of, 423
 unspecified sexual dysfunction, 423, 450
- Sexual masochism disorder, 685, 694–695
 associated features supporting diagnosis of, 694
 comorbidity with, 695
 development and course of, 695
 diagnostic criteria for, 694
 diagnostic features of, 694
 differential diagnosis of, 695
 functional consequences of, 695
 prevalence of, 694
- Sexual sadism disorder, 685, 695–697
 associated features supporting diagnosis of, 696
 comorbidity with, 697
 development and course of, 697
 diagnostic criteria for, 695
 diagnostic features of, 696
 differential diagnosis of, 697
 prevalence of, 696
- Shenjing shuairuo*, 835–836
Shubo-kyofu, 264
- Skin picking. *See* Excoriation (skin-picking) disorder
- Sleep-related hypoventilation, 387–390
 associated features supporting diagnosis of, 387–388
 comorbidity with, 389–390
 development and course of, 387
 diagnostic criteria for, 387
 diagnostic features, 387
 diagnostic markers for, 389
 differential diagnosis of, 389
 functional consequences of, 389
 gender-related diagnostic issues in, 389
 prevalence of, 388
 relationship to *International Classification of Sleep Disorders*, 390
 risk and prognostic factors for, 388
 subtypes of, 387
- Sleep terrors, 399–403. *See also* Non-rapid eye movement sleep arousal disorders
- Sleep-wake disorders, 361–422
 breathing-related sleep disorders, 361, 378–390
 central sleep apnea, 383–386
 obstructive sleep apnea hypopnea, 378–383
 sleep-related hypoventilation, 387–390
 circadian rhythm sleep-wake disorders, 361, 390–398
 advanced sleep phase type, 393–394
 delayed sleep phase type, 391–392
 irregular sleep-wake type, 394–396
 non-24-hour sleep-wake type, 396–397
 shift work type, 397–398
 highlights of changes from DSM-IV to DSM-5, 814
 hypersomnolence disorder, 361, 368–372
 other specified, 421
 unspecified, 421
 insomnia disorder, 361, 362–368
 other specified, 420
 unspecified, 420–421
 narcolepsy, 361, 372–378
 other specified sleep-wake disorder, 421
 parasomnias, 399–410
 nightmare disorder, 361, 404–407
 non-rapid eye movement sleep arousal disorders, 361, 399–404
 rapid eye movement sleep behavior disorder, 361, 407–410
 relationship to *International Classification of Sleep Disorders*, 361–362 (*See also specific sleep-wake disorders*)
 restless legs syndrome, 361, 410–413
 substance/medication-induced sleep disorder, 413–420
 unspecified sleep-wake disorder, 422
- Sleepwalking, 399–403. *See also* Non-rapid eye movement sleep arousal disorders
- Smoking. *See* Tobacco-related disorders
- Social anxiety disorder (social phobia), 190, 202–208
 associated features supporting diagnosis of, 204
 comorbidity with, 208
 culture-related diagnostic issues in, 205–206

- development and course of, 205
- diagnostic criteria for, 202–203
- diagnostic features of, 203–204
- differential diagnosis of, 206–207
- functional consequences of, 206
- gender-related diagnostic issues in, 204, 206
- prevalence of, 204
- risk and prognostic factors for, 205
- specifiers for, 203
- Social (pragmatic) communication disorder, 31, 47–49
 - associated features supporting diagnosis of, 48
 - development and course of, 48
 - diagnostic criteria for, 47–48
 - diagnostic features of, 48
 - differential diagnosis of, 49
 - risk and prognostic factors for, 48
- Somatic symptom disorder, 309, 310, 311–315
 - associated features supporting diagnosis of, 312
 - comorbidity with, 314–315
 - culture-related diagnostic issues in, 313
 - development and course of, 312–313
 - diagnostic criteria for, 311
 - diagnostic features of, 311–312
 - differential diagnosis of, 314
 - prevalence of, 312
 - risk and prognostic factors for, 313
- Somatic symptoms and related disorders, 309–327
 - conversion disorder (functional neurological symptom disorder), 309, 310, 318–321
 - factitious disorder, 309, 310, 324–326
 - highlights of changes from DSM-IV to DSM-5, 812–813
 - illness anxiety disorder, 309, 310, 315–318
 - other specified somatic symptom and related disorder, 309, 310, 327
 - psychological factors affecting other medical conditions, 309, 310, 322–324
 - somatic symptom disorder, 309, 310, 311–315
 - unspecified somatic symptom and related disorder, 309, 310, 327
- Specific learning disorder, 32, 66–74
 - associated features supporting diagnosis of, 70
 - comorbidity with, 72, 74
 - culture-related diagnostic issues in, 72–73
 - development and course of, 70–72
 - diagnostic criteria for, 66–68
 - diagnostic features of, 68–70
 - differential diagnosis of, 73–74
 - functional consequences of, 73
 - gender-related diagnostic issues in, 73
 - prevalence of, 70
 - recording procedures for, 68
 - risk and prognostic factors for, 72
- Specific phobia, 189–190, 197–202
 - associated features supporting diagnosis of, 199
 - comorbidity with, 202
 - culture-related diagnostic issues in, 201
 - development and course of, 199–200
 - diagnostic criteria for, 197–198
 - diagnostic features of, 198–199
 - differential diagnosis of, 201–202
 - functional consequences of, 201
 - prevalence of, 199
 - risk and prognostic factors for, 200
 - specifiers for, 198
 - suicide risk in, 201
- Specifiers, 21–22
- Specifiers for bipolar and related disorders, 149–154
- Specifiers for depressive disorders, 184–188
- Speech sound disorder, 31, 44–45
 - associated features supporting diagnosis of, 44
 - development and course of, 44–45
 - diagnostic criteria for, 44
 - diagnostic features of, 44
 - differential diagnosis of, 45
- Spouse or partner abuse, psychological, 721–722
- Spouse or partner neglect, 721
- Spouse or partner violence
 - physical, 720
 - sexual, 720
- Stereotypic movement disorder, 32, 77–80
 - comorbidity with, 80
 - culture-related diagnostic issues in, 79
 - development and course of, 79
 - diagnostic criteria for, 77–78
 - diagnostic features of, 78–79
 - differential diagnosis of, 79–80
 - prevalence of, 79
 - recording procedures for, 78
 - risk and prognostic factors for, 79
 - specifiers for, 78
- Stimulant intoxication, 567–569
 - associated features supporting diagnosis of, 568
 - diagnostic criteria for, 567–568
 - diagnostic features of, 568
 - differential diagnosis of, 568–569
- Stimulant-related disorders, 481, 561–570
 - diagnoses associated with, 482
 - other stimulant-induced disorders, 570
 - stimulant intoxication, 567–569
 - stimulant use disorder, 561–567
 - stimulant withdrawal, 484, 569–570
 - unspecified stimulant-related disorder, 570
- Stimulant use disorder, 561–567
 - associated features supporting diagnosis of, 563–564
 - comorbidity with, 566–567

- Stimulant use disorder (*continued*)
- culture-related diagnostic issues in, 565
 - development and course of, 564–565
 - diagnostic criteria for, 561–562
 - diagnostic features of, 563
 - diagnostic markers for, 565–566
 - differential diagnosis of, 566
 - functional consequences of, 566
 - prevalence of, 564
 - risk and prognostic factors for, 565
 - specifiers for, 563
- Stimulant withdrawal, 484, 569–570
- associated features supporting diagnosis of, 570
 - diagnostic criteria for, 569
 - differential diagnosis of, 570
- Stroke, 46, 73, 117
- bipolar disorder and, 146, 147
 - depressive disorders and, 164, 167, 181–182
- Stuttering. *See* Childhood-onset fluency disorder (stuttering)
- Substance-induced disorders, 481, 485–490. *See also specific substances of abuse*
- alcohol-related, 497–503
 - caffeine-related, 503–508
 - cannabis-related, 516–519
 - hallucinogen-related, 527–533
 - inhalant-related, 538–540
 - opioid-related, 546–549
 - other (or unknown) substance-related, 581–585
 - sedative-, hypnotic-, or anxiolytic-related, 556–560
- substance intoxication and withdrawal, 481, 485–487 (*See also* Intoxication; Withdrawal from substance)
- associated with use of multiple substances, 486
 - development and course of, 487
 - duration of effects and, 486
 - laboratory findings associated with, 486–487
 - recording procedures for, 487
 - related to route of administration and speed of substance effects, 486
- substance/medication-induced mental disorders, 481, 487–490
- development and course of, 489
 - features of, 488–489
 - functional consequences of, 490
 - recording procedures for, 490
- tobacco-related, 575–576
- Substance intoxication delirium, 596–597, 598
- Substance/medication-induced anxiety disorder, 190, 226–230
- associated features supporting diagnosis of, 228–229
 - diagnostic criteria for, 226–227
 - diagnostic features of, 228
 - diagnostic markers for, 229
 - differential diagnosis of, 229–230
 - prevalence of, 229
 - recording procedures for, 227–228
- Substance/medication-induced bipolar and related disorder, 123, 142–145
- associated features supporting diagnosis of, 144
 - comorbidity with, 146
 - development and course of, 144–145
 - diagnostic criteria for, 142–143
 - diagnostic features of, 144
 - diagnostic markers for, 145
 - differential diagnosis of, 145
 - prevalence of, 144
 - recording procedures for, 143–144
- Substance/medication-induced depressive disorder, 155, 175–180
- comorbidity with, 180
 - development and course of, 178
 - diagnostic criteria for, 175–176
 - diagnostic features of, 177–178
 - diagnostic markers for, 179
 - differential diagnosis of, 179–180
 - prevalence of, 178
 - recording procedures for, 176–177
 - risk and prognostic factors for, 178–179
 - suicide risk in, 179
- Substance/medication-induced neurocognitive disorder, 591, 603, 627–632
- associated features supporting diagnosis of, 630
 - comorbidity with, 632
 - development and course of, 631
 - diagnostic criteria for, 627–629
 - diagnostic features of, 629–630
 - diagnostic markers for, 631
 - differential diagnosis of, 631
 - functional consequences of, 631
 - prevalence of, 630
 - recording procedures for, 629
 - risk and prognostic factors for, 631
- Substance/medication-induced obsessive-compulsive and related disorder, 235, 236, 257–260
- associated features supporting diagnosis of, 259
 - diagnostic criteria for, 257–258
 - diagnostic features of, 259
 - differential diagnosis of, 259–260
 - prevalence of, 259
 - recording procedures for, 258–259
- Substance/medication-induced psychotic disorder, 89, 110–115
- associated features supporting diagnosis of, 113
 - development and course of, 114

- diagnostic criteria for, 110–111
- diagnostic features of, 112–113
- diagnostic markers for, 114
- differential diagnosis of, 114–115
- functional consequences of, 114
- prevalence of, 113
- recording procedures for, 112
- Substance/medication-induced sexual
 - dysfunction, 423, 446–450
 - associated features supporting diagnosis of, 448–449
 - culture-related diagnostic issues in, 449
 - development and course of, 449
 - diagnostic criteria for, 446–447
 - diagnostic features of, 448
 - differential diagnosis of, 450
 - functional consequences of, 450
 - gender-related diagnostic issues in, 449
 - prevalence of, 449
 - recording procedures for, 447–448
- Substance/medication-induced sleep disorder, 413–420
 - associated features supporting diagnosis of, 416–418
 - comorbidity with, 420
 - culture-related diagnostic issues in, 418
 - development and course of, 418
 - diagnostic criteria for, 413–415
 - diagnostic features of, 416
 - diagnostic markers for, 419
 - differential diagnosis of, 419–420
 - functional consequences of, 419
 - gender-related diagnostic issues in, 418
 - recording procedures for, 415–416
 - relationship to *International Classification of Sleep Disorders*, 420
 - risk and prognostic factors for, 418
- Substance-related and addictive disorders, 481–589
 - gambling disorder, 481, 585–589
 - highlights of changes from DSM-IV to DSM-5, 815
 - substance-related disorders, 481–585 (*See also specific substances of abuse*)
 - alcohol-related disorders, 490–503
 - caffeine-related disorders, 503–509
 - cannabis-related disorders, 509–519
 - diagnoses associated with substance class, **482**
 - drug classes in, 481
 - hallucinogen-related disorders, 520–533
 - inhalant-related disorders, 533–540
 - opioid-related disorders, 540–550
 - other (or unknown) substance-related disorders, 577–585
 - sedative-, hypnotic- or anxiolytic-related disorders, 550–560
 - stimulant-related disorders, 561–570
 - substance-induced disorders, 481, 485–490
 - substance use disorders, 481, 483–485, 490–585
 - tobacco-related disorders, 571–577
- Substance use disorders, 481, 483–485
 - alcohol use disorder, 490–497
 - caffeine use disorder, 792–795
 - cannabis use disorder, 509–516
 - features of, 483–484
 - inhalant use disorder, 533–538
 - opioid use disorder, 541–546
 - other hallucinogen use disorder, 523–527
 - other (or unknown) substance use disorder, 577–580
 - phencyclidine use disorder, 520–523
 - recording procedures for, 485
 - sedative, hypnotic, or anxiolytic use disorder, 550–556
 - severity and specifiers for, 484
 - stimulant use disorder, 561–567
 - tobacco use disorder, 571–574
 - tolerance and withdrawal in, 484
- Substance withdrawal delirium, 597, 598–599
- Suicidal behavior disorder, 801–803
 - comorbidity with, 803
 - culture-related diagnostic issues in, 802
 - development and course of, 802
 - diagnostic features of, 801–802
 - diagnostic markers for, 802
 - functional consequences of, 802
 - proposed criteria for, 801
 - specifiers for, 801
- Suicide risk
 - anorexia nervosa and, 343
 - bipolar I disorder and, 131
 - bipolar II disorder and, 138
 - body dysmorphic disorder and, 245
 - bulimia nervosa and, 349
 - depressive disorder due to another medical condition and, 182
 - depressive episodes with short-duration hypomania and, 788
 - disruptive mood dysregulation disorder and, 158
 - dissociative amnesia and, 300
 - dissociative identity disorder and, 295
 - major depressive disorder and, 164, 167
 - neurobehavioral disorder associated with prenatal alcohol exposure and, 800
 - obsessive-compulsive disorder and, 240
 - opioid use disorder and, 544
 - other hallucinogen intoxication and, 530

- Suicide risk (*continued*)
- panic attacks and, 215
 - panic disorder and, 212
 - persistent complex bereavement disorder and, 791
 - posttraumatic stress disorder and, 278
 - psychotic disorder due to another medical condition and, 118
 - schizoaffective disorder and, 109
 - schizophrenia and, 104
 - separation anxiety disorder and, 193
 - specific phobia and, 201
 - substance/medication-induced depressive disorder and, 180
- Susto*, 836–837
- Taijin kyofusho*, 205, 837
- Tardive akathisia, 712
- Tardive dyskinesia, 22, 712
- Tardive dystonia, 712
- Technical terms, glossary of, 817–831
- Tic disorders, 32, 81–85
- comorbidity with, 83, 85
 - culture-related diagnostic issues in, 83
 - development and course of, 83
 - diagnostic criteria for, 81
 - diagnostic features of, 81–82
 - differential diagnosis of, 84
 - functional consequences of, 84
 - gender-related diagnostic issues in, 83, 84
 - other specified tic disorder, 85
 - prevalence of, 83
 - risk and prognostic factors for, 83
 - specifiers for, 81
 - unspecified tic disorder, 85
- Tobacco-related disorders, 481, 571–577
- diagnoses associated with, 482
 - other tobacco-induced disorders, 576
 - tobacco use disorder, 571–574
 - tobacco withdrawal, 484, 575–576
 - unspecified tobacco-related disorder, 577
- Tobacco use disorder, 571–574
- associated features supporting diagnosis of, 573
 - comorbidity with, 574
 - culture-related diagnostic issues in, 574
 - development and course of, 573
 - diagnostic criteria for, 571–572
 - diagnostic features of, 572–573
 - diagnostic markers for, 574
 - functional consequences of, 574
 - prevalence of, 573
 - risk and prognostic factors for, 573–574
 - specifiers for, 572
- Tobacco withdrawal, 484, 575–576
- associated features supporting diagnosis of, 575
 - development and course of, 576
 - diagnostic criteria for, 575
 - diagnostic features of, 575
 - diagnostic markers for, 576
 - differential diagnosis of, 576
 - functional consequences of, 576
 - prevalence of, 576
 - risk and prognostic factors for, 576
- Tolerance to substance effects, 484
- Tourette's disorder, 32. *See also* Tic disorders
- diagnostic criteria for, 81
 - diagnostic features of, 81–82
 - functional consequences of, 84
 - prevalence of, 83
 - risk and prognostic factors for, 83
- Transvestic disorder, 685, 702–704
- associated features supporting diagnosis of, 703
 - comorbidity with, 704
 - development and course of, 703–704
 - diagnostic criteria for, 702
 - diagnostic features of, 703
 - differential diagnosis of, 704
 - functional consequences of, 704
 - prevalence of, 703
 - specifiers for, 703
- Trauma- and stressor-related disorders, 265–290
- acute stress disorder, 265, 280–286
 - adjustment disorders, 265, 286–289
 - disinhibited social engagement disorder, 265, 268–270
 - highlights of changes from DSM-IV to DSM-5, 812
 - other specified trauma- and stressor-related disorder, 289
 - posttraumatic stress disorder, 265, 271–280
 - reactive attachment disorder, 265–268
 - unspecified trauma- and stressor-related disorder, 290
- Traumatic brain injury
- bipolar disorder and, 146
 - depressive disorders and, 181
 - dissociative amnesia and, 298, 299, 301
 - hoarding disorder and, 247, 250
 - major or mild neurocognitive disorder due to, 591, 603, 624–627, 626
 - associated features supporting diagnosis of, 625
 - comorbidity with, 627
 - development and course of, 625–626
 - diagnostic criteria for, 624
 - diagnostic features of, 625
 - diagnostic markers for, 627
 - differential diagnosis of, 627
 - functional consequences of, 627

- prevalence of, 625
 - risk and prognostic factors for, 626–627
 - specifiers for, 625
- neurodevelopmental disorders and, 38, 39, 44, 73
- psychotic disorders and, 99, 117
- severity ratings for, 625, **626**
- trauma- and stressor-related disorders and, 280, 281, 284, 286
- Tremor, medication-induced, 712
- Trichotillomania (hair-pulling disorder), 235, 236, 251–254
 - associated features supporting diagnosis of, 252
 - comorbidity with, 254
 - culture-related diagnostic issues in, 253
 - development and course of, 253
 - diagnostic criteria for, 251
 - diagnostic features of, 251–252
 - diagnostic markers for, 253
 - differential diagnosis of, 253–254
 - functional consequences of, 253
 - prevalence of, 252
 - risk and prognostic factors for, 253
- Trúng gió*, 211, 212
- Unspecified mental disorder, 15–16, 19–20, 708
 - due to another medical condition, 708
- Vascular neurocognitive disorder, major or mild, 591, **603**, 621–624
 - associated features supporting diagnosis of, 622
 - comorbidity with, 624
 - development and course of, 623
 - diagnostic criteria for, 621
 - diagnostic features of, 621–622
 - diagnostic markers for, 623
 - differential diagnosis of, 623–624
 - functional consequences of, 623
 - prevalence of, 622–623
 - risk and prognostic factors for, 623
- Voyeuristic disorder, 685, 686–688
 - comorbidity with, 688
 - development and course of, 688
 - diagnostic criteria for, 686–687
 - diagnostic features of, 687
 - differential diagnosis of, 688
 - gender-related diagnostic issues in, 688
 - prevalence of, 687–688
 - risk and prognostic factors for, 688
 - specifiers for, 687
- Withdrawal from substance, 481, 485–487
 - alcohol, 499–501
 - caffeine, 506–508
 - cannabis, 517–519
 - delirium due to, 598
 - development and course of, 487
 - duration of effects and, 486
 - laboratory findings associated with, 486–487
 - multiple substances, 486
 - opioids, 484, 547–549
 - other (or unknown) substance, 583–584
 - recording procedures for, 487
 - related to route of administration and speed of substance effects, 486
 - sedative, hypnotic, or anxiolytic, 484, 557–560
 - stimulant, 484, 569–570
 - tobacco, 484, 575–576
- World Health Organization (WHO), 6, 23
 - International Classification of Diseases (ICD)*, 21
 - revision process for ICD-11, 6, 10, 11–12
 - use of ICD-9-CM and ICD-10 codes, 12, 16, 22, 23, 29
 - International Classification of Functioning, Disability and Health (ICF)*, 21, 734
- World Health Organization Disability Assessment Schedule 2.0 (WHODAS), 16, 21, 734, 745–748
 - additional scoring and interpretation guidance for DSM-5 users, 745–746
 - frequency of use of, 746
 - scoring instructions provided by WHO for, 745